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ABSTRACT 
 
Density and Geometry of the Third Metacarpal in Juvenile Racehorses 
Treated with Exogenous Equine Somatotropin. (August 2005) 
Katherine Lenore Thomson, B.S.; M.S., Tarleton State University; 
D.V.M., Texas A&M University 
Co-Chairs of Advisory Committee:     Dr. Gary D. Potter 
                           Dr. Pete G. Gibbs 
 
 The effect of exogenous somatotropin (eST) on bone changes were evaluated in 
twenty-nine juvenile horses in race training using radiographs of the third metacarpal 
obtained over the course of a 128 day research project.   A biodensitometer was used to 
measure bone density, and a micrometer was used to measure cortical bone width and 
medullary cavity width.  Fifteen horses were given daily intramuscular injections of eST 
and fourteen horses were given daily intramuscular injections of sterile saline and served 
as the control group.   
 By day 128, the increase in total radiographic bone aluminum equivalence (RBAE) 
was significantly greater in the eST horses than in the control horses.  The increases in 
RBAE in the dorsal and the medial cortices were greater in the eST horses than in the 
control horses, but these differences were not significant.  There was a trend for changes 
in the ratio of RBAE in the dorsal to palmar and in the medial to lateral cortices to be 
greater in the eST than in the control horses. 
  By day 128, the increases in both the dorsal and the medial cortical bone width were 
significantly greater in the eST than in the control group of horses.  The eST horses had a 
significantly greater decrease in dorsal to palmar medullary cavity width, and increase in 
dorsal to palmar bone diameter than the control group.  A computed index of dorsal 
cortical bone increased significantly more in the eST than in the control group.   
 The stresses applied to bone are greater in the dorso-medial direction in racehorses.  
To decrease the strain, bone must either increase in bone mineral density, cortical width, 
and/or bone diameter.  Both the eST group and the control group did make these changes 
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in bone over time, but the eST group more effectively remodeled and modeled bone to 
increase the strength of the third metacarpal than did the control group of horses. 
 In this research project, exogenous somatotropin treatment had a positive effect on the 
density and geometry of the third metacarpal.  These changes are believed to result in a 
decreased risk of bone injury to the eST treated horses.   
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INTRODUCTION 
 
Bone is a dynamic tissue that adjusts to the stresses placed upon it.  Long bone that is 
stressed beyond its physiological limit normally undergoes a response that includes 
enlarging its periosteal diameter to reduce the strain placed on the bone.  Also, in bone 
that has experienced microfractures, the damaged areas of bone normally undergo 
resorption by osteoclasts and then new bone material is laid down by osteoblasts.  Both 
of these methods, modeling and remodeling, allow bone to adjust to stress placed upon 
it.  However this adjustment takes time.  If bone is not given enough time to adjust, 
serious injury is more likely. 
Juvenile racehorses are often exposed to the amounts of repetitive stress that can 
cause stress fractures.  Allowing these juvenile horses more time to mature might 
decrease the likelihood of injury.  However, the current economics of the racing industry 
encourages racing of young horses.  As a result, researchers have been looking at other 
ways to decrease the prevalence of bone injuries in horses. 
Stress fractures and microfractures can be caused by stress beyond the normal 
physiological limit, stress within the normal physiological limit that is applied in a 
different plane than normal, or physiologically normal amounts of stress if the stress is 
repeated often enough.  One way to reduce the likelihood of stress fractures is by causing 
positive changes in bone modeling and/or remodeling.  Increasing the mineral density of 
a bone and/or increasing the diameter of a bone should result in decreased strain placed 
upon that bone by any given amount of stress.  In direct contrast to this ideal, juvenile 
racehorses typically undergo a decrease in bone mineral density of the third metacarpal 
that often occurs near the time that trainers increase the speed demands on these horses.  
Speed is thought to increase the strain placed upon these bones, thereby increasing the 
likelihood of the development of stress fractures and/or microfractures.  Other bones may 
also undergo a decrease in bone mineral density due to remodeling as a result of training.  
_______________ 
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Bone modeling and remodeling are both influenced by specific hormones.  Growth 
hormone, also known as somatotropin, has been shown to increase production of insulin-
like growth factor 1 (IGF-1) and osteoblastic activity.  Increased osteoblastic activity 
results in increased bone deposition. 
One technique to influence bone deposition positively in juvenile racehorses may be 
the administration of exogenous somatotropin to increase circulating IGF-1, thereby 
increasing osteoblastic activity and resulting in an increase in bone mineral density 
and/or bone diameter.  Either of these results could decrease the likelihood of injury to 
juvenile racehorses. 
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REVIEW OF LITERATURE 
 
The most important cause of training failure in Thoroughbreds is lameness (Lidner 
and Dingerkus, 1993).  Pre-existing stress fractures are often seen in humeral (Johnson, 
1993; Johnson et al., 1994; Stover et al., 1991), pelvic (Stover et al., 1993; Johnson et 
al., 1994), scapular (Stover et al., 1993) and tibial (Stover et al., 1993) fractures.  
Musculoskeletal injuries account for the majority of racing and training deaths in both 
Thoroughbreds and Quarter Horses (Johnson, 1993; Estberg et al., 1993, 1996).  
Musculoskeletal injuries in racehorses are a problem in the United States, Europe, and 
worldwide. 
 
Prevalence of Racehorse Injuries 
 
Racehorses in Australia have an incidence rate of 2.4 (Bailey et al., 1997) and 1.1 
(Bourke, 1994) musculoskeletal breakdowns and fatalities, respectively, per 1000 starts.  
Assuming 10 horses per race, 10 races per day, and 5 racing days per week, these 
indicate rates would be 1.2 breakdowns and 0.55 fatalities per week at a race track.  In 
Southern Africa 0.14% of starters broke down during racing (Macdonald and Toms, 
1994). 
At Cologne, Germany, 57% of training failures were due to lameness (Lindner and 
Dingerkus, 1993).  
 A study in Newmarket found racehorses had a 9% annual incidence of fracturing a 
bone (Bathe, 1994).  Of the 245 fractures observed, 11 were dorsal metacarpal stress 
fractures.  This study found that the majority of fractures occurred during training rather 
than racing, as have other studies (Kobluk et al., 1992; Wilson et al., 1996; Verheyen and 
Wood, 2004) while some studies found Thoroughbred fatal injuries were equally 
associated with racing and training (Johnson, 1993; Estberg et al., 1993; Johnson et al., 
1994).  The majority of Quarter Horse fatal injuries occurred during racing (Johnson, 
1993; Johnson et al., 1994). 
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British Thoroughbred racehorses suffered 1.15 fractures per 100 horse months 
(Verheyen and Wood, 2004).  Analysis of the 148 fractures included in the study found 
that 22 were stress fractures of the third metacarpal. 
During 1992, in the United States, 0.32% of Thoroughbred 2-year-old starters on dirt 
tracks suffered an injury while only one injury was reported on a turf track (Wilson et al., 
1996).  Five of the injuries on the dirt tracks were bucked shins and another 7 of the total 
57 reported were fractures of the third metacarpal.  Fatal injuries occurred in 0.159% of 
overall starts.  
In California, 0.17 per 100 race entrants sustained a fatal musculoskeletal injury 
(Estberg et al., 1996).  This is about 1 fatality every 6 racing days.  Of the 79 fatal 
musculoskeletal injuries they observed during racing, 19 involved fracture of the 
metacarpus.  When they also included horses that sustained an exercise-related fatal 
injury during training, they found 41 of the 163 injuries involved third metacarpal 
fractures (Esterberg et al., 1993).  This study was then extended for 3 more years and 
found that in Thoroughbred horses, 75 of 258 fatal fractures during racing and 61 of 286 
fatal fractures during training involved the third metacarpal bone (Johnson et al., 1994).  
These same authors noted 2 of 24 fatal musculoskeletal injuries in Quarter Horses during 
one year were fractures of the third metacarpal (Johnson, 1993). 
Haynes and Robinson (1988) studied Thoroughbreds at Canterbury Downs and 
observed that 81% developed musculoskeletal injuries.  Additionally they reported that 
35% of the horses sustained musculoskeletal injuries that were severe enough to prevent 
training or racing.  These authors noted 3.2 breakdowns per 100 horses that started in at 
least one race (Haynes and Robinson, 1988; Robinson et al., 1988).   
A study in New York concluded that the fracture incidence during races for 
Thoroughbreds in that state was approximately 2 per 100 horses (Hill et al., 1986).  
Metacarpal bone fractures accounted for 13% of the musculoskeletal injuries observed 
(Mohammed et al., 1991). 
Thoroughbred racehorses in Kentucky suffered injuries at a rate of 0.33% per start and 
catastrophic injuries at a rate of 0.14% per start (Peloso et al., 1994).   
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The exact percentages of injuries to racehorses vary in these reports.  Besides normal 
chance variation in the amount of injuries, different authors used different criteria to 
determine what constituted an injury and used different types of animals for their control 
group.  Additionally, the reports from outside the United States were from areas that tend 
to run the majority of their races on turf rather than on dirt tracks, which has been 
speculated to affect the rate of injury (Mohammed et al., 1991).  Even with these 
variations these reports verify that musculoskeletal injuries are of great concern to the 
horse racing industry. 
 
Factors Associated with Racehorse Injuries 
 
Authors have looked at various factors that may influence racetrack injuries, but have 
been unable to agree on all the causative agents. 
They have found that increasing age does not (Hill et al., 1986), or alternately does 
(Haynes and Robinson, 1988; Robinson et al., 1988; Mohammed et al., 1991; Kobluk et 
al., 1992; Bourke, 1994; Macdonald and Toms, 1994; Estberg et al., 1996; Bailey et al., 
1997) increase a horse’s risk of injury.  Verheyen and Wood (2004) found that young 
horses suffered more fractures during training, while aged horses were more likely to 
experience a fracture during racing than during training.  Fillies have more (Lidner and 
Dingerkus, 1993), or alternately fewer injuries than males (Macdonald and Toms, 1994; 
Estberg et al., 1996; Wilson et al., 1996).   Differences in breeds have been noted, but are 
confounded by the different types of racing associated with the various breeds 
(Nunamaker, 1986; Nunamaker et al., 1990; Pool and Meagher, 1990; Wilson et al., 
1996).   
Track conditions have been contemplated as contributing to racehorse injuries.  Dirt 
tracks have been observed to be associated with an increased risk of injury over turf 
tracks (Mohammed et al., 1991), while no significant difference between the type of 
track was seen by others (Hill et al., 1986; Robinson et al., 1988; Kobluk et al., 1992).  
Kane et al. (1996) investigated the type of horseshoe as being a contributing factor to 
injury.  They found that the likelihood of injury was increased by the use of front toe 
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grabs and decreased when horses were shod with rim shoes.  Pratt (1997) also noted that 
toe grabs increase the rate of injury. 
Some authors have documented a negative correlation between risk of injury and the 
cumulative exercise distance during the time period preceding a race (Kobluk et al., 
1992; Cohen et al., 2000) while other authors noted a positive correlation (Lidner and 
Dingerkus, 1993; Estberg et al., 1994, 1995, 1998).  Robinson and others (1988) saw a 
significant difference in injury occurrence between trainers and theorized that it was due 
to differences in the exercise programs used by the various trainers.  Haynes and 
Robinson (1988) found an increased risk for horses that had raced within the previous 12 
days, but a decreased risk for animals with higher overall exercise scores.  In this study 
they also observed that horses with a catastrophic injury often had a preceding injury. 
Horses with more starts per year tend to have fewer breakdowns (Haynes and 
Robinson, 1988; Mohammed et al., 1991; Kobluk et al., 1992).  Horses in stakes races 
(Bailey et al., 1997) or horses in claiming races (Haynes and Robinson, 1988; Robinson 
et al., 1988; Kobluk et al., 1992) were found to have an increased chance of injury in 
some studies, while no difference was seen in another study (Wilson et al., 1996). 
Other factors that have been contemplated as influencing the injury rate to racehorses 
include field size (Bailey et al., 1997), barrier position (Bailey et al., 1997), distance ran 
in the last preceding race (Bailey et al., 1997), location on the track (Hill et al., 1986; 
Robinson et al., 1988; Kobluk et al., 1992; Mohammed et al., 1992; Bourke, 1994; 
Wilson et al., 1996), distance of the race (Hill et al., 1986; Kobluk et al., 1992; Bourke, 
1994; Peloso et al., 1994), hoof angle (Kobluk et al., 1992), conformation (Kobluk et al., 
1992), season of the year (Mohammed et al., 1991), season of racing (Mohammed et al., 
1991), and number of days between previous races (Peloso et al., 1994). 
 
Stress Fractures, a Specific Type of Injury 
 
Stress fractures are bone fractures, either partial or complete, that are not associated 
with a single traumatic episode (Carter and Hayes, 1977).  Instead they are caused by 
repetitive occurrences of stress that are beneath the fracture threshold (Burr, 1997).  They 
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are one of the most commonly occurring overuse injuries experienced by athletes (Jones 
et al., 1989).  Stress fractures are well documented in military recruits and have been 
discussed by various authors (Scully and Besterman, 1982; Burr, 1997; Popovich et al., 
2000).  Some authors reserve the term stress fracture for those cases with a fracture line 
visible by radiograph (Stover et al., 1988).  Fatigue fracture is another term that is often 
used to refer to this type of bone damage. 
One type of stress related injury that often occurs in racehorses is dorsal metacarpal 
disease, also commonly called “bucked shins”.  In dorsal metacarpal disease 
microfracture of the cortical bone is thought to be the primary lesion (Stover et al., 
1988).  Clinical signs of dorsal metacarpal disease include heat, swelling, and pain upon 
palpation of the dorsal metacarpal area while necropsy signs are congestion and edema 
of the periosteum and subcutaneous tissue associated with the dorsal metacarpal area 
(Katayama et al., 2001).  Dorsal metacarpal disease has been found to occur in 42% 
(Bailey et al., 1999), or 59% (in one study) and 70-80% on average (Larkin and Davies, 
1996) of 2-year-old Thoroughbred racing horses in Australia.  It occurs in 70% 
(Norwood, 1978) to 91% (Stover et al., 1988) of 2-year-old Thoroughbred racing horses 
in the United States, and in 5 - 50% of racing Quarter Horses (Goodman, 1987).  Shin 
soreness was found to be the most common injury occurring to Thoroughbred 2-year-
olds in race training in Australia (Bailey et al., 1999).  In a study in Australia, they found 
that of the horses that developed dorsal metacarpal disease as two-year-olds, 40% had a 
recurrence sometime during their two or three year-old years (Bailey et al., 1999).  In 
contrast, Nunamaker et al. (1990) state that once a horse has recovered from bucked 
shins the condition rarely recurs. 
Another stress related injury that occurs in racehorses is tibial stress fracture (Bathe, 
1994, Verheyen and Wood, 2004).  Additionally, humeral fractures in racehorses often 
show signs of pre-existing stress fractures (Stover et al., 1991; Johnson, 1993). 
Various authors have reported that long bone fractures of racehorses often show 
evidence of a pre-existing stress fracture (Stover et al., 1991; Johnson, 1993; Stover et 
al., 1993; Johnson et al., 1994) or other pre-existing pathological condition (Pool and 
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Meager, 1990; Kobluk et al., 1992; Stover et al., 1994).  Thus many long bone fractures 
in racehorses may begin with microfracture damage to the cortical bone. 
 
Microfractures in Cortical Bone 
 
Cortical bone is the dense compact bone that makes up the shafts of long bones and 
the outer layer of all bones.  Microfractures are typically defined as a matrix failure that 
can be detected by light microscopy (Burr et al., 1997).  Microfractures have been seen 
to occur in cortical bone loaded in vivo (Mori and Burr, 1993; Burr et al., 1997) and in 
vitro (Carter and Hayes, 1977).  Horses in race training have microfractures (Stover et 
al., 1992).  Microfractures weaken the bone and may therefore lead to catastrophic 
failure (Schaffler et al., 1989).  Tension damage to bone resulting in modulus reduction 
of less than 20% does not significantly reduce the impact strength of the bone (Reilly and 
Currey, 2000).   In contrast, bone damaged in compression, and then loaded in tension 
appeared to have a reduction in impact strength that presumably results from the long 
and discrete microcracks produced by compression (Reilly and Currey, 2000).  However, 
if bone remodeling can repair the microfracture damage before it becomes too great, 
bone failure may be delayed or prevented (Martin and Burr, 1982). 
 
Intracortical Bone Remodeling 
 
Intracortical bone is remodeled by a several step process.  The steps are coupled to 
one another and always proceed in the same order with bone resorption preceding bone 
deposition (Parfitt and Chir, 1987; Pool, 1991).  The remodeling is done in individual 
packets of bone cells referred to as basic multicellular units (BMU) (Frost, 1987).   
The first step is the least understood.  Somehow the bone reabsorbing cells, 
osteoclasts, are activated and begin resorbing bone at a specific site.  This activation has 
been postulated to be triggered by strain magnitudes (Lanyon, 1984; Frost, 1987, 1990; 
Burr et al., 1989) that may be sensed by osteocytes, the resident cells of bone (Lean et al., 
1996), stress-related electrical potentials (Davidovitch et al., 1984; Lanyon, 1993), 
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microfractures (Carter, 1984; Frost, 1990; Lanyon, 1993; Mori and Burr, 1993), 
retraction of bone lining cells (Mundy, 1990), fluid shear stress as sensed by osteocytes 
(Johnson, 1984; Lanyon, 1993; Burger et al., 1995; Parfitt et al., 1996; Sakai et al., 
1999). and/or the loss of osteocyte integrity as a result of microfractures (Vashishth et 
al., 2000; Verborgt et al., 2000).  Recently Yasuda et al. (1999) reported the discovery of 
an osteoclastic differentiation factor which can be expressed by cells of the osteoblastic 
lineage and appears to be a major ligand involved in mediating osteoclast activation.  
This may be related to osteoprotegerin, a glycoprotein found by Simonet et al. (1997), 
that also inhibits osteoclastic activation.  Once activated, mononuclear precursor cells 
from the hematopoitic cell line combine to form the large, multinucleated osteoclasts 
(Mundy, 1990; Athanasou, 1996). 
The second step is resorption.  Resorption takes place by individual osteoclast cells 
forming a ruffled border with the bone (Athanasou, 1996), sealing these edges to the 
bone and using proton pumps to pump proteolytic enzymes and hydrogen ions into this 
“clear zone” (Mundy, 1990).  Once an osteoclast has resorbed a given area of bone, it 
can become motile and move to a new area of bone (Mundy, 1990).  Teams of 
osteoclasts erode a cutting cone in the cortical bone at a rate of 20-40µm (Parfitt and 
Chir, 1987) to 50µm (Jaworski, 1984) per day in a direction that is roughly parallel to the 
long axis of the bone.  The rate and duration of bone resorption are thought to be 
regulated by genetics, local and systemic factors (Jaworski, 1984), with some of these 
factors working indirectly through osteoblasts (Athanasou, 1996).  According to Parfitt 
and associates (1996), throughout the life of the BMU new osteoclast precursors are 
recruited, this recruitment is done by the osteoclasts, and this determines the rate and 
duration of the cutting cone.  The precise signal for this recruitment is speculated to 
involve interleukin-6, annexin-II, and /or interleukin-1 (Mundy, 1990; Athanasou, 1996; 
Parfitt et al., 1996; Qu et al., 1999; Franchimont et al., 2000).  The resorption stage takes 
1 to 3 weeks (Parfitt and Chir, 1987). 
Next there is a reversal phase that lasts for 1 to 2 weeks (Parfitt and Chir, 1987) at any 
given location of the cutting cone.  During this step osteoblasts, the bone forming cells, 
are recruited to the cutting cone (Jaworski, 1984; Parfitt and Chir, 1987).  Osteoblasts are 
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cuboidal and originate from the mesenchymal stem cells (Baron, 1990; Rodan, 1992).  
Analogously to the osteoclasts, osteoblasts are recruited as pre-osteoblast cells and the 
precise mechanism of signaling involved in recruitment is not known but may be strain-
regulated (Smit and Burger, 2000).  Once at the site of the cutting cone, the pre-
osteoblasts differentiate into mature osteoblasts (Rodan, 1992).  Unlike osteoclasts, 
osteoblasts are not motile and stay at the same site as long as they are laying down bone 
(Jaworski, 1984).  However, as the osteoclasts continue to advance the front of the 
cutting cone, more osteoblasts are recruited to the newly resorbed areas of the cutting 
cone (Jaworski, 1984). 
The fourth step is bone formation.  This is a two-part process.  First the teams of 
osteoblasts (100-400 per team) (Baron, 1990) produce and secrete the protein matrix of 
bone, which is 85-90% type 1 collagen (Baron, 1990; Teitelbaum, 1990; Termine, 1990; 
Rodan, 1992).  The matrix is secreted at the approximate rate of 0.5µm (Rodan, 1992), 
1.0-1.5µm (Jaworski, 1984), or 2-3µm per day (Parfitt and Chir, 1987).  As they deposit 
the matrix some osteoblasts become embedded in the matrix and then change to become 
osteocytes (Jaworski, 1984; Rodan, 1992).  The collagen matrix must undergo 
maturation for 5-10 days before the second part of the bone formation process can take 
place (Parfitt and Chir, 1987; Baron, 1990; Puzas, 1990).  The collagen matrix that lies 
between the osteoblasts and the mineralized bone surface is called the osteoid seam and 
is 5-50µm thick (Puzas, 1990).  Osteoblasts control matrix maturation and the 
subsequent mineralization of the bone (Puzas, 1990).  Most of the mineral in bone is in 
the form of spindle-shaped crystals of hydroxyapatite, Ca10(PO4)6(OH)2 (Baron, 1990; 
Puzas, 1990).  Because new osteoblasts are recruited as long as the osteoclasts are 
resorbing bone, the mineralization front follows the osteoid front, which follows the 
resorption front (Jaworski, 1984).  During the first 2 weeks of mineralization about 70% 
of the mineral is deposited (Pool, 1991).  The new bone does not reach its maximum 
density for 3-6 months (Parfitt and Chir, 1987).  
The fifth step is quiescence.  Remaining osteoblast cells flatten out and become bone-
lining cells (Parfitt and Chir, 1987; Rodan, 1992) or disappear (Parfitt and Chir, 1987).  
The remodeling of this area of bone is complete. 
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Periosteal and Endosteal Bone Remodeling and Modeling 
 
Periosteal and endosteal bone remodels in much the same manner as intracortical 
bone.  The only real difference being that rather than a cutting cone, the BMU is in the 
form of a more diffuse (Jaworski, 1984) resorption pit, a Howship lacuna (Buckwalter et 
al., 1995). 
However, in addition to remodeling, modeling can also take place on the periosteal 
and endosteal surfaces.  Modeling differs from cortical remodeling in two important 
ways.  First, modeling can involve the laying down of new bone without a preceding 
resorption phase (Pead et al., 1988; Baron, 1990; Bloomfield, 1995).  Secondly, since 
bone resorption and formation are uncoupled, modeling changes the geometry of the 
bone (Baron, 1990; Teitelbaum, 1990).  This change in geometry allows the bone to 
adapt to different stresses placed on it by modifying the cross-sectional area and/or 
changing the moment of inertia of the bone.   
During growth, modeling is used to sculpt the metaphyses to retain the shape of the 
bone (Baron, 1990; Buckwalter et al., 1995).  After the bone has reached its maximum 
length, modeling typically focuses on increasing the diameter of the bone by adding bone 
to the periosteal surface (Buckwalter et al., 1995) by intramembranous ossification (Pool, 
1991).  Modeling also typically decreases the thickness of the cortical bone by removing 
bone from the endosteal surface (Pool, 1991; Buckwalter et al., 1995).  However, in 
foals, modeling normally increases the thickness of the dorsal cortex, as periosteal bone 
growth exceeds endosteal absorption in this area (Pool, 1991).  In the young 
Thoroughbred racehorse modeling can add 1-2µm/day of lamellar bone to the periosteal 
surface (Nunamaker and Provost, 1991).  
 
Effects of Exercise on Bone Modeling and Remodeling 
 
According to Wolff’s law, bones adapt to the stresses placed upon them.  Bones that 
are overloaded, such as those in a young growing animal, are adapted by modeling 
(Jones et al., 1977; Goodship et al., 1979; Woo et al., 1981; Bloomfield, 1995).  Even in 
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mature animals bone can adapt to increased strain by modeling (Lanyon, 1984; Meade et 
al., 1984; Rubin and Lanyon, 1984, 1985; Burr et al., 1989; Bloomfield, 1995).  In both 
these cases, modeling increases the deposition of bone on the periosteal surface 
(Goodship et al., 1979) and may also decrease the resorption of bone from the endosteal 
surface (Jones et al., 1977; Woo et al., 1981).  As noted previously this change takes 
time.  New bone laid down in response to increased load was still not as dense or strong 
as mature bone 2 months after the increased strain was applied (Meade et al., 1984).   
Bones that are underloaded, such as occurs in space flight (Cavolina et al., 1997), bed 
rest (Leblanc et al., 1990), disuse (Lanyon, 1984; Rubin and Lanyon, 1984, 1985; Skerry 
and Lanyon, 1995; Thomas et al., 1996), or deconditioning (Porr et al., 1998) are 
remodeled to decrease the amount of bone present. 
Changing the shape of a bone, especially by increasing the outer diameter of the 
cortex, can decrease the strain experienced by that bone at a given level of stress. As the 
outside wall of the cortex of bone increases in diameter it, like any other cylinder, 
increases the area moment of inertia.  In military recruits the area moment of inertia of 
the tibia correlates with the risk of stress fractures (Milgrom et al., 1989).  Also, width of 
the tibia was significantly related to risk of stress fracture although cortical thickness was 
not (Giladi et al., 1987).  
The third metacarpal (MC III) of a yearling Thoroughbred has a nearly round cross-
section and a centrally located medullary cavity. The same cross-sectional view of an 
older Thoroughbred’s third metacarpal shows a bone that has been modeled due to the 
strains placed upon it.  The total area of cortical bone is increased and the area of the 
medullary cavity is also increased (Welch, 1999).  The change in the shape of the bone is 
influenced by the exercise the horse undergoes (Welch, 1999). 
In one study exercise was shown to increase bone modeling but decrease intracortical 
bone remodeling (Lanyon, 1984), though others have not seen changes in intracortical 
remodeling due to strain (Meade et al., 1984), or have seen an increase in intracortical 
remodeling (Goodship et al., 1979).  Birch and Goodship (1999) saw a decrease in 
markers of bone remodeling in horses that were in high intensity training and suggest 
that this was due to exercise causing decreased remodeling.  Frost (1990) theorized that 
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if enough microdamage occurs it will trigger cortical bone remodeling regardless of any 
normal depressive effect of exercise. 
Juvenile racehorses have been shown to experience changes in bone mineral density 
of the third metacarpal that is related to exercise (McCarthy and Jeffcott, 1992; Nielsen 
et al., 1997; Porr et al., 1998, 2000). 
 
Somatotropin 
 
Somatotropin (STH) is also known as growth hormone.  This hormone is a protein 
molecule made up of 191 amino acids in man (Guyton and Hall, 1996), and 190 amino 
acids in the horse (Ascacio-Martínez and Barrera-Saldaña, 1994).  It is produced in the 
anterior pituitary by the somatotroph cells (Greenstein, 1994).  Secretion of STH is 
regulated by the hypothalamus via the production of growth hormone releasing hormone 
(GHRH), which stimulates STH secretion and somatostatin, also from the hypothalamus, 
which inhibits the secretion of STH.  Secretion of STH is increased by sleep, exercise, 
and stress (Reichlin, 1998).  Release of STH is not steady, but instead is episodic, 
climbing during sleep, shortly after rising, and twice during the day (Greenstein, 1994), 
or up to 13 pulses per 24-hour period (Reilchlin, 1998).  Feedback control is both a 
direct negative feedback loop, as increasing levels of STH cause a decrease in GHRH 
secretion, and an indirect negative feedback loop, as increasing STH causes an increase 
in circulating IGF-1 which causes a decrease in GHRH secretion (Reilchlin, 1998). 
Exogenous STH has been used in humans and animals.  In humans, STH has 
primarily been used to correct deficiencies in endogenous STH (Ohlsson et al., 1998).  In 
animals, effects of exogenous STH have been studied since Asdell (1932) treated dairy 
goats with hypophyseal extract.  In dairy cattle, STH treatment has been shown to 
increase the lactational yield (Bauman et al., 1999) and the amount of milk produced per 
amount of feed input (Bauman, 1992).  In swine, exogenous STH has been shown to 
increase growth performance (Chung et al., 1985).  Studies have found that STH does 
not (Veum et al., 1997), or alternately does (Wester et al., 1998; Wang et al., 1999) affect 
growth of neonatal pigs.  In an overview of STH use in animal production, Etherton and 
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Bauman (1998) state that exogenous STH increases the food output per unit of feed 
input. 
Unlike most hormones, STH does not target a specific organ but has its influence on 
almost all body tissues including bone (Guyton and Hall, 1996).  Many of the effects of 
STH are indirect and occur due to STH stimulating the liver to increase its secretion of 
IGF-1. 
 
Indirect Effects of Somatotropin on Bone Via IGF-1 
 
Somatomedin, IGF-1, mediates many of the actions of STH (Greenstein, 1994).   
Under the influence of STH the liver increases its secretion of IGF-1 into the circulation.  
However the increase in serum IGF-1 does not occur until 12 hours after the rise in STH 
(Salih et al., 1999).  In the circulation almost all IGF-1 is bound to IGF-1 binding 
proteins (IGFBP) (Rosen and Pollak, 1999).  There are six known IGFBPs and they 
function to help control the rate at which IGF-1 is delivered to its target cells (Root, 
1994).  In bone it is primarily IGFBP-5 that allows storage of IGF-1 in the matrix tissue 
(Rosen and Pollak, 1999).  In addition to increasing circulating levels of IGF-1, STH also 
stimulates bone to increase secretion of IGF-1 (Raisz et al., 1998) as well as other 
growth factors (Mohan and Baylink, 1990).  As a result, STH causes an increase of IGF-
1 at both systemic and local levels. 
According to Canalis (1990), IGF-1 stimulates osteoblasts to replicate and to increase 
their production of bone protein matrix.  In contrast, Puzas (1990) claims that osteoblasts 
do not replicate.  While not affecting bone resorption, IGF-1 does decrease bone collagen 
breakdown (Canalis, 1990).  Additionally, IGF-1 has anabolic effects on osteoblasts 
(Ohlsson et al. 1998). 
 
Direct Effects of Somatotropin on Bone 
 
Nilsson et al. (1995) established that osteoblasts have receptors for STH.  Kassem and 
coworkers (1993) found that STH may have direct anabolic effects on osteoblasts, which 
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can stimulate osteoblast proliferation.  Ohlsson et al. (1998) also noted that STH 
stimulates osteoblasts to proliferate.  Thus, STH appears to affect bone metabolism in 
two ways, direct stimulatory effects on osteoblasts and indirect effects via increase in 
IGF-1 levels.  Directly, STH may stimulate prechondrocytes and preostesoblasts, while 
indirectly, via IGF-1, STH stimulates more mature cells (Ohlsson et al., 1998). 
 
Combined Use of Somatotropin and Exercise 
 
A study by Oxlund and workers (1998) found that the combined use of STH and 
exercise increases cortical bone growth in rats.  Similarly, Banu et al. (1999) found that 
STH and exercise had additive effects on some measurements of bone, as did Yeh and 
co-workers (1994).   
A previous study in this laboratory found trends for exogenous STH to increase bone 
mineral density in juvenile racehorses (Julen-Day et al., 1998).  Another study utilizing a 
larger group of horses was needed to further evaluate the potential beneficial effects of 
the combination of STH treatment and exercise in increasing bone strength in young 
racehorses. 
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MATERIALS AND METHODS 
 
This was one of a two part study examining specific effects of exogenous 
somatotropin administration to juvenile horses in race training.  The first part of this 
study has previously been published (Sutfin, 2000).  This part of the study concentrated 
on changes in the third metacarpal that were measureable via radiographs.   
 
Management of Animals 
 
Thirty-two long-yearling Quarter Horses, each obtained from a volunteer horse owner 
across the United States as a loan for the duration of the project, were paired by age 
within sex (mean age at entry into study was 629 ± 11 days).  One horse from each pair 
was randomly assigned to a treatment group and the other to a control group.  During the 
study three horses were removed from the project.  One of these horses had a pre-
existing bone cyst, the other two horses developed extended lameness caused by stone 
bruises to the feet.  A total of twenty-nine horses completed the project, fourteen in the 
control group and fifteen in the treatment group.  Mean starting weight of the horses in 
the treatement group was 360.1 ± 13.3 kg, and 379.7 ± 10.2 kg in the control group. 
The protocol for management of the animals was approved by the Texas A&M 
University Agriculture Animal Care and Use Committee.  On arrival, all horses were 
vaccinated and dewormed using procedures and products typically prescribed for horses 
in Central Texas.  Hoof care was provided as needed throughout the project.  The horses 
were housed in 3.7m x 3.7m box stalls and exercised on a dirt training track.  All of the 
horses were fed the same balanced diet formulated to supply 130% of the current 
National Research Council (1989) recommendations for protein, minerals and vitamins 
for horses in training.  Complete composition of the ration was published previously 
(Sutfin, 2000). 
The horses were fed the same diet throughout the study, with amounts offered per 
feeding adjusted to maintain a constant body condition score of 5 - 6 using the system 
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developed by Henneke et al. (1983).  The study was conducted at Steephollow Farm, a 
racehorse training facility near College Station, Texas.   
 
Treatments 
 
Horses in the treatment (eST) group were given intramuscular injections of a 
recombinant equine growth hormone (EquiGen™)1 daily at 1900h.  The form of 
EquiGen™ used in this study was a powder that was reconstituted according to the 
manufacturer’s directions.  EquiGen™ contains 191 amino acids, one more amino acid 
than naturally occurring equine somatotropin.  An extra methionine residue was 
intentionally added to facilitate growth in bacteria.  The dosage administered was 
10µg/Kg BW per day for the first 7 days, followed by 20µg/Kg BW per day for the 
remaining 121 days of the study, as per the manufacturer’s recommendation.  The horses 
in the control group were given intramuscular injections of an equivalent volume of 
sterile saline.  All injections were given daily at 1900h.  Injection sites alternated 
between the neck and the pectoral region.   
The experiment was conducted in four, 32-day periods.  On days 0, 32, 50, 64, 82, 96 
and 128 of the study, radiographs were taken of the entire left third metacarpal with an 
aluminum (Al) stepwedge penetrometer attached to the radiographic cassette.   After the 
initial radiographs were taken, the horses were started in training.  The training regimen 
was similar to that reported by Nielsen et al. (1997) which was developed to be typical 
for Quarter Horse race training. 
 
Training Protocol 
 
During the first week the horses were worked six days and rested one day.  The riding 
started on day one in a round pen and advanced to the track by day two or day three 
depending on the temperament of the horse.  On the initial days, horses were walked 550 
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m, trotted 1100 m and galloped 275 m.  For the rest of week one the horses were ridden 
the same as on day 2-3, except that an additional 275 m of galloping was added each day.  
By day six the horses were galloped 1375 m.  In weeks two-to-four the horses were 
ridden five days per week.  The horses were walked and trotted as in the first week and 
galloped 1650 m per day.  The total distance galloped per week during these three weeks 
was 8250 m.  During the next period of four weeks the horses were ridden four days per 
week.  Total distance galloped per horse per week was increased to 8440 m.  For the 
third period of four weeks the horses were again ridden four days per week. On three of 
these days the horses were trotted 550 m and galloped 1925 m, and on one day the horses 
were warmed up, sprinted, and galloped.  The horses were sprinted 230 m and galloped a 
total of 8210 m each week during the third period.  In the fourth period the program was 
the same as the third period except the sprint was increased to 275 m and the gallop was 
decreased to 8165 m per week.  During the entire trial the horses were walked for at least 
one hour on a mechanical walker on non-riding days.  At the start of the trial and during 
the last four days of each 32-day period the horses were confined to tie stalls for a total 
collection of feces and urine, which was used in another study. 
 
Samples Collected for This Study 
 
Dorsal-palmar and lateral-medial radiographic views of the left third metacarpal were 
taken with an Al stepwedge penetrometer attached to each radiographic cassette.  The 
radiographs were taken at a focal distance of 28 inches, using 70 KVP, 20 mA and 
exposure times of 0.2 seconds (dorsal-palmar views) and 0.16 seconds (lateral-medial 
views) 
 
Measurements of Bone Density 
 
The radiographs were then scanned using a Bio-Rad Model 620 Video densitometer.  
A logarithmic regression was formed using the optical density (OD) of the steps of the 
Al penetrometer as a standard.  The maximum OD of four cortices of the bone was 
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measured at a point 1 cm distal to the nutrient foramen and perpendicular to the long axis 
of the bone, and compared to the Al standard to determine bone density in radiographic 
bone aluminum equivalence (RBAE).  This location on the bone was used both because 
the nutrient foramen serves as a landmark and because this location has been examined 
by several authors (Lawrence et al., 1994; Nielsen et al., 1997, 1998; Porr and Ott, 1997; 
Porr et al., 1998, 2000; Waite et al., 2000).  This location is referred to in this paper as 
Site 1 (Figure 1). 
Bone density was expressed as RBAE in millimeters of aluminum. Also, the area 
under the density curve from the dorsal-palmar radiographs was calculated and 
standardized with the corresponding area under the curve from the Al stepwedge on the 
corresponding radiograph to give an estimate of total bone density expressed as RBAE in 
mm
2Al. 
It was possible that any changes in bone mineral density seen at the nutrient foramen 
would be unique to that location on the bone.  To determine if these same patterns in 
bone mineral density occurred at other areas, additional locations on the third metacarpal 
were also examined using the same procedures as outlined above.   
One area evaluated in this same manner was the mid-diaphysis region.  Two different 
locations in this region were studied.  One location was the midpoint of the bone as 
measured along the longitudinal axis from the carpal-metacarpal joint surface to the 
distal extreme of the articular condyles of metacarpal III.  This area was chosen because 
it has been examined by several authors (Turner et al., 1975; Rybicki et al., 1977; 
Schryver, 1978; El Shorafa et al., 1979; Meakim et al., 1981; Nunamaker et al., 1989; 
Gross et al., 1992; McCarthy and Jeffcott, 1992; Gibson et al., 1995; Davies, 1996; 
Larkin and Davies, 1996; Skedros et al., 1996; Birch and Goodship, 1999) and also 
coincided with the area often affected by dorsal metacarpal disease (Stover et al., 1988; 
Nunamaker et al., 1990).  This location is referred to in this paper as Site 2 (Figure 1). 
The second location in this region was the midpoint of the bone as measured from the 
proximal end of the bone to the distal limit of the diaphysis as this area has been 
examined by Stover and coworkers (1992).  This location is referred to in this paper as 
Site 3 (Figure 1). 
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1
2
3
• Site 1   1cm below nutrient foramen
Figure 1.  Diagram of the 4 sites of metacarpal III evaluated.
• Site 3   Midpoint of bone from proximal 
end of bone  to distal end of articular
surface
• Site 4   Junction of the proximal two-
thirds and the distal one third of the bone 
• Site 2   Midpoint of bone from proximal 
end of bone to distal end of diaphysis
4
 
 
 
The final area to be evaluated in the same manner was the junction of the proximal 
two-thirds and the distal one third of the third metacarpal bone as measured along the 
longitudinal axis from the carpal-metacarpal joint surface to the distal extreme of the 
articular condyles of metacarpal III.  This area was chosen because it is also often 
affected by dorsal metacarpal disease (Norwood, 1978; Stover et al., 1988) and is the 
area with the greatest cortical area in yearling Thoroughbreds (Nunamaker et al., 1989).  
This location is referred to in this paper as Site 4 (Figure 1). 
It was anticipated that some of the radiographs would not show the entire third 
metacarpal.  When this occurred, radiographs from the same horse, but on different dates 
were used to provide the needed total length in mm of the metacarpus.  The specific 
locations to be evaluated were then measured from the nutrient foramen to ensure that 
the same location was measured on each successive radiograph of an individual horse.  
The equine third metacarpal only has one growth plate (Krook and Maylin, 1988), or at 
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least only one growth plate that is not closed before birth (Getty, 1975; Pool, 1991).  
This plate, located distally, closes at 6 - 12 months (Evans, 1990) or 6 - 18 months 
(Getty, 1975).   Because the horses in this study were approximately 21 months old at the 
start of the study, the third metacarpal growth plates were closed and the length of the 
metacarpus of an individual horse would not vary over the course of the experiment.  
Radiograph evaluation confirmed the closure of the third metacarpal physes in these 
horses.  Additionally, every effort was made to take true lateral-medial and dorsal-palmar 
views and to avoid radiographic aberrations by keeping the radiographic plates both 
parallel and as close as possible to the third metacarpal.  
 
Measurements of Bone Geometry 
 
Geometric changes of the third metacarpal bone were also evaluated on these 
radiographs at the same locations where bone mineral density was evaluated.  Because it 
was anticipated that measurable changes in the geometry of the third metacarpal would 
occur slowly, only radiographs from day 0, day 64 and day 128 were used for geometric 
measurements.  A digital caliper was used to measure the thickness of the dorsal, medial, 
lateral and palmar cortical bone and the width of the medullary cavity in a manner 
similar to that reported by Larkin and Davies (1996).  A radiographic view box and 
magnifying lens was used to assist in determining the edges of the cortical bone.  These 
data were then analyzed to determine if measurable changes in the geometry of the third 
metacarpal of the individual horses occurred over the course of this experiment.  Because 
changes in geometry were seen, further analyses were run to see if the changes were 
consistent over the two treatment groups.  
Larkin and Davies (1996) report a significant correlation between shin soreness in 
racehorses and an Index calculated by using the dorsal and palmar cortical bone widths 
and the medullary cavity width.  The Index describes the extent to which bone is 
modeled for increase of dorsal cortical bone relative to palmar cortical bone.  This Index 
was calculated on the horses in this experiment on day 0, day 64 and day 128 using the 
method of Larkin and Davies (1996).   
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Index = X * Y, where X = (T-M)/M, and Y = D/P 
D = dorsal cortical bone width, M = medullary cavity width, 
P = palmar cortical bone width, and T = D + M + P 
 
As changes were seen in the Index values over the course of the experiment, analyses 
were run to determine if treatment with STH influenced the magnitude of these changes 
in the Index. 
 
Statistical Analyses 
 
SAS 8.1 was used to analyze the data and is the source of the statistics reported in this 
paper.  To compare effects of treatment and time on measurable changes in bone, much 
of the data were normalized to day 0 values.  Both measured values and normalized 
values are reported in this paper. 
ANOVA Repeated Measures, type III, with day, treatment, and day*treatment as the 
effects, and the degrees of freedom determined by the Satterthwaite method were used to 
analyze the changes over time in RBAE in the dorsal, palmar, lateral and medial cortices, 
and total RBAE; changes over time in micrometer readings of the dorsal, palmar, lateral 
and medial cortical bone width, lateral-to-medial and dorsal-to-palmar medullary cavity 
width, and lateral-to-medial and dorsal-to-palmar bone diameter; changes over time in 
the ratios of dorsal/palmar, lateral/palmar, medial/palmar, and medial/lateral RBAE 
cortical measurements; and changes over time in the Index.  Least square means were 
used to identify time by treatment interactions using Tukey’s procedure to declare 
significant differences.  Each of the four sites measured on the third metacarpal were 
evaluated independently.  Significant difference was set at P0.05 throughout this study. 
Trends, when reported, were set at P0.10. 
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RESULTS 
 
The daily injections of eST did not result in any observable side effects on the horses.  
The horses treated with eST had an average feed consumption of 7.8 kg/day while the 
controls consumed an average of 8.1 kg/day. The difference between groups in average 
daily feed consumption was small and not unexpected as the eST horses began the 
project with a slightly lower average body weight than the control horses. 
 
Total RBAE 
Site 1 
Total RBAE at site 1 was significantly affected by day (P.0001) but not by treatment 
or day*treatment (Figure 2, Tables A-1 and B-1).   The differences seen between the two 
treatment groups in total RBAE at Site 1 at the start of the project had disappeared by the 
end of the trial. 
 
 
Figure 2. Total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 1.
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Data were normalized to remove the differences that were present between treatment 
groups on day 0 (Figure 3, Tables A-2 and B-2). 
 
 
Figure 3. Normalized total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 1.
a
 Treatments differ (P.05).
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Both treatment groups showed similar patterns of gain in total RBAE with an increase 
in total RBAE from day 0 to day 32, decline in total RBAE from day 32 to day 50, 
increase in total RBAE from day 50 to day 82, decline in total RBAE from day 82 to day 
96, and a final gain in total RBAE from day 96 to the end of the study.  The main 
difference seen between the groups was a greater magnitude of gain in total RBAE in the 
eST treatment group that resulted in a significantly greater gain in total RBAE by day 
128 than that seen in the control group (P<.05).   
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Site 2 
Total RBAE at site 2 was significantly affected by time (P<.0001) but not by 
treatment or day*treatment (Figure 4, Tables A-1 and B-3).   
 
 
Figure 4. Total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 2.
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Differences that were seen between the two treatment groups on day 0 had 
disappeared by day 128.  Data were normalized to day 0 values to better view any 
differences between the treatment groups in the change in total RBAE over time (Figure 
5, Tables A-2 and B-4). 
The overall pattern of gain in total RBAE at site 2 was very similar to that seen at site 
1 (Figure 3), with a general gain in total RBAE over the 128 days of the trial in both 
groups, but a decrease in net gain seen on days 50 and 96.  There was a trend for the two 
treatment groups to differ on day 128, with the eST horses having a greater gain in total 
RBAE than the control horses (P=.07). 
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Figure 5. Normalized total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 2.
a
 Trend for treatments to differ (P.10).
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Site 3 
Total RBAE at site 3 was significantly affected by time (P<.0001) but not by 
treatment or day*treatment (Figure 6, Tables A-1 and B-5).   
Differences that were seen between the two treatment groups on day 0 had 
disappeared by day 128.  Data were normalized to day 0 values to better view any 
differences between the treatment groups in the change in total RBAE over time (Figure 
7, Tables A-2 and B-6). 
Similar to the changes in total RBAE seen at site 1 (Figure 3) and site 2 (Figure 5), the 
overall pattern of net increase in total RBAE at site 3 was interrupted by a decrease in 
total RBAE on days 50 and 96.  The eST horses had a trend for greater net increase in 
total RBAE at site 3 on day 32 (P=0.09) and on day 128 (P=0.07) than the control horses. 
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Figure 6. Total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 3.
vwxyz
 Days not sharing the same superscript differ (P.05).
400.00
450.00
500.00
550.00
600.00
650.00
700.00
0 32 50 64 82 96 128
Day of study
To
ta
l R
BA
E 
(m
m
2  
A
l)
site 3, Con
site 3, eST
v                                     wx               v                vw              y                xy                                   z
 
 
 
 
 
Figure 7. Normalized total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 3.
a
 Trend for treatments to differ (P.10).
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Site 4 
Total RBAE at site 4 was significantly affected by time (P<.0001) but not by 
treatment or day*treatment (Figure 8, Tables A-1 and B-7).  Once again, the differences 
in total RBAE that existed between the two treatment groups at the start of the project 
had disappeared by the end of the 128 days.  
 
 
Figure 8. Total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 4.
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Data were normalized to day 0 to better view the changes in total RBAE over time 
(Figure 9, Tables A-2 and B-8).  Both of the two treatment groups had a net gain in total 
RBAE at site 4 over the 128 day trial, with decreases in total RBAE measured on days 
50 and 96.  There was a trend for the eST group to have a greater gain in total RBAE 
than the control group at site 4 on day 32 (P=.07).  On day 128 the difference in gain of 
total RBAE between the two treatment groups at site 4 was not significant (P=.101). 
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Figure 9. Normalized total radiographic bone aluminum equivalence (RBAE) (mm2 Al) at site 4.
a
 Trend for treatments to differ (P.10).
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Dorsal RBAE 
Site 1 
A significant day effect was seen in dorsal RBAE at site 1 (P<.0001), but there was 
not a treatment*day interaction (Figure 10, Tables A-3 and B-9).  There was a trend for a 
difference (P=.09) between the two treatment groups, with the control horses having a 
greater amount of cortical bone in the dorsal cortex than the eST horses (as measured by 
RBAE) at the start of the project and maintaining a greater RBAE in the dorsal cortex to 
the end of the experiment.  A significant difference between treatment groups occurred 
on day 0 (P=.05) and day 50 (P=.03).   
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Figure 10. Dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 1.
a
 Treatments differ (P.05).
wxyz
 Days not sharing the same superscript differ (P.05).
16.0000
16.5000
17.0000
17.5000
18.0000
18.5000
19.0000
19.5000
0 32 50 64 82 96 128
Day of study
D
o
rs
a
l R
BA
E 
(m
m
 
A
l)
site 1, Con
site 1, eST
wx                                w                wx               x                 yz               y                                   z
 a a
 
 
 
Figure 11. Normalized dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
1. 
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Dorsal RBAE data were normalized to day 0 (Figure 11, Tables A-4 and B-10).  There 
was not a treatment difference or a treatment*day interaction.  There was a significant 
day effect (P<.0001) with a pattern for the change in dorsal RBAE to decline from day 0 
to day 32 (control group) or from day 0 to day 50 (eST group), and then an overall 
increase to the end of the trial, with temporary decreases on day 64 (control group), or 
day 96 (eST group).   
 
Site 2 
A significant day effect was seen in dorsal RBAE at site 2 (P<.0001), but there was 
not a treatment*day interaction or a significant treatment effect (Figure 12, Tables A-3 
and B-11).  The control horses had a trend for a greater amount of cortical bone in the 
dorsal cortex at site 2 than the eST horses (as measured by RBAE) at the start of the 
project on day 0 (P=.06), and maintained a greater RBAE in the dorsal cortex until day 
96.  By day 128, the eST horses had a greater RBAE in the dorsal cortex at site 2 than the 
control horses, but this difference was not statistically significant.  A significant 
difference did occur between treatment groups on day 50 (P<.05).  
Data were normalized to day 0 and reevaluated to observe any differences in dorsal 
cortical bone deposition at site 2 over the duration of the experiment (Figure 13, Tables 
A-4 and B-12).  Day effects were significant (P<.0001), but no significant treatment or 
treatment*day effects occurred.  Both treatment groups had an initial decrease in dorsal 
RBAE at site 2.  The eST group recovered to above day 0 values in RBAE by day 64, but 
the control group did not rise above day 0 values until day 82.  The eST group had a 
moderate decrease in dorsal RBAE from day 82 to day 96 that was not seen in the 
control group.  Both groups had a similar increase in dorsal RBAE from day 96 to day 
128.  The change in dorsal RBAE was greater in the eST group than in the control group 
from day 64 to the end of the study, though this difference was not statistically 
significant.  The increase in dorsal RBAE from day 0 values was significant in the 
control group on day 128 (P<.05), while in the eST group the increase was significant by 
day 82 (P=.02) and remained significantly different from day 0 through the end of the 
trial. 
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Figure 12. Dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 2.
a
 Treatments differ (P.05).
b
 Trend for treatments to differ (P.10).
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Figure 13. Normalized dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
2.
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 Days not sharing the same superscript differ (P.05).
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Site 3 
There was a significant day effect (P<.0001) and a trend for treatment effect (P<.10) 
on dorsal RBAE at site 3, but there was not a day*treatment interaction (Figure 14, 
Tables A-3, B-13).  Overall there was a pattern of significant decrease in dorsal RBAE 
from the start of the trial to day 32 (P<.01).  There was a gradual gain in dorsal RBAE 
from day 32 to the end of the study.   Values for dorsal RBAE were significantly greater 
than day 0 on day 82 (P<.05) and day 128 (P=.0004), and significantly greater (P<.0001) 
than day 32 on days 82, 96, and 128.  Treatments were significantly different on day 0 
(P=.05), and tended to be different on day 50 (P=.100).  Both treatment groups had a 
decrease in dorsal RBAE from day 0 to day 32, then a gain in RBAE from day 32 to day 
82.  A minor decrease in dorsal RBAE from day 82 to day 96 was followed by a minor 
increase in dorsal RBAE from day 96 to day 128.  The control group did show a minor 
decrease in RBAE from day 50 to day 64 that did not occur in the eST treatment group. 
Data were normalized to day 0 and reevaluated to observe any differences in dorsal 
cortical bone deposition at site 3 over the duration of the experiment (Figure 15, Tables 
A-4 and B-14).  Day effects were significant (P<.0001), but no significant treatment or 
treatment*day effects occurred.  There was a significant decrease in dorsal RBAE from 
day 0 to day 32 (P=.01) and then an increase from day 32 to day 82.  The increase in 
dorsal RBAE on day 82 was significant when compared to day 0 (P=.04) and day 32 
(P<.0001).  Another decrease in dorsal RBAE occurred from day 82 to day 96, followed 
by an increase in RBAE from day 96 to the end of the trial period. 
The Control group of horses had a greater loss of bone mineral density as measured by 
RBAE from day 0 to day 32 than did the eST treatment group of horses.  A gain in 
RBAE seen in the eST horses from day 50 to day 64 was not seen in the control horses.  
However, neither of these differences was large enough to be statistically significant. 
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Figure 14. Dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 3.
a
 Treatments differ (P.05).
b
 Trend for treatments to differ (P.10).
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Figure 15. Normalized dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
3.
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Site 4 
There was a significant day effect (P<.0001), but no treatment effect or day*treatment 
interaction on dorsal RBAE at site 4 (Figure 16, Tables A-3, B-15).  After a decrease in 
RBAE from day 0 to day 32, RBAE increased from day 32 to day 128. 
 
 
Figure 16. Dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 4.
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The Control group of horses started the project with a non-significantly greater 
amount of dorsal RBAE at site 4 than the eST group.  The difference seen between the 
two groups on day 0 had decreased by day 32. 
Data were normalized to day 0 and reevaluated to observe any differences in dorsal 
cortical bone deposition at site 4 over the duration of the experiment (Figure 17, Tables 
A-4 and B-16).  The significant decrease in dorsal RBAE that occurred from day 0 to day 
32 (P=.02) was more pronounced in the Con group than it was in the eST group, but 
there were no significant differences observed between the two groups in dorsal RBAE 
at site 4.  Though the two treatment groups appeared to differ on day 82 in Figure 17, 
they were not statistically different (P=.101).  Both groups had an increase in RBAE 
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from day 32 until day 82.  From day 82 to day 96 the eST group had a decrease in RBAE 
that was not seen in the Con group.  Day 128 dorsal RBAE values were significantly 
greater than those seen on days 0 (P=.0009), 32 (P<.0001), 50 (P<.0001), and 64 
(P=.0001). 
 
 
Figure 17. Normalized dorsal radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
4.
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Lateral RBAE 
Site 1 
The lateral RBAE at site 1 was significantly affected by day (P<.0001) but not by 
treatment or by day*treatment interaction (Figure 18, Tables A-5 and B-17).  Except for 
a decline in measured RBAE from day 32 to day 50, lateral RBAE at site 1 showed a 
slow but steady increase throughout the experiment.  This increase resulted in significant 
differences between day 0 and day 96 (P=.008) and between day 0 and day 128 
(P<.0001) in lateral RBAE. 
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Figure 18. Lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 1.
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Data were normalized to day 0 to better observe and evaluate any differences in lateral 
cortical bone deposition at site 1 over the duration of the experiment (Figure 19, Tables 
A-6 and B-18).  This increase in lateral RBAE at site 1 resulted in significant differences 
between day 0 and both day 96 (P=.008) and day 128 (P<.0001), and between day 96 and 
day 128 (P=.002).  Day effects were significant (P<.0001), but no differences due to 
treatment or day*treatment interactions occurred.  On day 0 the Con group of horses had 
a non-significantly greater RBAE in the lateral cortex than the eST group.  This 
difference between the two groups decreased over the course of the trial, but did not 
entirely disappear.   
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Figure 19. Normalized lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
1.
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Site 2 
There was a significant day effect (P<.0001), but no treatment effect or day* treatment 
interaction on RBAE in the lateral cortex at site 2 (Figure 20, Tables A-5 and B-19).  
There was an increase in RBAE from day 0 to day 32, then a decrease in RBAE from day 
32 to day 50.  A gradual but steady increase in RBAE continued from day 50 to the end 
of the experiment on day 128.  Days 82, 96, and 128 all had a significantly greater RBAE 
in the lateral cortex than did day 0 (P=.04, P=.07, and P<.0001 respectively).  The 
increase in RBAE from day 96 to day 128 was significant (P=.0008).   
Data were normalized to day 0 values and re-evaluated (Figure 21, Tables A-6 and B-
20).  Once again day effects were significant (P<.0001), but treatment effects and 
day*treatment interactions did not effect lateral RBAE at site 2.   
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Figure 20. Lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 2.
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Figure 21. Normalized lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
2.
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 Days not sharing the same superscript differ (P.05).
-1.0000
-0.5000
0.0000
0.5000
1.0000
1.5000
2.0000
2.5000
3.0000
0 32 50 64 82 96 128
Day of study
ch
a
n
ge
 
in
 
la
te
ra
l R
BA
E 
(m
m
 
A
l)
site 2, Con
site 2, eST
x                                     xy               x                xy               y                y                                     z
 
 
 
 
  
40 
Site 3 
Lateral RBAE at site 3 was significantly effected by day (P<.0001), but not by 
treatment or by day*treatment interaction (Figure 22, Tables A-5 and B-21).  The pattern 
of change in lateral RBAE at site 3 was very similar to that seen at site 2.  There was an 
increase in RBAE from day 0 to day 32, a decrease in RBAE from day 32 to day 50, and 
finally an increase in RBAE from day 50 to day 128.  Day 96 lateral RBAE was 
significantly greater than day 0 (P=.01).  Day 128 lateral RBAE at site 3 was 
significantly greater than day 96 (P=.0004) and day 0 (P<.0001).  Treatment groups were 
not different on any day. 
 
 
Figure 22. Lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 3.
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Data were normalized to better evaluate changes that occurred over time in lateral 
RBAE at site 3.  Day effects were significant (P<.0001), but no treatment effects or 
day*treatment interactions were observed (Figure 23, Tables A-6 and B-22).  Lateral 
RBAE increased from day 0 to day 32, decreased significantly from day 32 to day 50 
(P=.03), and increased from day 50 to day 128.  Day 96 values were significantly greater 
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than those on day 0 (P=.01).  Day 128 values were significantly greater than those on day 
0 (P<.0001) or day 96 (P=.0004).  The decrease in lateral RBAE at site 3 that occurred 
from day 32 to day 50 was more pronounced in the Con group of horses, though the 
difference between the two groups was not significant.  By day 128 there was no 
difference in lateral RBAE at site 3 between the two treatment groups. 
 
 
Figure 23. Normalized lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
3.
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Site 4 
Lateral RBAE at site 4 was significantly affected by day (P<.0001) but not 
significantly affected by treatment or by day*treatment interaction (Figure 24, Tables A-
5 and B-23).  Lateral RBAE increased from day 0 to day 32, decreased from day 32 to 
day 50, and increased from day 50 through the end of the trial.  By day 82, lateral RBAE 
at site 4 was significantly greater than the initial measurements taken on day 0 (P=.04).  
Day 128 RBAE values of 19.02 mm aluminum were significantly greater than those seen 
on any of the other sampling dates. 
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Figure 24. Lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 4.
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 Days not sharing the same superscript differ (P.05).
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Figure 25. Normalized lateral radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
4.
wxyz
 Days not sharing the same superscript differ (P.05).
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Data were normalized to better view changes in lateral RBAE at site 4 that occurred 
over the course of this experiment (Figure 25, Tables A-6 and B-24).  There was a day 
effect (P<.0001) but not a significant treatment effect or day*treatment interaction.   
 
Medial RBAE 
Site 1 
There was a significant day effect (P<.0001) but no treatment effect or day*treatment 
interaction in RBAE in the medial cortex at site 1 (Figure 26, Tables A-7 and B-25).  
There was a pattern of steady increase in RBAE from day 0 to the end of the trial on day 
128, with the exception of a minor decrease in RBAE on day 96.  Day 32 values were 
significantly greater than those seen on day 0 (P=.006).  Increases seen from day 32 to 
day 64 were not significant until day 82 values, which  were significantly greater than 
those seen on day 32 (P<.0001), day 50 (P=.0004), and day 64 (P=.02).  A decrease in 
medial RBAE at site 1 from day 82 to day 96 was followed by a significant increase in 
RBAE by day 128.  Day 128 RBAE was significantly greater than day 82 (P=.01) and 
day 96 (P=.002).  A non-significant difference between the two treatment groups on day 
0 had totally disappeared by day 96.  No significant differences were seen between the 
two treatment groups at this site. 
Medial RBAE data from site 1 were normalized to better evaluate changes in RBAE 
over the course of the trial (Figure 27, Tables A-8 and B-26).  Day effects were 
significant (P<.0001).  No treatment effects or day*treatment interactions were seen.  
The increase in RBAE from day 0 to day 32 was significant (P=.006).  From day 32 to 
day 50 medial RBAE continued to increase in the eST treatment group, but decreased in 
the Con group.  Both groups had a gain in RBAE from day 50 to day 64 and on to day 
82.  Day 82 was significantly greater than day 64 (P=.02).  Both groups had a decrease in 
RBAE from day 82 to day 96 and then an increase in RBAE from day 96 to day 128.  
Day 128 medial RBAE at site 1 was significantly greater than day 96 (P=.002), day 82 
(P=.01), and days 0, 32, 50, and 64 (all P<.0001).  The eST group of horses had a non-
significant greater increase in RBAE than the Con group of horses. 
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Figure 26. Medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 1.
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 Days not sharing the same superscript differ (P.05).
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Figure 27. Normalized medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
1.
vwxyz
 Days not sharing the same superscript differ (P.05).
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Site 2 
At site 2, medial RBAE day effects were significant (P<.0001) but no treatment 
effects or day*treatment interactions occurred (Figure 28, Tables A-7 and B-27).  The 
increase in RBAE from day 0 to day 32 was significant (P=.003).  Further increases were 
not statistically significant until day 82, which had a greater RBAE value than did day 32 
(P=.0002), day 50 (P=.0007), or day 64 (P=.02).  A small decrease in RBAE was seen 
from day 82 to day 96, followed by a significant increase in RBAE from day 96 to day 
128 (P=.001).   
 
 
Figure 28. Medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 2.
vwxyz
 Days not sharing the same superscript differ (P.05).
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Data were normalized to day 0 values (Figure 29, Tables A-8 and B-28).  Change in 
medial RBAE at site 2 was significantly affected by day (P<.0001), but not by treatment 
or day*treatment interaction.  Measured RBAE on day 32 was significantly greater than 
on day 0 (P=.004).  The gain in RBAE continued in the eST group to day 82.  There was 
a non-significant loss in RBAE from day 32 to day 50, then a gain in RBAE from day 50 
to day 82 in the Con group.  A loss in RBAE occurred in both treatment groups from day 
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82 to day 96, followed by a gain in RBAE from day 96 to day 128.  The medial RBAE 
measurements at site 2 on day 128 were significantly greater than that seen on day 0 
(P<.0001), day 32 (P<.0001), day 50 (P<.0001), day 64 (P<.0001), day 82 (P=.009), and 
day 96 (P=.001).  Differences seen between the two treatment groups were not 
significant. 
 
 
Figure 29. Normalized medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
2.
vwxyz
 Days not sharing the same superscript differ (P.05).
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Site 3 
Medial RBAE at site 3 was significantly affected by day (P<.0001), but not by 
treatment or day*treatment interaction (Figure 30, Tables A-7 and B-29).  Overall, an 
increase in RBAE occurred from day 0 to day 82 and from day 96 to day 128.  From day 
82 to day 96 a decrease in RBAE was seen.  Within the treatment groups, the non-
significantly greater RBAE in the Con group compared to the eST group on day 0 had 
disappeared by day 64. 
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Figure 30. Medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 3.
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 Days not sharing the same superscript differ (P.05).
17.0000
18.0000
19.0000
20.0000
21.0000
22.0000
23.0000
24.0000
0 32 50 64 82 96 128
Day of study
M
ed
ia
l R
BA
E 
(m
m
 
A
l)
site 3, Con
site 3, eST
v                                     w               w                wx              y                xy                                  z
 
 
 
Figure 31. Normalized medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
3.
vwxyz
 Days not sharing the same superscript differ (P.05).
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Data were normalized to day 0 and re-evaluated.  Once again, changes in medial 
RBAE at site 3 were significantly affected by day (P<.0001) but not by treatment or 
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day*treatment interaction (Figure 31, Tables A-8, B-30).  More apparent in the 
normalized data than in the raw data was the non-significant, but persistently greater 
RBAE in the eST group than in the Con group.  This difference was first apparent on day 
50 and continued through the end of the trial.   
 
Site 4 
Medial RBAE at site 4 was significantly affected by day (P<.0001) but not by 
treatment or day*treatment interaction (Figure 32, Tables A-7 and B-31).  Day 0 RBAE 
was significantly less than day 32 RBAE (P=.003).  A non-significant difference in 
RBAE between the two treatment groups on day 0 had been eliminated by day 64 due to 
the eST group experiencing a greater increase in RBAE than the Con group.  The eST 
group continued to show a more rapid increase in medial RBAE at site 4 than the Con 
group from day 64 to day 82.  However, from day 82 to day 96 the eST group had a 
decrease in RBAE at the same time that the Con group had a gain in RBAE.  After day 
96 both groups increased in RBAE to the end of the trial on day 128.  As a result, the 
eST group had a higher RBAE than the Con group only on day 82.   
Normalized data were re-evaluated to better observe changes over time in medial 
RBAE at site 4 (Figure 33, Tables A-8 and B-32).  Day effects were significant 
(P<.0001), but no treatment or day*treatment interactions were seen.  The greater gain in 
RBAE in the eST group compared to the Con group was most pronounced on day 82, but 
was not significant (P=.101).  In spite of a decrease in RBAE in the Con group from day 
50 to day 64, and in the eST group from day 82 to day 96, there was a general gain in 
medial RBAE at site 4 over the course of the trial.  Gain in RBAE caused day 50 to be 
significantly different than day 0 (P=.03), and day 128 to be significantly different than 
day 96 (P=.0004), day 82 (P=.06), day 64 (P=.0001), day 50 (P<.0001), day 32 
(P<.0001), and day 0 (P<.0001). 
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Figure 32. Medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 4.
vwxyz
 Days not sharing the same superscript differ (P.05).
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Figure 33. Normalized medial radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
4.
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 Days not sharing the same superscript differ (P.05).
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Palmar RBAE 
Site 1 
There was an overall day effect on palmar RBAE at site 1 (P<.002) but there was no 
significant difference between treatment groups on any given day (Figure 34, Tables A-9 
and B-33).  Changes in palmar RBAE at site 1 were not affected significantly by 
treatment or day*treatment interaction.  Palmar RBAE decreased significantly from day 
0 to day 32 (P=.004).  From day 32 to day 96 the Con group had a gradual and steady 
increase in RBAE that leveled off from day 96 to day 128.  From day 32 to day 50 the 
eST group had decrease in RBAE, followed by an increase in RBAE from day 32 to day 
82, another decrease in RBAE from day 82 to day 96, and ending the trial with an 
increase in RBAE from day 96 to day 128.  The RBAE values on day 128 were not 
statistically different from day 0.   
 
 
Figure 34. Palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 1.
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Palmar RBAE at site 1 data were normalized to day 0 and statistics were re-run to 
better observe changes in RBAE over time (Figure 35, Tables A-10 and B-34).  Day 
effects were significant (P=.002).  Neither treatment effects nor day*treatment 
interactions were significant.  A significant loss of palmar RBAE at site 1 from day 0 to 
day 32 (P=.004), was followed by a gain in palmar RBAE from day 32 to day 128.  Day 
128 palmar RBAE data were not statistically different from day 0.   
 
 
Figure 35. Normalized palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
1.
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 Days not sharing the same superscript differ (P.05).
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Site 2 
Palmar RBAE at site 2 was significantly affected by day (P=.004) but not by treatment 
or by day*treatment interaction (Figure 36, Tables A-9 and B-35).  Bone mineral density, 
as measured by RBAE, decreased significantly from day 0 to day 32 (P=.006), and 
continued to decrease to day 50.  From day 50 to day 128 palmar RBAE increased and by 
day 82 this increase resulted in RBAE values significantly greater than on day 32 (P=.04) 
and day 50 (P=.01), but not statistically different from day 0.  The Con group of horses 
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had a non-significant greater palmar RBAE at site 2 on day 0 that continued to the end of 
the project. 
 
 
Figure 36. Palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 2.
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Palmar RBAE data from site 2 were normalized and statistics re-run to more closely 
evaluate changes over time (Figure 37, Tables A-10 and B-36).  Day effects were 
significant (P=.003) but no treatment effect or a day*treatment interaction occurred.  
There was a significant decrease in palmar RBAE from day 0 to day 32 (P=.006) that 
continued to day 50 (P=.001).  From day 50 to day 128 palmar RBAE increased 
significantly (P=.001), but did not exceed day 0 values.  The Con group of horses had a 
non-significantly less decrease in palmar RBAE than did the eST horses at day 50.  The 
Con group also had a non-significantly greater increase in palmar RBAE from day 82 to 
day 128, which resulted in the Con group, but not the eST group exceeding day 0 values 
in palmar RBAE at site 2 on days 96 and 128. 
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Figure 37. Normalized palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
2.
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Site 3 
Palmar RBAE at site 3 was significantly affected by day (P=.01) but not by treatment 
or day*treatment interaction (Figure 38, Tables A-9 and B-37).  Palmar RBAE at site 3 
decreased significantly from day 0 to day 32 (P=.007) and continued to decrease to day 
50, which was also significantly different from day 0 (P=.003).  After day 50, palmar 
RBAE increased through the end of the project on day 128, but did not exceed day 0 
values.  A non-significantly larger palmar RBAE in the Con group than in the eST group 
continued through the project and increased from day 82 to day 96. 
Data from palmar RBAE at site 3 were normalized and re-evaluated (Figure 39, 
Tables A-10 and B-38).  Once again, day effects were significant (P=.01) and no 
treatment effects or day*treatment interaction were observed.  A significant loss of bone 
mineral density as measured by RBAE occurred between day 0 and day 32 (P=.01) and 
between day 0 and day 50 (P=.002).  A gain in palmar RBAE followed from day 50 to 
the end of the trial on day 128, with day 128 values not exceeding day 0 values.  The 
Con group had a non-statistically greater gain in palmar RBAE at site 3 than the eST 
group from day 82 to day 96. 
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Figure 38. Palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 3.
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Figure 39. Normalized palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
3.
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 Days not sharing the same superscript differ (P.05).
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Site 4 
Palmar RBAE at site 4 had a trend for day effects (P=.07), but no effects occurred due 
to treatment or day*treatment interaction (Figure 40, Tables A-9 and B-39).  A 
significant decrease in palmar RBAE took place between day 0 and day 32 (P=.02).  
Palmar RBAE increased from day 32 through day 128, and had increased enough to 
exceed day 0 values by day 96.  The non-significantly larger bone density in the palmar 
cortex at site 4 seen in the Con group as compared to the eST group continued 
throughout the testing period, and increased in magnitude between day 82 and day 96 but 
was still not significant (P=.104). 
 
 
Figure 40. Palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 4.
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Data from palmar RBAE at site 4 were normalized to day 0 (Figure 41, Tables A-10 
and B-40).  There was a trend for day effects (P=.09), but not for treatment effects or for 
day*treatment interactions.  A decrease in RBAE in the palmar cortex from day 0 to day 
32 was significant (P=.03).  An increase in RBAE occurred from day 32 to day 128, with 
day 96 palmar cortical bone mineral density exceeding day 0 values, though there was no 
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statistical difference between day 0 and any of the measured days with the exception of 
the aforementioned day 32.  Differences between the two treatment groups were not 
significant, nor were there a consistent pattern observed between the two groups in the 
palmar cortex at site 4. 
 
 
 
Figure 41. Normalized palmar radiographic bone aluminum equivalence (RBAE) (mm Al) at site 
4.
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Ratios of RBAE Measurements 
 
Ratios of bone mineral density, as measured by RBAE, between various cortices were 
evaluated as this is an indication of bone remodeling.  These ratios have been examined 
by Nielsen et al. (1997).  Ratios examined and reported herein are dorsal/palmar, 
normalized dorsal/palmar, lateral/palmar, normalized lateral/palmar, medial/lateral, 
normalized medial/lateral, medial/palmar, and normalized medial/palmar. 
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Ratio of Dorsal to Palmar RBAE 
Site 1 
The ratio of dorsal to palmar RBAE at site 1 was significantly affected by day 
(P=.009) but not by treatment or by day*treatment interaction (Figure 42, Tables A-11 
and B-41).  From day 0 to day 32 the ratio of dorsal to palmar RBAE increased 
significantly (P=.02), then decreased from day 32 to day 64, but did not decrease to day 0 
levels.  There was a slight increase in the ratio of dorsal to palmar RBAE at site 1 
measured on day 82, followed by a slight decrease on day 96, and then an additional 
slight increase on day 128.  A non-significant difference between the two treatment 
groups in the ratio on day 0 had increased to be a trend by day 32 (P=.10).  The 
difference between the two treatment groups then decreased until it was gone by day 64, 
as the eST group continued a pattern of a gradual increase in the ratio of dorsal to palmar 
RBAE through the entire trial while the Con group experienced an increase in the ratio, 
followed by a decrease in the ratio, before leveling off into a more consistent slow gain. 
 
 
Figure 42. Ratio of dorsal to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 1.
a
 Trend for treatments to differ (P.10).
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Figure 43. Normalized ratio of dorsal to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 1.
a
 Treatments differ (P.05).
b Trend for treatments to differ (P.10).
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The data were normalized to day 0 and re-evaluated to better observe the change in 
the ratio of dorsal to palmar RBAE at site 1 over time (Figure 43, Tables A-12 and B-
42).  Day effects were significant (P=.008).  There were no significant treatment effects 
or a day*treatment interaction.  The ratio increased significantly from day 0 to day 32 
(P=.02).  From day 32 to day 64 the ratio decreased non-significantly.  The increase in 
normalized dorsal/palmar RBAE from day 64 to day 128 was significant (P=.01).  The 
eST group of horses displayed a fairly consistent increase in the ratio of dorsal to palmar 
RBAE from day 0 to day 128.  In contrast, the Con group of horses had a gain in the ratio 
from day 0 to day 32, a significant loss in the ratio from day 32 to day 64 (P=.04), a gain 
in the ratio that trended toward significance from day 64 to day 82 (P=.09), a non-
statistically important loss in the ratio from day 82 to day 96, and a non-significant gain 
in the ratio from day 96 to day 128.  The two treatment groups were significantly 
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different from each other on day 64 (P=.05) and had a trend to be different from each 
other on day 96 (P=.100). 
 
Site 2 
At site 2 the ratio of dorsal to palmar RBAE was significantly affected by day 
(P=.007), but not by treatment or by a day*treatment interaction (Figure 44, Tables A-11 
and B-43).  The dorsal to palmar ratio increased significantly from day 0 to day 50 
(P=.002), decreased from day 50 to day 64 (P=.06), increased slightly from day 64 to day 
82, and demonstrated no real change from day 82 to the end of the trial.  The Con group 
had a non-significantly larger ratio of dorsal to palmar RBAE on day 0 than did the eST 
group.  This non-statistical difference between the groups disappeared entirely by day 64 
due to a significant decrease in the dorsal to palmar ratio in the Con group from day 52 
to day 64 (P=.02).   
 
 
Figure 44. Ratio of dorsal to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 2.
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The data of dorsal to palmar RBAE ratio at site 2 were normalized and re-evaluated 
(Figure 45, Tables A-12 and B-44).  Day effects were significant (P=.005), but treatment 
effects were not of statistical importance.  No day*treatment interaction was seen.  There 
was a gain in the normalized ratio from day 0 to day 50 (P=.001), a decrease in the 
normalized ratio from day 50 to day 64 (P=.04), and a gain in the normalized ratio from 
day 64 to day 128 (P=.03).  The two treatment groups both had a decrease in the 
normalized ratio from day 50 to day 64.  However, the decrease in the eST group was 
minor and non-significant while the decrease in the Con group was statistically important 
(P=.01), and resulted in a real difference in the normalized dorsal to palmar RBAE ratio 
between the two groups on day 64 at site 2 (P=.04).  By day 82 there was no longer a 
statistical difference between the two treatment groups, but there was a trend for the ratio 
to once again be greater in the eST group than in the Con group by day 128 (P=.06). 
 
 
Figure 45. Normalized ratio of dorsal to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 2.
a Treatments differ (P.05).
b Trend for treatments to differ (P.10).
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 Days not sharing the same superscript differ (P.05).
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Site 3 
The ratio of dorsal to palmar RBAE at site 3 (Figure 46, Tables A-11 and B-45) was 
not affected by treatment or by a day*treatment interaction, but there was a significant 
day affect (P=.004).  The increase in the ratio that occurred early in the trial resulted in 
the dorsal to palmar ratio on day 50 being significantly greater than on day 0 (P=.0007).  
There was no significant change in the ratio from day 50 to the end of the trial.  Though 
there were minor decreases in the ratio from day 50 to day 64 and from day 82 to day 96, 
these were offset by minor increases in the ratio from day 64 to day 82 and from day 96 
to day 128.  The difference seen between the two treatment groups in the ratio of dorsal 
to palmar RBAE at site 3 on day 0 was not statistically important.  Over the course of the 
project, this difference disappeared entirely. 
 
 
Figure 46. Ratio of dorsal to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 3.
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 Days not sharing the same superscript differ (P.05).
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Data from the dorsal to palmar RBAE ratio at site 3 were normalized to day 0 values 
and re-evaluated (Figure 47, Tables A-12 and B-46).  There was no treatment effect or 
day*treatment interaction.  Day effects were significant (P=.003).  There was a 
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significant increase in the dorsal to palmar ratio from day 0 to day 50 (P=.0005).  The 
normalized dorsal to palmar ratio was at the highest level on day 50, decreased non-
significantly from day 50 to day 64, had no change from day 64 to day 96, and increased 
non-significantly to near the day 50 level by day 128.  There was a trend for the increase 
in normalized dorsal to palmar RBAE ratio at site 3 to be greater in the eST group than 
in the Con group on day 128 (P=.100). 
 
 
Figure 47. Normalized ratio of dorsal to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 3.
a
 Trend for treatments to differ (P.10).
yz
 Days not sharing the same superscript differ (P.05).
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Site 4 
There was not a significant day, treatment, or day*treatment interaction on the ratio of 
dorsal to palmar RBAE at site 4 (Figure 48, Tables A-11 and B-47), but there was a 
trend for a day effect (P=.07).  The ratio of dorsal to palmar RBAE increased slowly but 
steadily in the eST group of horses resulting in significant differences from day 0 on day 
96 (P=.04) and day 128 (P=.0005).  In contrast, there were no significant differences 
between any of the days measured in the Con group of horses. 
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Figure 48. Ratio of dorsal to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 4.
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 Days not sharing the same superscript differ (P.05).
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Figure 49. Normalized ratio of dorsal to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 4.
a
 Treatments differ (P.05).
b
 Trend for treatments to differ (P.10).
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 Days not sharing the same superscript differ (P.05).
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Data from the dorsal to palmar RBAE ratio at site 4 were normalized to day 0 and the 
statistical analysis were re-run (Figure 49, Tables A-12 and B-48).  No statistical 
differences were seen due to treatment, day, or day*treatment interaction.  The 
normalized ratio increased significantly from day 0 to day 128 (P=.004).  The pattern of 
change in the eST group was a slow but fairly steady gain in the ratio, resulting in the 
ratio on day 128 being significantly greater than on day 0 (P=.001) or on day 32 (P=.05).  
In contrast, the Con group had no statistical increase in the ratio during the experiment.  
The gain in the ratio in the eST group was significantly greater than the ratio in the Con 
group on day 96 (P=.04), and still had a trend to be greater than the Con group on day 
128 (P=.09). 
 
Ratio of Lateral to Palmar RBAE 
Site 1 
The ratio of lateral to palmar RBAE at site 1 was significantly affected by day 
(P=.0002), but was not affected by treatment nor by day*treatment interaction (Figure 
50, Tables A-13 and B-49).  There was a significant increase in the ratio of lateral to 
palmar RBAE from day 0 to day 32 (P=.002).  From day 32 to day 50 there was a 
decrease in the ratio that showed a trend toward significance (P=.08).  The ratio did not 
change significantly from day 50 to day 96, then increased significantly from day 96 to 
day 128 (P=.01).  The ratio of lateral to palmar RBAE on day 128 was also significantly 
greater than it had been on day 0 (P<.0001), day 50 (P=.001), day 64 (P=.001), and day 
82 (P=.003).  The Con group did have a non-statistically greater increase in lateral to 
palmar RBAE from day 0 to day 32 than the eST group.  Additionally, the Con group 
had a non-significant decrease in the lateral to palmar RBAE ratio from day 82 to day 96 
that was not seen in the eST group. 
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Figure 50. Ratio of lateral to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 1.
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 Days not sharing the same superscript differ (P.05).
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Figure 51. Normalized ratio of lateral to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 1.
xyz
 Days not sharing the same superscript differ (P.05).
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Data were normalized to day 0 to better observe changes in time in the lateral to 
palmar RBAE ratio at site 1 (Figure 51, Tables A-14 and B-50).  There was a significant 
day effect (P=.0002) but no treatment effect or day*treatment interaction.  There was a 
significant increase in the ratio from day 0 to day 32 (P=.002).  The decrease in the ratio 
from day 32 to day 50 was not significant.  No change was seen in the ratio from day 50 
to day 96.  The increase in the ratio from day 96 to day 128 resulted in the ratio on day 
128 being significantly greater than the ratio on day 0 (P<.0001), day 50 (P=.001), day 
64 (P=.001), day 82 (P=.003), and day 96 (P=.01).  The two treatment groups did not 
vary significantly from each other in normalized lateral to palmar RBAE ratio at site 1. 
 
Site 2 
The day affects on the ratio of lateral to palmar RBAE at site 2 were significant 
(P<.0001), but no treatment affects or day*treatment interaction were seen (Figure 52, 
Tables A-13 and B-51).  An increase in the ratio from day 0 to day 32 was significant 
(P=.001), as was an increase in the ratio from day 96 to day 128 (P=.003).  The increase 
in the ratio was similar between the two treatment groups. 
The data were normalized to day 0 values to more closely evaluate changes over time 
in the lateral to palmar RBAE ratio at site 2 (Figure 53, Tables A-14 and B-52).  The 
normalized data were subjected to statistical analysis.  There was not a treatment effect 
or a day*treatment interaction.  There was a significant day effect (P<.0001).  A 
significant gain in the ratio occurred from day 0 to day 32 (P=.001), no change in the 
ratio occurred from day 32 to day 96, and another significant gain in the ratio occurred 
from day 96 to day 128 (P=.003).  The two treatment groups did not vary significantly 
from each other in the normalized lateral to palmar RBAE ratio at site 2 on any of the 
measured days. 
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Figure 52. Ratio of lateral to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 2.
xyz
 Days not sharing the same superscript differ (P.05).
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Figure 53. Normalized ratio of lateral to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 2.
xyz
 Days not sharing the same superscript differ (P.05).
-0.0500
0.0000
0.0500
0.1000
0.1500
0.2000
0 32 50 64 82 96 128
Day of study
C
ha
n
ge
 
in
 
ra
tio
 
o
f l
a
te
ra
l t
o
 
pa
lm
a
r 
R
BA
E 
(m
m
 
A
l)
site 2, Con
site 2, eST
x                                     y                xy               y                y                y                                     z
 
 
 
  
68 
Site 3 
There was a significant day effect on the ratio of lateral to palmar RBAE at site 3 
(P<.0001) but there was not a treatment effect or a day*treatment interaction (Figure 54, 
Tables A-13 and B-53).  The lateral to palmar ratio increased significantly from day 0 to 
day 32 (P=.002).  From day 32 to day 50 the ratio had a non-statistical decrease.  No 
change was seen in the ratio from day 50 to day 96.  There was a significant increase in 
the lateral to palmar ratio from day 96 to day 128 (P=.0006).  The ratio on day 128 was 
also significantly greater than the ratio on day 0 (P<.0001), day 32 (P=.007), day 50 
(P<.0001), day 64 (P<.0001), and day 82 (P=.0002).  The pattern of change in the lateral 
to palmar RBAE ratio did not differ between the two treatment groups. 
 
 
Figure 54. Ratio of lateral to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 3.
xyz
 Days not sharing the same superscript differ (P.05).
1.1500
1.2000
1.2500
1.3000
1.3500
1.4000
1.4500
1.5000
1.5500
0 32 50 64 82 96 128
Day of study
R
a
tio
 
o
f l
a
te
ra
l t
o
 
pa
lm
a
r 
R
BA
E 
(m
m
 
A
l) site 3, Con
site 3, eST
x                                    y                 xy              xy                y                y                                    z
 
 
 
Lateral to plamar RBAE ratio data from site 3 were normalized to day 0 values and 
statistics were re-run to evaluate changes in the ratio over time (Figure 55, Tables A-14 
and B-54).  Day significantly affected the ratio (P<.0001), but the ratio was not affected 
by treatment or by any day*treatment interaction.  The ratio had a significant gain from 
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day 0 to day 32 (P=.003), no change from day 32 to day 96, and a significant gain from 
day 96 to day 128 (P=.0007).  The two treatment groups were not significantly different 
from each other on any of the measured days. 
 
 
Figure 55. Normalized ratio of lateral to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 3.
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 Days not sharing the same superscript differ (P.05).
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Site 4 
There were no affects on the ratio of lateral to palmar RBAE at site 4 due to treatment 
or to day*treatment interaction, but there was a significant day effect (P<.0001) (Figure 
56, Tables A-13 and B-55).  Similar to what was seen at site1 (Figure 50), site 2 (Figure 
52), and site 3 (Figure 54), a significant increase in the ratio of lateral to palmar RBAE 
occurred from day 0 to day 32 (P=.002), followed by a non-significant decrease from day 
32 to day 50, no change from day 50 to day 96, and a significant increase from day 96 to 
day 128 (P=.0005).  The ratio of lateral to plamar RBAE on day 128 was significantly 
greater than the ratio on day 0 (P<.0001), day 32 (P=.005), day 50 (P<.0001), day 64 
(P=.0001), and day 82 (P<.0001).  No statistical difference was seen between the two 
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treatment groups in the pattern of change in the lateral to palmar ratio of RBAE at site 4 
over the course of the project. 
 
 
Figure 56. Ratio of lateral to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 4.
xyz
 Days not sharing the same superscript differ (P.05).
1.0500
1.1000
1.1500
1.2000
1.2500
1.3000
1.3500
1.4000
1.4500
0 32 50 64 82 96 128
Day of study
R
a
tio
 
o
f l
a
te
ra
l t
o
 
pa
lm
a
r 
R
B
A
E 
(m
m
 
A
l) site 4, Con
site 4, eST
x                                    y                 xy              xy               xy               y                                    z
 
 
 
The lateral to palmar RBAE ratios at site 4 data were normalized to day 0 values and 
statistically analyzed (Figure 57, Tables A-14 and B-56).  The day effects were 
significant (P<.0001) but no treatment effects or day*treatment interaction occurred.  
Similarly to what was seen in the normalized lateral to palmar RBAE ratio data from site 
1 (Figure 51), site 2 (Figure 53) and site 3 (Figure 55), there was a significant gain in the 
ratio from day 0 to day 32 (P=.004), no change from day 32 to day 96, and another 
significant gain in the ratio from day 96 to day 128 (P=.0006).  The two treatment groups 
did not statistically differ from each other on any given day.  There was a non-statistical 
pattern for the eST group to have a greater normalized lateral to palmar ratio than the 
Con group on day 50, day 64, day 82, and day 96.  A greater gain in the Con group in the 
ratio from day 96 to day 128 than in the eST group resulted in the two treatment groups 
being nearly identical in the total change in the lateral to palmar RBAE ratio by day 128. 
  
71 
Figure 57. Normalized ratio of lateral to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 4.
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 Days not sharing the same superscript differ (P.05).
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Ratio of Medial to Lateral RBAE 
Site 1 
The ratio of medial to lateral RBAE at site 1 was significantly affected by day 
(P=.001), but was not affected by treatment or by day*treatment interaction (Figure 58, 
Tables A-15 and B-57).  The ratio increased significantly from day 0 to day 50 (P=.002).  
No real change in the ratio occurred between day 50 and day 64.  A non-significant 
increase in the medial to lateral ratio of RBAE took place between day 64 and day 82. 
There was a decrease in the ratio from day 82 to the end of the trial.  The medial to 
lateral RBAE ratio on day 82 was significantly greater than on day 0 (P<.0001), day 32 
(P=.003), or day 128 (P=.04).  The ratio was non-statistically greater in the Con group on 
day 0 than in the eST group.  This changed by day 32.  No difference was seen between 
the two groups on day 96.  The medial to lateral ratio of RBAE was non-significantly 
greater in the eST group than in the Con group on day 128, a reverse of what was seen on 
day 0. 
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Figure 58. Ratio of medial to lateral radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 1.
xyz
 Days not sharing the same superscript differ (P.05).
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The data were normalized to day 0 values to better visualize changes in the medial to 
lateral RBAE ratio at site 1 over time (Figure 59, Tables A-16 and B-58).  Day 
significantly affected the ratio (P=.0008) but treatment did not significantly affect the 
ratio (P=.101) nor did any day*treatment interaction.  There was a significant gain in the 
ratio from day 0 to day 50 (P=.002).  Day 50 values were also significantly greater than 
those on day 32 (P=.05).  There was no change in the ratio from day 50 to day 64.  The 
ratio increased non-significantly from day 64 to day 82.  The ratio decreased significantly 
from day 82 to day 128 (P=.03), but on day 128 the ratio was still significantly greater 
than on day 0 (P=.03).  From day 0 to day 32, the eST group of horses had a trend to 
increase the normalized medial to lateral RBAE ratio (P=.08).  The increase continued to 
day 50, and resulted in the ratio becoming significantly greater than day 0 by day 50 
(P=.002) in the eST group of horses.  The Con group of horses did not have a change in 
the normalized medial to lateral RBAE ratio from day 0 to day 32.  This group did have a 
non-significant increase in the ratio from day 32 to day 50.  The difference seen in the 
normalized ratio between the two groups on day 32 continued throughout the trial, and 
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by day 128 there was a trend for the eST group to have a greater increase in the medial to 
lateral RBAE ratio than the Con group (P=.09). 
 
 
Figure 59. Normailzed ratio of medial to lateral radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 1.
a
 Trend for treatments to differ (P.10).
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Site 2 
The ratio of medial to lateral RBAE at site 2 was significantly affected by day 
(P=.02), but not by treatment or by a day*treatment interaction (Figure 60, Tables A-15 
and B-59).  The ratio increased slightly from day 0 to day 32, and increased significantly 
from day 32 to day 50 (P=.02).  The ratio on day 50 was also significantly greater than on 
day 0 (P=.005) and day 128 (P=.04).  No real change in the ratio occurred from day 50 to 
day 82.  The ratio of medial to lateral RBAE at site 2 decreased from day 82 to day 128 
(P=.05).  No real change was observed between the two treatment groups, though the 
slightly greater ratio seen in the Con group on day 0 was reversed by day 128, with a 
slightly greater ratio in the eST group than the Con group on that day. 
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Figure 60. Ratio of medial to lateral radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 2.
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 Days not sharing the same superscript differ (P.05).
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Treatment effects were not significant, nor was there a day*treatment interaction, but 
day effects were significant (P=.02) when the medial to lateral RBAE ratio data were 
normalized to day 0 (Figure 61, Tables A-16 and B-60).  The non-significant gain in the 
ratio from day 0 to day 32 increased from day 32 to day 50.  Day 50 medial to lateral 
RBAE ratio at site 2 was larger than that seen on any other day and was significantly 
greater than the same ratio on day 0 (P=.004), day 32 (P=.02) and day 128 (P=.03).  
There was no significant difference in the ratio from day 50 to day 96.  A decrease in the 
ratio from day 96 to day 128 was not significant.  The ratio on day 128 was significantly 
less than on day 50 (P=.03) and day 82 (P=.04), but was not statistically different than 
the ratio on any of the other days that were sampled.  The eST treatment group did gain 
in the ratio from day 0 to day 32 while the Con group remained unchanged during that 
same time.  However, the two groups did not significantly vary from each other on any 
day and had a similar pattern of change in the normalized RBAE ratio over the course of 
the research project. 
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Figure 61. Normailzed ratio of medial to lateral radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 2.
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Site 3 
Day effects were significant (P=.02), but treatment effects and day*treatment 
interaction were not observed to affect the medial to lateral RBAE ratio at site 3 (Figure 
62, Tables A-15 and B-61).  The ratio increased significantly from day 0 to day 50 
(P=.005), decreased slightly from day 50 to day 82, and decreased significantly from day 
82 to day 128 (P=.04).  Day 128 medial to lateral ratio of RBAE was not different from 
the same ratio on day 0.  No difference was noted in the two treatment groups until day 
64.  The day 64 ratio of medial to lateral RBAE decreased in the Con group and 
remained unchanged in the eST group, though this difference was not statistically 
important.   
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Figure 62. Ratio of medial to lateral radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 3.
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 Days not sharing the same superscript differ (P.05).
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Figure 63. Normalized ratio of medial to lateral radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 3.
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 Days not sharing the same superscript differ (P.05).
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Data were normalized to better observe any changes over time in the medial to lateral 
RBAE ratio at site 3 (Figure 63, Tables A-16 and B-62).  Day effects were significant 
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(P=.02).  There were no effects due to treatment or due to any day*treatment interaction.  
The ratio did not change from day 0 to day 32, but increased significantly from day 32 to 
day 50 (P=.01).  No statistical change in the ratio occurred from day 50 to day 82.  There 
was a significant decrease in the medial to lateral RBAE ratio from day 82 to day 128 
(P=.03).  The ratio on day 128 was not significantly different from on day 0.  The two 
treatment groups did not statistically differ from each other on any of the sample days, 
however the Con group did have a decrease in the ratio on day 64 that did not occur in 
the eST group. 
 
Site 4 
There was not a day*treatment interaction or a treatment effect on the ratio of medial 
to lateral RBAE at site 4 (Figure 64, Tables A-15 and B-63), but there was a significant 
day effect (P=.05).  The ratio increased significantly from day 0 to day 50 (P=.05).  The 
ratio decreased from day 50 to day 64, and increased from day 64 to day 82, but neither 
change was significant.  The medial to lateral ratio decreased significantly from day 82 to 
day 128 (P=.007).  The ratio on day 128 was below the ratio on day 0, though the two 
were not statistically different.  No differences were appreciated between the two 
treatment groups. 
The data from the medial to lateral RBAE ratio at site 4 were normalized to day 0 and 
re-evaluted (Figure 65, Tables A-16 and B-64).  Day effects were significant (P=.03), but 
there were still no treatment effects or day*treatment interaction.  The ratio increased 
significantly from day 0 to day 50 (P=.04), with most of the increase occurring between 
day 32 and day 50.  The ratio decreased non-significantly from day 50 to day 64, and 
increased non-significantly from day 64 to day 82.  The ratio decreased significantly 
from day 82 to day 128 (P=.005).  The ratio on day 128 was less than the ratio was on 
day 0, but the difference between the ratio on day 0 and day 128 was not significant.  The 
pattern of change was not different between the two treatment groups. 
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Figure 64. Ratio of medial to lateral radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 4.
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Figure 65. Normalized ratio of medial to lateral radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 4.
yz
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Ratio of Medial to Palmar RBAE 
Site 1 
Day significantly affected the ratio of medial to lateral RBAE at site 1 (P<.0001), but 
treatment did not affect the ratio, nor did day*treatment interaction (Figure 66, Tables A-
17 and B-65).  The ratio increased significantly from day 0 to day 32 (P<.0001), 
increased non-significantly from day 32 to day 96, and once again increased significantly 
from day 96 to day 128 (P=.03).  No differences were seen between the two treatment 
groups. 
 
 
Figure 66. Ratio of medial to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 1.
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The data were normalized to day 0 to better evaluate changes in the medial to palmar 
RBAE ratio at site 1 over time (Figure 67, Tables A-18 and B-66).  Day effects were 
significant (P<.0001), but there were no significant effects due to treatment or to 
day*treatment interaction.  There was a significant increase in the ratio from day 0 to day 
32 (P<.0001), no change from day 32 to day 96, and a second significant increase in the 
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ratio from day 96 to day 128 (P=.03).  The Con group had a non-significant decrease in 
the ratio from day 32 to day 50.  In contrast, the eST group had a non-significant increase 
in the ratio from day 32 to day 50.  Though never significant, the difference in gain in the 
medial to palmar RBAE ratio that occurred between the two treatment groups as a result 
of the difference in gain from day 32 to day 50 continued through the end of the trial, 
with a greater increase in the ratio in the eST group than in the Con group. 
 
 
Figure 67. Normalized ratio of medial to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 1.
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Site 2 
The ratio of medial to palmar RBAE at site 2 was significantly affected by day 
(P<.0001), but not by treatment or by day*treatment interaction (Figure 68, Tables A-17 
and B-67).  The pattern of change in the medial to palmar RBAE ratio at site 2 was the 
similar to that seen at site 1 (Figure 66).  A significant increase in the ratio occurred from 
day 0 to day 32 (P<.0001), no real change in the ratio occurred from day 32 to day 96, 
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and a second significant increase in the ratio was seen from day 96 to day 128 (P=.02).  
No difference in the ratio was seen between the two treatment groups at site 2. 
 
 
Figure 68. Ratio of medial to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 2.
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 Days not sharing the same superscript differ (P.05).
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The medial to palmar RBAE ratio data from site 2 were normalized to day 0 and 
statistical analysis were run on the normalized data (Figure 69, Tables A-18 and B-68).  
Treatment effects were not significant, nor was there a day*treatment interaction.  Day 
effects were significant (P<.0001).  An increase in the normalized medial to palmar 
RBAE ratio from day 0 to day 32 was significant (P<.0001).  There was no change in the 
ratio from day 32 to day 96, and then a significant increase in the ratio from day 96 to 
day 128 (P=.02).  There was not a significant difference between the two treatment 
groups though the eST group had an increase in the ratio from day 32 to day 50 that was 
not seen in the control group.  The resulting greater increase in the ratio in the eST group 
than in the Con group continued through day 128 but never reached statistical 
importance. 
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Figure 69. Normalized ratio of medial to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 2.
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Site 3 
The ratio of medial to palmar RBAE at site 3 was significantly affected by day 
(P<.0001), but was not affected by treatment, nor by a day*treatment interaction (Figure 
70, Tables A-17 and B-69).  The pattern of change in the ratio was similar to that seen at 
site 1 (Figure 66) and site 2 (Figure 68).  There was an increase in the medial to palmar 
ratio from day 0 to day 32 (P<.0001).  No statistical change in the ratio occurred from 
day 32 to day 96.  The ratio increased significantly from day 96 to day 128 (P=.007).  
The two treatment groups had the same pattern of change in the ratio of medial to palmar 
RBAE at site 3. 
Data from the ratio of medial to palmar RBAE at site 3 were compared to day 0 
values and the resulting normalized data were subjected to statistical analysis (Figure 71, 
Tables A-18 and B-70).  Day effects were significant (P<.0001), but treatment effects 
were not significant, nor was there a day*treatment interaction.  An increase in the ratio 
from day 0 to day 32 was significant (P<.0001), as was an increase in the ratio from day 
96 to day 128 (P=.008).  There was no significant difference in the ratio from day 32 to 
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day 96.  There was no significant difference between the two treatment groups on any of 
the observed days. 
 
 
Figure 70. Ratio of medial to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 3.
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Figure 71. Normalized ratio of medial to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 3.
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Site 4 
Day effects on the ratio of medial to palmar RBAE at site 4 were significant 
(P<.0001) but treatment effects were not significant, nor was there a day*treatment 
interaction (Figure 72, Tables A-17 and B-71).  The overall pattern of increase in the 
medial to palmar RBAE ratio was similar to that seen at site 1 (Figure 66), site 2 (Figure 
68) and site 3 (Figure 70).  There was an increase in the ratio from day 0 to day 32 
(P=.0004).  There was not a significant change in the ratio from day 32 to day 96.  There 
was a significant increase in the ratio from day 96 to day 128 (P=.002).  There was no 
statistical difference between the two treatment groups in the medial to palmar RBAE 
ratio at site 4.  There was, however, a decrease in the ratio on day 64 in the Con group 
that did not occur in the eST group.   
 
 
Figure 72. Ratio of medial to palmar radiographic bone aluminum equivalence (RBAE) (mm Al) 
at site 4.
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Figure 73. Normalized ratio of medial to palmar radiographic bone aluminum equivalence 
(RBAE) (mm Al) at site 4.
a
 Trend for treatments to differ (P.10).
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The medial to palmar RBAE ratio data from site 4 were normalized to day 0 values 
and statistics were re-run (Figure 73, Tables A-18 and B-72).  Day had significant affects 
on the ratio (P<.0001), but treatment did not have an affect on the ratio, nor did 
day*treatment interaction.  The normalized medial to lateral ratio at site 4 increased 
significantly from day 0 to day 32 (P=.0005), did not change from day 32 to day 96, and 
increased significantly from day 96 to day 128 (P=.005).  The two treatment groups 
began to differ from each other, though not statistically, on day 32.  The eST group had a 
greater increase in the ratio from day 0 to day 32 than did the Con group.  From day 32 to 
day 82, the eST group continued to increase the normalized medial to palmar ratio, 
though not significantly.  From day 32 to day 64, the Con group, in direct contrast, had a 
non-significant decrease in the ratio.  By day 64, the difference in the ratio between the 
two treatment groups had a trend to differ (P=.08).  The Con group had a non-significant 
increase in the ratio from day 64 to day 82.  Both treatment groups had a non-significant 
decrease in the ratio from day 82 to day 96.  The decrease from day 82 to day 96 was 
greater in the Con group than in the eST group, causing a trend for the two groups to 
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differ on day 96 (P=.100).  There was no statistical difference between the two treatment 
groups on day 128. 
 
Dorsal Cortical Bone Width Micrometer Readings 
Site 1 
There was a significant day effect (P<.0001) and a significant day*treatment 
interaction (P=.03), but not a significant treatment effect on the dorsal cortical bone 
width micrometer readings at site 1 (Figure 74, Tables A-19 and B-73).  There was a 
non-significant increase in the width of the dorsal cortical bone from day 0 to day 64, 
and a significant increase in the width from day 64 to day 128 (P<.0001).  The eST group 
of horses started the trial with a dorsal cortical bone at site 1 that was less thick than the 
dorsal cortical bone in the Con group of horses, and this continued through day 64.  
From day 64 to day 128 the eST group had a greater gain in the thickness of the dorsal 
cortical bone than did the Con group.  Though the difference between the two groups 
was not significant, the greater gain in the eST group allowed that group to finish the 
trial with greater dorsal cortical bone thickness than did the Con group. 
The data from the micrometer readings of the dorsal cortical bone width at site 1 were 
normalized to day 0 and re-evaluated to better observe the changes in the bone width 
over time (Figure 75, Tables A-20 and B-74).  There was a significant day effect 
(P<.0001) and a significant day*treatment interaction (P=.03), but not a significant 
treatment effect on the normalized dorsal cortical bone micrometer readings at site 1.  
There was a non-significant increase in the width of the dorsal cortical bone from day 0 
to day 64, and a significant increase in the width from day 64 to day 128 (P<.0001).  
There was no difference between the two treatment groups on day 64.  The eST group 
had a significant increase in the micrometer reading from day 64 to day 128 (P<.0001), 
while the Con group had a trend for an increase in the micrometer reading to be 
significant during the same time period (P=.09).  This resulted in a significantly greater 
increase in the dorsal cortical width in the eST group of horses as compared to the Con 
group of horses on day 128 (P=.003). 
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Figure 74. Dorsal cortical bone width in mm, at site 1, vs day of study.
yz
 Days not sharing the same superscript differ (P.01).
10.0000
10.5000
11.0000
11.5000
12.0000
12.5000
13.0000
13.5000
14.0000
14.5000
15.0000
0 64 128
Day of study
D
o
rs
a
l c
o
rt
ica
l b
o
n
e 
w
id
th
, 
m
m
site 1, Con
site 1, eST
y y z
 
 
 
Figure 75. Change in dorsal cortical bone width in mm, at site 1, vs day of study.
a
 Treatments differ (P.01).
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Site 2 
The dorsal cortical bone width at site 2 was significantly affected by day (P<.0001), 
and by a day*treatment interaction (P=.02), but not by treatment (Figure 76, Tables A-19 
and B-75).  No significant difference in the dorsal cortical bone width occurred from day 
0 to day 64.  There was a significant increase in the dorsal bone width from day 64 to day 
128 (P<.0001).  The Con group started the project with a non-statistical greater dorsal 
cortical bone width than the eST group, and this continued to day 64.  Between day 64 
and day 128 this pattern was reversed, with a greater, but not statistically different, dorsal 
cortical bone thickness at site 2 in the eST group on day 128 than in the Con group.   
 
 
Figure 76. Dorsal cortical bone width in mm, at site 2, vs day of study.
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The data of the dorsal cortical bone width at site 2 were adjusted to remove day 0 
values from the values at day 64 and day 128 (Figure 77, Tables A-20 and B-76).  When 
the resulting data were evaluated significant effects were seen due to day (P<.0001) and 
due to day*treatment interaction (P=.09).  A trend for a treatment effect was also seen 
(P=.09).  An increase in dorsal cortical bone width at site 2 was not significant from day 
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0 to day 64, but was significant (P<.0001) from day 64 to day 128.  The treatments did 
not differ from each other on day 64 but did differ from each other on day 128 (P=.002) 
due to a greater increase in dorsal cortical bone width in the eST group than in the Con 
group from day 64 to day 128. 
 
 
Figure 77. Change in dorsal cortical bone width in mm, at site 2, vs day of study.
a
 Treatments differ (P.05).
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Site 3 
There were significant day effects (P<.0001) and a day*treatment interaction (P=.03), 
but no significant treatment effects on the dorsal cortical bone width at site 3 (Figure 78, 
Tables A-19 and B-77).  There was a gain in the cortical bone width in the dorsal cortex 
at site 3 that reached significance from day 64 to day 128 (P<.0001).  The increase from 
day 64 to day 128 was greater in the eST group of horses than in the Con group of 
horses, though this difference was not significant.   
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Figure 78. Dorsal cortical bone width in mm, at site 3, vs day of study.
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Figure 79. Change in dorsal cortical bone width in mm, at site 3, vs day of study.
a
 Treatments differ (P.01).
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The data were normalized to better evaluate any significant changes between the two 
treatment groups in dorsal cortical bone width at site 3 over time (Figure 79, Tables A-20 
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and B-78).   Statistical ananlysis showed significant effects due to day (P<.0001), and 
due to a day*treatment interaction (P=.03), but not due to treatment.  There was an 
increase in the normalized dorsal cortical bone width that became significant from day 
64 to day 128 (P<.0001).  The two treatment groups did not differ from each other until 
after day 64.  From day 64 to day 128, the eST group of horses had a greater gain in 
dorsal cortical bone width at site 3 than did the Con group, thus the two groups differed 
from each other on day 128 (P=.004).   
 
Site 4 
There were no treatment effects or day*treatment interactions that affected the dorsal 
cortical bone width at site 4, but day effects were significant (P<.0001) (Figure 80, 
Tables A-19 and B-79).  There were no significant changes in cortical width from day 0 
to day 64.  Between day 64 and day 128 a significant (P<.0001) increase in the dorsal 
cortical width occurred.  No statistical difference occurred between the two treatment 
groups in the dorsal cortical width over the course of the experiment. 
 
 
Figure 80. Dorsal cortical bone width in mm, at site 4, vs day of study.
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The dorsal cortical width data from site 4 were normalized to day 0 values and re-
evaluated (Figure 81, Tables A-20 and B-80).  Day effects were significant (P<.0001), 
but there was not a treatment effect or a day*treatment interaction.  The non-significant 
increase in dorsal cortical bone width from day 0 to day 64 increased in magnitude and 
was significant (P<.0001) from day 64 to day 128.  The two treatment groups did not 
differ from each other on day 64.  A greater increase in dorsal cortical bone width at site 
4 in the eST group than in the Con group from day 64 to day 128 caused the two 
treatments to have a trend to differ from each other on day 128 (P=.08). 
 
 
Figure 81. Change in dorsal cortical bone width in mm, at site 4, vs day of study.
a
 Trend for treatments to differ (P.10).
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Lateral Cortical Bone Width Micrometer Readings 
Site 1 
There were no significant effects on the lateral cortical bone width at site 1 due to 
treatment, day, or day*treatment interaction (Figure 82, Tables A-21 and B-81).  No 
significant changes occurred in the width of the lateral cortical cortex at site 1 over the 
course of the trial, though there was a trend for the increase from day 0 to day 64 to be 
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important (P=.06).  There was no change over the experiment in the lateral cortical width 
at site 1 in the eST group of horses.  The Con group of horses, however, had a trend for 
the increase in lateral cortical bone width from day 0 to day 64 to be significant (P=.07).   
 
 
Figure 82. Lateral cortical bone width in mm, at site 1, vs day of study.
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The data from the lateral cortical bone width at site 1 were normalized to day 0 values 
to better evaluate changes over time and statistical analysis was re-run (Figure 83, Tables 
A-22 and B-81).  Once again, at site 1 there was not a treatment, day, or day*treatment 
interaction that significantly affected the lateral cortical bone width during this project.  
There was a trend for an increase in cortical width from day 0 to day 64 (P=.06) due to a 
non-statistical (P=.07) increase in the lateral cortex of the Con group of horses.  There 
were no significant changes in the lateral cortical bone width of eST group of horses 
during the research project. 
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Figure 83. Change in lateral cortical bone width in mm, at site 1, vs day of study.
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Site 2 
The lateral cortical bone width at site 2 was significantly affected by day (P=.04), but 
not by treatment or by any day*treatment interaction (Figure 84, Tables A-21 and B-83).  
The day 64 measured cortical width was significantly greater than that measured on day 
0 (P=.02) and on day 128 (P=.05).  The Con group of horses started the trial with a non-
significantly greater width of the lateral cortex at site 2 than the eST group of horses, and 
this continued through day 128. 
The data from the lateral cortical bone width at site 2 were normalized by subtracting 
the day 0 values from each measurement to better evaluate changes in the bone width 
over the course of the experiment.  The resulting normalized data were statistically 
analysed (Figure 85, Tables A-22 and B-84).  The normalized lateral cortical bone width 
at site 2 was significantly affected by day (P=.04), but not by treatment or by a 
day*treatment interaction.  There was a significant increase in the width of the lateral 
cortex from day 0 to day 64 (P=.02), followed by a significant decrease from day 64 to 
day 128 (P=.05).  From day 64 to day 128, the eST group of horses had a greater 
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decrease in the width of the lateral cortical bone than did the Con group of horses, but 
this difference was not of statistical importance. 
 
 
Figure 84. Lateral cortical bone width in mm, at site 2, vs day of study.
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Figure 85. Change in lateral cortical bone width in mm, at site 2, vs day of study.
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 Days not sharing the same superscript differ (P.05).
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Site 3 
There was a trend for day effects (P=.07), but no treatment or day*treatment 
interaction that affected the lateral cortical bone width at site 3 (Figure 86, Tables A-21 
and B-85).  There was a significant increase in the width of the lateral cortex at site 3 
from day 0 to day 64 (P=.03) followed by a trend for a decrease in the cortical width 
from day 64 to day 128 (P=.07).  On day 0 the Con group had a non-statistically greater 
width in the lateral cortical bone at site 3 than did the eST group.  This was gone by day 
128. 
 
 
Figure 86. Lateral cortical bone width in mm, at site 3, vs day of study.
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The data from the lateral cortical bone width at site 3 were normalized to day 0 values 
and re-evaluated (Figure 87, Tables A-22 and B-86).  There was a trend for day affects 
(P=.07), but no treatment or day*treatment affects on the width of the lateral cortex at 
site 3.  The width of the lateral cortical bone increased significantly (P=.03) from day 0 
to day 64, and then had a trend to decrease (P=.07) from day 64 to day 128.  The change 
in the lateral cortical width was the same in both the treatment groups through day 64, 
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but the Con group had a greater loss in lateral cortical width at site 3 from day 64 to day 
128 than did the eST group.  Thus, there was a trend (P=.09) for the eST group to have a 
greater increase in lateral cortical bone on day 128 than did the Con group. 
 
 
Figure 87. Change in lateral cortical bone width in mm, at site 3, vs day of study.
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Site 4 
There were no treatment, day, or day*treatment effects on the lateral cortical bone 
width at site 4 (Figure 88, Tables A-21 and B-87).  No significant differences in the 
width of the lateral cortex at site 4 occurred during the research trial.  The Con group of 
horses did start the project with a non-significantly greater width of the lateral cortex 
than the eST group, and this difference increased, but did not reach significance during 
the duration of the experiment.   
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Figure 88. Lateral cortical bone width in mm, at site 4, vs day of study.
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Figure 89. Change in lateral cortical bone width in mm, at site 4, vs day of study.
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The data from the lateral cortical bone width at site 4 were normalized to day 0 and 
re-evaluated to more closely evaluate any changes that may have occurred between the 
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two treatment groups over the course of the project (Figure 89, Tables A-22 and B-88).  
There were no effects of day or treatment, nor where there any day*treatment interaction 
affects, on the changes in the width of the lateral cortical bone at site 4.  There were no 
significant differences between the two treatment groups, but there was a pattern for the 
change in lateral cortical bone width to vary between the two treatment groups during the 
last half of the trial.  From day 64 to day 128, the Con group of horses had an increase in 
the width of the lateral cortex, which is in direct contrast to the decrease in the width of 
the lateral cortex seen in the eST group of horses during this same time period. 
 
Medial Cortical Bone Width Micrometer Readings 
Site 1 
There were significant day effects (P=.02), but no treatment effects nor any 
day*treatment interaction on the medial cortical bone width at site 1 (Figure 90, Tables 
A-23 and B-89).  The width of the medial cortex at site 1 did not change from day 0 to 
day 64, but did increase significantly (P=.008) from day 64 to day 128.  The Con group 
started the project with a non-significant greater width of the medial cortex than did the 
eST group, and this difference was still present on day 64.  From day 64 to day 128, the 
Con group had no change in the medial cortical width at site 1, while in contrast, the eST 
group had a significant (P=.004) increase in the medial cortical width.   
The data from the medial cortical bone width at site 1 were normalized to day 0 
values and statistics were re-run (Figure 91, Tables A-24 and B-90).  Day significantly 
(P=.02) effected the change in the width of the medial cortex at site 1, but treatment did 
not, nor was there a day*treatment interaction.  There was no change in the medial bone 
width from day 0 to day 64, but a significant increase in the medial bone width occurred 
from day 64 to day 128 (P=.02).  The two treatment groups had a trend to differ from 
each other by day 128 (P=.100) due to a greater increase in the width of the medial 
cortical bone from day 64 to day 128 in the eST group than in the Con group.  On day 
128 the change in the width of the medial cortex in the eST group was significantly 
greater than that on day 0 (P=.004) and day 64 (P=.004), while the Con group did not 
change significantly during the course of the project. 
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Figure 90. Medial cortical bone width in mm, at site 1, vs day of study.
yz
 Days not sharing the same superscript differ (P.05).
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Figure 91. Change in medial cortical bone width in mm, at site 1, vs day of study.
a
 Trend for treatments to differ (P.10).
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 Days not sharing the same superscript differ (P.05).
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Site 2 
The medial cortical bone width at site 2 was significantly affected by day (P=.002), 
but was not affected by treatment or by any day*treatment interaction (Figure 92, Tables 
A-23 and B-91).  The medial cortical bone width did not change from day 0 to day 64, 
then increased significantly (P=.008) from day 64 to day 128.  The Con group of horses 
had a non-statistically greater width of the medial cortex at site 2 than did the eST group 
of horses that was present on day 0 and continued through the end of the trial on day 128.  
The Con group of horses had a non-statistical gain in the width of the medial cortex from 
day 0 to day 64, and from day 64 to day 128, with a significant increase in the width of 
the medial cortex from day 0 to day 128 (P=.05).  The eST group of horses had a non-
statistical gain in the width of the medial cortex from day 0 to day 64, and a signficant 
gain from day 64 to day 128 (P=.01).   
 
 
Figure 92. Medial cortical bone width in mm, at site 2, vs day of study.
yz
 Days not sharing the same superscript differ (P.01).
11.0000
11.5000
12.0000
12.5000
13.0000
13.5000
14.0000
0 64 128
Day of study
M
ed
ia
l c
o
rt
ica
l b
o
n
e 
w
id
th
, 
m
m
site 2, Con
site 2, eST
y y z
 
 
 
Data from the medial cortical bone width at site 2 were normalized to day 0 values 
and re-evaluated to better examine any differences in the changes in the bone width over 
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the course of the experiment (Figure 93, Tables A-24 and B-92).  Changes in the medial 
cortical bone width were significantly affected by day (P=.002), but not by treatment or 
by a day*treatment interaction.  There was no significant change in the medial cortical 
bone width at site 2 from day 0 to day 64.  There was a significant increase in the width 
of the medial cortex from day 64 to day 128 (P=.008).  The eST group did have a greater 
gain in cortical bone width than the Con group from day 64 to day 128, but this 
difference was not significant. 
 
 
Figure 93. Change in medial cortical bone width in mm, at site 2, vs day of study.
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 Days not sharing the same superscript differ (P.05).
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Site 3 
Medial cortical bone width at site 3 was not affected by treatment or by day*treatment 
interaction, but was significantly (P=.02) affected by day (Figure 94, Tables A-23 and B-
93).  There was not any statistically important change in the medial cortical bone 
thickness at site 3 from day 0 to day 64.  A statistical gain in bone width in the medial 
cortex did occur between day 64 and day 128 (P=.04).  The Con group had a non-
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statistically greater width in the medial cortex than the eST group at the start of the 
project that continued to day 128. 
Figure 94. Medial cortical bone width in mm, at site 3, vs day of study.
yz
 Days not sharing the same superscript differ (P.05).
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To better evaluate the changes that occurred in the thickness of the medial cortex at 
site 3 over the course of the trial, these data were normalized to day 0 and re-evaluated 
(Figure 95, Tables A-24 and B-94).    
Day effects were significant (P=.02), but there was no affect on the medial cortical 
bone width at site 3 due to treatment or to any day*treatment interaction.  The medial 
cortical width did not change from day 0 to day 64, then increased significantly from day 
64 to day 128 (P=.04).  The pattern of change was different between the two treatment 
groups, though the two treatment groups did not differ significantly from each other on 
any given day.  The Con group had a small, non-significant, increase in the medial 
cortical width from day 0 to day 64, and then no real change in the width from day 64 to 
day 128.  The eST group, however, had a small, non-significant, decrease in the medial 
cortical width from day 0 to day 64, and then had a significant gain in the medial cortical 
width from day 64 to day 128 (P=.01). 
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Figure 95. Change in medial cortical bone width in mm, at site 3, vs day of study.
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 Days not sharing the same superscript differ (P.05).
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Site 4 
Medial cortical bone width at site 4 was not significantly affected by day, treatment, 
or by any day*treatment interaction (Figure 96, Tables A-23 and B-95).  There was a 
trend for day 128 to have a greater medial cortical bone width than day 0 (P=.100).  The 
two treatment groups did not differ significantly from each other on any given day, but 
there did appear to be a difference between the two groups.  The Con group had no 
change in the width of the medial cortex from day 0 to day 128.  The eST group had a 
significant increase in the width of the medial cortex from day 0 to day 128 (P=.01). 
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Figure 96. Medial cortical bone width in mm, at site 4, vs day of study.
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Figure 97. Change in medial cortical bone width in mm, at site 4, vs day of study.
a
 Treatments differ (P.05).
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Medial cortical bone width data from site 4 were normalized to day 0 and statistics 
were run on the resulting data (Figure 97, Tables A-24 and B-96).  There were no 
  
106 
significant effects on the change in medial cortical bone width at site 4 due to treatment, 
day, or to day*treatment interaction.  There were no significant overall changes in the 
medial cortical bone width, but there was a trend for day 128 to have a greater overall 
medial cortical bone width at site 4 than day 0 (P=.100).  The Con group of horses had a 
non-significant gain in the thickness of the medial cortex from day 0 to day 64 and a 
non-significant loss in the thickness of the medial cortex from day 64 to day 128, 
resulting in day 128 having a less thick medial cortex than day 0, though the two were 
not statistically different.  The eST group of horses had a continual gain in the thickness 
of the medial cortical bone at site 4, resulting in day 128 values that were significantly 
greater than those on day 0 (P=.01).  The eST group had a significantly greater gain in 
medial cortical bone width at site 4 on day 128 than did the Con group (P=.02). 
 
Palmar Cortical Bone Width Micrometer Readings 
Site 1 
There were no day effects, treatment effects, or any day*treatment interaction that 
significantly affected the palmar cortical bone width at site 1 (Figure 98, Tables A-25 
and B-97).  There were not any overall changes nor were there any significant 
differences between the two treatment groups in the palmar cortical bone width at site 1. 
Data from the palmar cortical bone width at site 1 were normalized to day 0 values 
and statistics were run on the resulting data to better observe any significant changes in 
the bone thickness at that site over the course of the experiment (Figure 99, Tables A-26 
and B-98).  There were still no significant treatment, day, or day*treatment effects on the 
palmar cortical bone width at site 1.  There were no significant differences between the 
two treatment groups, though there was a pattern for the Con group to have a decrease in 
the thickness of the palmar cortex at site 1 over the course of the trial, while the eST 
group gained in palmar cortical thickness during the same time period. 
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Figure 98. Palmar cortical bone width in mm, at site 1, vs day of study.
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Figure 99. Change in palmar cortical bone width in mm, at site 1, vs day of study.
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Site 2 
There were no significant affects on the palmar cortical bone width at site 2 due to 
day, treatment, or to any day*treatment interaction (Figure 100, Tables A-25 and B-99).  
The two treatments did not differ from each other statistically at this site. 
 
 
 
Figure 100. Palmar cortical bone width in mm, at site 2, vs day of study.
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The data from the palmar cortical bone width at site 2 were normalized to day 0 
values and the resulting data were analyzed statistically to determine if any treatment or 
day differences could be elicited in that manner (Figure 101, Tables A-26 and B-100).  
Once again, no treatment, day, or day*treatment effects were seen in the width of the 
palmar cortex at site 2.  No significant differences occurred between the two treatment 
groups. 
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Figure 101. Change in palmar cortical bone width in mm, at site 2, vs day of study.
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Site 3 
Palmar cortical bone width at site 3 was not significnatly affected by treatment, day, 
or day*treatment interaction (Figure 102, Tables A-25 and B-101).  The thickness of the 
palmar cortical bone at site 3 did not change significantly during the experiment.  The 
eST group had a non-significantly thinner palmar cortical wall on day 0 than did the Con 
group.  This had reversed by day 64, but all the differences between the two groups were 
well within normal deviations, and were not statistically important. 
Data from the palmar cortical bone width at site 3 were normalized to day 0 values 
and statistics were run on the resulting data (Figure 103, Tables A-26 and B-102).  
Similar to the raw data, the normalized data showed that there were no significant affects 
on any changes in the palmar cortical bone width at site 3 due to treatment, day, or 
day*treatment interaction.  The eST group did have a non-significant gain in the width of 
the palmar cortex from day 0 to day 64 while the Con group had a non-significant 
decrease in the width of the palmar cortex from day 0 to day 64, but the two treatment 
groups were not significantly different from each other on any of the days. 
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Figure 102. Palmar cortical bone width in mm, at site 3, vs day of study.
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Figure 103. Change in palmar cortical bone width in mm, at site 3, vs day of study.
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Site 4 
The palmar cortical bone width at site 4 was significantly affected by day, though not 
by treatment or by any day*treatment interaction (Figure 104, Tables A-25 and B-103).  
There was a gradual, continual gain in the width of the palmar cortical bone through the 
trial.  By day 128, the width of the palmar cortical bone at site 4 was significantly greater 
than it had been on day 0 (P<.0001) or on day 64 (P=.005).  Within the treatment groups, 
the Con group had no change in the thickness of the palmar cortex at site 4 from day 0 to 
day 64, then a trend for an increase in the thickness of the cortex from day 64 to day 128 
(P=.07), with the cortex on day 128 being significantly wider than it had been on day 0 
(P=.03).  The eST group had a more rapid increase in palmar cortical thickness, with a 
trend for significant increase from day 0 to day 64 (P=.07), a significant increase from 
day 64 to day 128 (P=.03), and day 128 values being greater than those seen on day 0 
(P=.0002).  The two treatment groups did not significantly differ from each other. 
 
 
Figure 104. Palmar cortical bone width in mm, at site 4, vs day of study.
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 Days not sharing the same superscript differ (P.01).
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Palmar cortical bone width at site 4 data were normalized to remove day 0 values and 
were then re-evaluated (Figure 105, Tables A-26 and B-104).  Day effects were 
significant (P=.0002), but treatment effects and day*treatment interaction were not 
statistically important.  There was a non-significant increase in the palmar cortical bone 
width at site 4 from day 0 to day 64 that reached significance from day 64 to day 128 
(P=.005).  The width of the palmar cortex at site 4 was significantly greater on day 128 
than on day 0 (P<.0001).  The two treatment groups did not statistically differ from each 
other.  The Con group of horses had no change in palmar cortical thickness from day 0 to 
day 64, a trend for an increase from day 64 to day 128 (P=.07), and a significant gain in 
cortical thickness from day 0 to day 128 (P=.03).  The eST group of horses had a more 
consistent increase in the palmar cortical thickness at site 4 that lasted the full course of 
the project, with the increase from day 0 to day 64 having a trend toward significance 
(P=.07), a significant increase from day 64 to day 128 (P=.03), and a significant gain in 
cortical width from day 0 to day 128 (P=.0002).   
 
 
Figure 105. Change in palmar cortical bone width in mm, at site 4, vs day of study.
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 Days not sharing the same superscript differ (P.01).
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Dorsal to Palmar Medullary Cavity Width Micrometer Readings 
Site 1 
The width of the medullary cavity in the dorsal to palmar direction at site 1 was 
significantly affected by day (P=.006), but not by treatment or by a day*treatment 
interaction (Figure 106, Tables A-27 and B-105).  The width of the medullary cavity 
decreased through the experiment.  The decrease that occurred from day 0 to day 64 was 
not significant, the decrease that occurred from day 64 to day 128 trended toward being 
significant (P=.08), and the overall decrease from day 0 to day 128 was significant 
(P=.001).  The decrease in medullary cavity width in the dorsal to palmar direction at site 
1 was not significant in the Con group of horses.  The eST group of horses, in contrast, 
had a decrease in the medullary cavity width in the dorsal to palmar direction at site 1 
that had a trend to be significant from day 0 to day 64 (P=.09), and was significant from 
day 64 to day 128 (P=.03) and from day 0 to day 128 (P=.0003).  The differences 
between the two treatment groups were not significant. 
 
 
Figure 106. Dorsal to palmar medullary cavity width in mm, at site 1, vs day of study.
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 Days not sharing the same superscript differ (P.01).
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Data from the width of the medullary cavity in the dorsal to palmar direction at site 1 
were normalized to remove day 0 values and better evaluate changes that occurred over 
the course of the trial (Figure 107, Tables A-28 and B-106).  Day effects were significant 
(P=.005), but treatment and day*treatment interaction did not affect the meduallary 
cavity width at this site.  There was an overall pattern of decrease in the width of the 
medullar cavity at this site that was not significant from day 0 to day 64, had a trend for 
significance from day 64 to day 128 (P=.08), and was significant from day 0 to day 128 
(P=.001).  The Con group of horses had a decrease in medullary cavity width that never 
did reach significance.  In contrast, the decrease in the medullary cavity width in the eST 
group of horses trended toward significance from day 0 to day 64 (P=.09), and was 
significant from day 64 to day 128 (P=.03) and from day 0 to day 128 (P=.0003).  The 
eST group of horses had a significantly greater decrease in the width of the medullary 
cavity than did the Con group of horses on day 128 (P=.02). 
 
 
Figure 107. Change in dorsal to palmar medullary cavity width in mm, at site 1, vs day of study.
a
 Treatments differ (P.05).
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 Days not sharing the same superscript differ (P.05).
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Site 2 
There were significant day effects (P=.0005), a trend for an effect due to 
day*treatment interaction (P=.07), and no significant treatment effect on the width of the 
dorsal to palmar medullary cavity at site 2 (Figure 108, Tables A-27 and B-107).  There 
was a decrease in the medullary cavity width that was significant from day 0 to day 128 
(P<.0001), day 0 to day 64 (P=.04, and day 64 to day 128 (P=.04).  The decrease in 
medullary width at site 2 in the Con group did not reach significance.  The decrease in 
medullary width at site 2 in the eST group was significant from day 0 to day 64 (P=.005), 
day 0 to day 128 (P<.0001), and trended toward significance from day 64 to day 128 
(P=.100).  The two treatment groups did not significantly differ from each other. 
 
 
Figure 108. Dorsal to palmar medullary cavity width in mm, at site 2, vs day of study.
xyz
 Days not sharing the same superscript differ (P.05).
11.0000
11.5000
12.0000
12.5000
13.0000
13.5000
14.0000
0 64 128
Day of study
D
o
rs
a
l t
o
 
pa
lm
a
r 
m
ed
u
lla
ry
 
ca
v
ity
 
w
id
th
, 
m
m
site 2, Con
site 2, eST
x y z
 
 
 
The data from the dorsal to palmar medullary cavity width at site 2 were normalized 
to remove day 0 values and to more closely examine the changes in the medullary width 
that occurred over the course of the research project (Figure 109, Tables A-28 and B-
108).  Treatment effects (P=.03) and day effects (P=.0005) were significant, and there 
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was a trend (P=.07) for day*treatment interaction to effect the change in the dorsal to 
palmar medial cavity width at site 2.  There was a significant decrease in the medullary 
cavity width from day 0 to day 64 (P=.04), day 64 to day 128 (P=.04), and day 0 to day 
128 (P<.0001).  The Con group had no significant change in the width of the medullary 
cavity during the experiment.  The eST group, in contrast, had a trend for a decrease 
from day 64 to day 128 (P=.100), and a significant decrease in the width of the medullar 
cavity at site 2 from day 0 to day 64 (P=.005), day 0 to day 128 (P<.0001).  The two 
treatment groups significantly differed from each other on day 64 (P=.02) and day 128 
(P=.01) due to the greater decrease in the dorsal to palmar medullary cavity width at site 
2 in the eST group as compared to the Con group. 
 
 
Figure 109. Change in dorsal to palmar medullary cavity width in mm, at site 2, vs day of study.
a
 Treatments differ (P.05).
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Site 3 
The dorsal to palmar medullary cavity width at site 3 was not significantly affected by 
day, treatment, or by day*treatment interaction (Figure 110, Tables A-27 and B-109).  
There was a decrease in the medullary cavity width at site 3 from day 0 to day 128 that 
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trended toward significance (P=.100).  The Con group had no change in the dorsal to 
palmar diameter of the medullary cavity at site 3 during this experiment.  The eST group 
had a significant decrease in the dorsal to palmar medullary cavity width from day 0 to 
day 128 (P=.01).  The differences between the two treatment groups were not significant. 
 
 
Figure 110. Dorsal to palmar medullary cavity width in mm, at site 3, vs day of study.
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Data from the dorsal to palmar medullary cavity width at site 3 were normalized to 
day 0 values and the resulting normalized data were statistically analyzed to better 
evaluate any changes in the medullary width over the course of the trial (Figure 111, 
Tables A-28 and B-110).  There were still no significant affects on the medullary cavity 
width due to day, treatment, or day*treatment interaction.  A decrease in the medullary 
cavity width was not significant from day 0 to day 64 or day 64 to day 128, but did have 
a trend toward significance from day 0 to day 128 (P=.100).  No significant changes 
occurred in the dorsal to palmar medullary cavity width in the Con group during the trial.  
A decrease in the medullary cavity width in the eST group was not significant from day 0 
to day 64, or from day 64 to day 128, but was significant from day 0 to day 128 (P=.01) 
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and resulted in a significant difference between the two treatment groups on day 128 
(P=.02). 
 
 
Figure 111. Change in dorsal to palmar medullary cavity width in mm, at site 3, vs day of study.
a
 Treatments differ (P.05).
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Site 4 
There were no significant treatment, day, or day*treatment effects on the dorsal to 
palmar medullary cavity width at site 4 (Figure 112, Tables A-27 and B-111).  A minor 
decrease in the diameter of the medullary cavity did not reach significant levels.  The 
Con group started the trial on day 0 with a non-statistically larger medullary cavity width 
at site 4 than did the eST group.  There was no significant change in the medullary cavity 
width in the Con group during the project.  The decrease in medullary cavity width in the 
eST group had a trend toward significance by day 128 (P=.07).   
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Figure 112. Dorsal to palmar medullary cavity width in mm, at site 4, vs day of study.
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Figure 113. Change in dorsal to palmar medullary cavity width in mm, at site 4, vs day of study.
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The data from the dorsal to palmar medullary cavity width at site 4 were normalized 
to day 0 values and statistics were re-run (Figure 113, Tables A-28 and B-112).  Similar 
to the raw data at this site (Figure 112), no significant changes in the medullary cavity 
width resulted from treatment, day, or any day*treatment interaction.  No significant 
overall changes in the medullary cavity width occurred.  No significant differences were 
seen between the two treatment groups.  The eST group did have a trend (P=.07) for the 
decrease in the medullary cavity diameter from day 0 to day 128 to be important, and this 
was not seen in the Con group. 
 
Dorsal to Palmar Bone Diameter Micrometer Readings 
Site 1 
There was a significant day effect (P=.002), but not a treatment effect or a 
day*treatment interaction that affected the dorsal to palmar bone diameter at site 1 
(Figure 114, Tables A-29 and B-113).  A non-significant gain in the diameter of the bone 
at site 1 from day 0 to day 64 increased to be a significant gain from day 64 to day 128 
(P=.006).  The diameter of the bone in the dorsal to palmar direction was significantly 
greater on day 128 than on day 0 (P=.0006).  Though there was an increase in the 
diameter of the bone from day 0 to day 128 in the Con group, this increase was not 
significant.  The increase in the eST group was significant, with the total width of the 
bone at site 1 on day 128 statistically different from day 64 (P=.003) and day 0 
(P=.0003).  The Con group had greater bone diameter than the eST group on day 0 and 
day 64, and less bone diameter than the eST group on day 128, but these differences 
were not great enough to be of statistical importance. 
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Figure 114. Dorsal to palmar bone diameter in mm, at site 1, vs day of study.
yz
 Days not sharing the same superscript differ (P.01).
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Figure 115. Change in dorsal to palmar bone diameter in mm, at site 1, vs day of study.
a
 Treatments differ (P.05).
yz
 Days not sharing the same superscript differ (P.05).
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Treatment did not affect the normalized dorsal to palmar bone diameter at site 1, 
neither did any day*treatment interaction, however day effects were significant (Figure 
115, Tables A-30 and B-114).  A gradual increase in the bone width from day 0 to day 64 
became more pronounced from day 64 to day 128 and resulted in day 128 values being 
significantly greater than those on day 0 (P=.0006) or on day 64 (P=.006).  The Con 
group of horses had a non-significant increase in the diameter of the bone in the dorsal to 
palmar direction from day 0 to day 128.  The eST group of horses had a steeper increase 
in the diameter of the bone that was significant from day 64 to day 128 (P=.003), and 
caused the day 128 values to be statistically greater than the values on day 0 (P=.0003).  
Additionally, the greater gain in bone diameter of the eST group of horses as compared 
to the Con group of horses was significant by day 128 (P=.05). 
 
Site 2 
Day effects were significant (P=.0001), but neither treatment nor day*treatment 
interaction significantly affected the dorsal to palmar bone diameter at site 2 (Figure 116, 
Tables A-29 and B-115).  The width of the bone did not change significantly from day 0 
to day 64 but did increase significantly after day 64, causing the bone on day 128 to have 
a greater diameter than on day 0 (P<.0001) or day 64 (P=.001).  The Con group started 
the trial with a non-statistically wider bone at site 2 than did the eST group, but this was 
reversed by day 128 due to a greater increase in the width of the bone from day 64 to day 
128 in the eST group than in the Con group.  The increase in bone diameter from day 0 
to day 128 was significant in the eST group (P<.0001), while the Con group only had a 
trend for significance (P=.07).  The differences between the two treatment groups were 
not great enough to be significant. 
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Figure 116. Dorsal to palmar bone diameter in mm, at site 2, vs day of study.
yz
 Days not sharing the same superscript differ (P.01).
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Figure 117. Change in dorsal to palmar bone diameter in mm, at site 2, vs day of study.
a
 Treatments differ (P.05).
yz
 Days not sharing the same superscript differ (P.05).
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To better compare changes between the two treatment groups over the duration of the 
research trial, the data from the dorsal to palmar bone diameter at site 2 were normalized 
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by removing day 0 values and the resulting data were subjected to statistical analyses 
(Figure 117, Tables A-30 and B-116).  Day effects were significant (P=.0001), but 
treatment effects and day*treatment interactions did not significantly affect the width of 
the bone at site 2.  The increase in bone diameter at site 2 was significant during the last 
half of the experiment, consequentially the width of the bone on day 128 was 
significantly greater than on day 0 (P<.0001) or day 64 (P=.001).  The two treatment 
groups did not differ from each other during the first half of the trial.  During the second 
half of the trial, the increase in bone width in the Con group was not great enough to be 
significant while the increase in bone width in the eST group was significant (P=.0006).  
At the end of this project on day 128, the eST group had a significantly greater increase 
in the dorsal to palmar bone diameter at site 2 than did the Con group (P=.04). 
 
Site 3 
There were day effects (P<.0001) but no significant treatment or day*treatment effects 
on the dorsal to palmar bone diameter at site 3 (Figure 118, Tables A-29 and B-117).  
The increase in the bone diameter from day 0 to day 64 was not significant.  The increase 
in bone diameter from day 64 to 128 was great enough that day 128 values were 
significantly larger than day 0 (P<.0001) or day 64 (P<.0001).  In the Con group, the 
bone width on day 128 was significantly greater than on day 0 (P=.01) or on day 64 
(P=.04).  In the eST group, the bone width on day 128 was also significantly greater than 
on day 0 (P<.0001) or on day 64 (P<.0001).  There were not significant differences 
between the two treatment groups on any given day. 
The data from the bone diameter in the dorsal to palmar direction at site 3 were 
normalized to remove day 0 values and re-examined statistically to more closely evaluate 
changes that occurred during this experiment (Figure 119, Tables A-30 and B-118).  
There were significant day effects (P<.0001), but no effects due to treatment or to a 
day*treatment interaction.  No significant increase in bone diameter at site 3 occurred 
from day 0 to day 64.  From day 64 to day 128 there was a significant increase in total 
bone width at site 3 (P<.0001).  The same pattern occurred in both treatment groups, 
with no real change in the bone width from day 0 to day 64, and a significant increase in 
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bone width from day 64 to day 128 in both the Con group (P=.04) and the eST group 
(P<.0001).  The amount of increase in diameter of the bone at site 3 was greater in the 
eST group than the Con group, consequently the two groups differed from each other in 
the amount of gain on day 128 (P=.03). 
 
 
Figure 118. Dorsal to palmar bone diameter in mm, at site 3, vs day of study.
yz
 Days not sharing the same superscript differ (P.01).
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Figure 119. Change in dorsal to palmar bone diameter in mm, at site 3, vs day of study.
a
 Treatments differ (P.05).
yz
 Days not sharing the same superscript differ (P.05).
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Site 4 
There were no treatment effects, nor any day*treatment interaction that affected the 
bone width in the dorsal to palmar direction at site 4, but day effects were significant 
(P<.0001) (Figure 120, Tables A-29 and B-119).  There was a trend for an increase in the 
bone width from day 0 to day 64 (P=.07) that became significant from day 64 to day 128 
(P<.0001).  A non-significant difference between the two groups on day 0 had 
disappeared by day 128.  The Con group day 0 values were not significantly different 
from day 64, but were less than day 128 values (P<.0001), and day 64 values were 
significantly less than day 128 (P=.0006).  The eST group day 0 values had a trend to be 
less than day 64 (P=.100) and were less than day 128 (P<.0001), and day 64 values were 
significantly less than day 128 (P<.0001).   
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Figure 120. Dorsal to palmar bone diameter in mm, at site 4, vs day of study.
yz
 Days not sharing the same superscript differ (P.05).
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Data from the dorsal to palmar bone diameter at site 4 were normalized to day 0 
values and statistics were run on the resulting data to better examine changes in the bone 
width over the course of the experiment (Figure 121, Tables A-30 and B-120).  Day 
effects were significant (P<.0001), with the gain in bone width from day 0 to day 64 
trending toward significance (P=.07), and the gain from day 64 to day 128 (P<.0001) and 
the gain from day 0 to day 128 (P<.0001) both being significant.  Treatment effects did 
not significantly affect the bone width at site 4, nor did any day*treatment interaction.  
The Con group had a non-significant increase in the bone diameter from day 0 to day 64, 
that became significant from day 64 to day 128 (P=.0006).  The increase in the bone 
diameter in the eST group trended toward significance from day 0 to day 64 (P=.100) 
and was significant from day 64 to day 128 (P<.0001).  On day 128 the gain in the 
diameter of the bone at site 4 was greater in the eST group than in the Con group, but 
this difference was not statistically important. 
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Figure 121. Change in dorsal to palmar bone diameter in mm, at site 4, vs day of study.
yz
 Days not sharing the same superscript differ (P.05).
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Lateral to Medial Medullary Cavity Width Micrometer Readings 
Site 1 
There were no significant effects on the lateral to medial medullary cavity width at 
site 1 due to day, treatment, or day*treatment interaction (Figure 122, Tables A-31 and 
B-121).  No changes occurred in the width of the medullary cavity overall, or in either of 
the two treatment groups.  The Con group did have a non-significantly greater width of 
the medullary cavity than did the eST group on day 0, and this pattern remained 
unchanged through day 128. 
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Figure 122. Lateral to medial medullary cavity width in mm, at site 1, vs day of study.
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Figure 123. Change in lateral to medial medullary cavity width in mm, at site 1, vs day of study.
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The data from lateral to medial medullary cavity width at site 1 were normalized to 
day 0 values and re-evaluated (Figure 123, Tables A-32 and B-122).  There were no 
effects due to day, treatment, or any day*treatment interaction.  The pattern of gain 
varied between the two treatment groups.  The Con group enlarged the medullary cavity 
from day 0 to day 64, and then decreased the medullary cavity width to below day 0 
values by day 128.  The eST group had a decrease in the medullary cavity width from 
day 0 to day 64 followed by an increase in the width from day 64 to day 128.  However, 
none of the changes, in either treatment group were significant, nor did the two treatment 
groups significantly differ from each other at any point during this trial in the diameter of 
the lateral to medial medullary cavity at site 1. 
 
Site 2 
Neither treatment, day, nor day*treatment interaction significantly affected the lateral 
to medial medullary cavity width at site 2 (Figure 124, Tables A-31 and B-123).  The 
diameter of the medullary cavity did not change over the course of the trial.  The two 
treatment groups did not differ from each other at any point during the trial. 
Normalized data from the lateral to medial medullary cavity width at site 2 were also 
evaluated (Figure 125, Tables A-32 and B-124).  Once again, there were no significant 
effects to the lateral to medial medullary cavity width at site 2 due to treatment, day, or a 
day*treatment interaction.  The diameter of the medullary cavity did not change 
significantly during the research project.  There was a different pattern of change in the 
two treatment groups.  The Con group had a minor gain in medullary cavity width at day 
64 followed by a minor loss back to day 0 values by day 128.  The eST group had a 
larger, but also non-significant loss in medullary cavity width at day 64 that partially 
disappeared by day 128.  There were no significant differences between the two 
treatment groups. 
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Figure 124. Lateral to medial medullary cavity width in mm, at site 2, vs day of study.
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Figure 125. Change in lateral to medial medullary cavity width in mm, at site 2, vs day of study.
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Site 3 
The lateral to medial medullary cavity width at site 3 was not affected by treatment, 
day, or day*treatment interaction (Figure 126, Tables A-31 and B-125).  No significant 
changes in the medullary width occurred overall or in the Con group.  The eST group did 
not change from day 0 to day 64 or day 64 to day 128, but did have a trend (P=.08) for 
the decrease in width from day 0 to 128 to be statistical.  The two treatment groups did 
not differ from each other. 
 
 
Figure 126. Lateral to medial medullary cavity width in mm, at site 3, vs day of study.
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The data from the lateral to medial medullary cavity width at site 3 were normalized 
to day 0 values and re-evaluated to more closely examine any changes in medullary 
cavity width that may have occurred during the course of the experiment (Figure 127, 
Tables A-32 and B-126).  The medullary cavity width was not significantly affected by 
day, treatment, or by any day*treatment interaction.  The medullary cavity width did not 
vary significantly from day 0 to day 128.  The Con group had a non-significant increase 
in the diameter of the medullary cavity from day 64 to day 128, while the eST group had 
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a non-significant decrease in the diameter of the medullary cavity during the same time 
period, and a trend for the decrease from day 0 to day 128 to be significant (P=.08).  
Consequently, the two groups differed on day 128, with the Con group having less of a 
decrease in medullary cavity width at site 3 than the eST group, but this difference was 
not of statistical importance. 
 
 
Figure 127. Change in lateral to medial medullary cavity width in mm, at site 3, vs day of study.
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Site 4 
There were no significant effects on the lateral to medial medullary cavity width at 
site 4 due to treatment, day, or day*treatment interaction (Figure 128, Tables A-31 and 
B-127).  There was no change in the medullary cavity width from day 0 to day 128 in 
either the entire group of horses or in the Con treatment group.  The eST treatment group 
had a significant decrease in medullary cavity width from day 0 to day 64 (P=.02), and a 
non-significant increase from day 64 to day 128.  The two treatment groups did not 
significantly differ from each other on any of the sample days. 
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Figure 128. Lateral to medial medullary cavity width in mm, at site 4, vs day of study.
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Day 0 values were subtracted from the lateral to medial medullary cavity width at site 
4 to more closely examine any changes in the width of the medullary cavity over the time 
frame of the project and statistics were run on the transformed data (Figure 129, Tables 
A-32 and B-128).  There were no significant effects due to day, treatment, or 
day*treatment interaction on the width of the medullary cavity at site 4.  No significant 
changes in the diameter of the medullary cavity occurred from day 0 to day 128 in either 
the overall group of horses or in the Con treatment group.  The eST treatment group had 
a significant decrease in the width of the medullary cavity from day 0 to day 64 (P=.02) 
followed by a non-significant increase in the width of the medullary cavity from day 64 
to day 128.  The two treatment groups differed from each other on day 64 (P=.04) due to 
the decrease in medullary cavity width that occurred in the eST treatment group.  The 
difference between the two treatment groups decreased after day 64, and was not 
significant on day 128. 
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Figure 129. Change in lateral to medial medullary cavity width in mm, at site 4, vs day of study.
a
 Treatments differ (P.05).
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Lateral to Medial Bone Diameter Micrometer Readings 
Site 1 
The lateral to medial bone diameter at site 1 had a trend to be affected by a 
day*treatment interaction (P=.09) but was not significantly affected by day or by 
treatment (Figure 130, Tables A-33 and B-129).  There was no significant change in the 
bone diameter from day 0 to day 64 or from day 64 to day 128, but there was a trend 
(P=.09) for day 128 to be different from day 0.  The Con group had a non-statistical 
increase in the bone diameter from day 0 to day 64 and a non-statistical decrease in bone 
diameter from day 64 to day 128.  In contrast, the eST group had a non-statistical 
decrease in the bone diameter from day 0 to day 64 and a significant increase in bone 
diameter from day 64 to day 128 (P=.02).  The eST group had a lateral to medial bone 
diameter at site 1 on day 128 that was significantly greater than on day 0 (P=.04).  The 
Con group had a non-significantly greater bone diameter than the eST group on day 0 
that increased and trended toward significance on day 64 (P=.09) and decreased back 
into non-significance on day 128.   
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Figure 130. Lateral to medial bone diameter in mm, at site 1, vs day of study.
a
 Trend for treatments to differ (P.10).
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The lateral to medial bone diameter at site 1 data were normalized to remove day 0 
values and re-evaluated to better define any changes that occurred over the time span of 
this trial (Figure 131, Tables A-34 and B-130).  There was a trend for a day*treatment 
interaction to affect the bone diameter (P=.09), but no treatment or day effect.  A non-
significant gain in bone diameter from day 0 to day 64 and from day 64 to day 128 
resulted in a trend for the gain in bone diameter from day 0 to day 128 to be significant 
(P=.09).  The Con group of horses had an increase in bone diameter from day 0 to day 64 
and a decrease in bone diameter from day 64 to day 128, neither of which was 
significant.  The eST group of horses had a contrasting pattern of change.  The eST 
group of horses had a non-significant decrease in bone diameter from day 0 to day 64 
and a significant increase in bone diameter from day 64 to day 128 (P=.02).  The day 128 
bone diameter in the eST group of horses was significantly greater than the day 0 value 
in the same group of horses (P=.04).  The two treatment groups did not significantly 
differ from each other on the sample days. 
 
  
137 
Figure 131. Change in lateral to medial bone diameter in mm, at site 1, vs day of study.
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Site 2 
The lateral to medial bone diameter at site 2 had a trend to be affected by day (P=.06) 
but was not significantly affected by treatment or by a day*treatment interaction (Figure 
132, Tables A-33 and B-131).  There was a non-significant increase in bone diameter in 
the lateral to medial direction from day 0 to day 64 and from day 64 to day 128.  When 
day 0 was compared to day 128 the increase in bone diameter was significant (P=.02).  
Both treatment groups had the same pattern of change in bone diameter with non-
significant increases from day 0 to day 64 and from day 64 to day 128, and with a trend 
for the increase from day 0 to day 128 to be significant in both the Con group (P=.100) 
and the eST group (P=.09).  The Con group started the trial on day 0 with a non-
statistically greater bone diameter than the eST group that continued through the end of 
the trial. 
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Figure 132. Lateral to medial bone diameter in mm, at site 2, vs day of study.
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Data from the lateral to medial bone diameter at site 2 were normalized to day 0 
values and statistics were ru-run to look at changes in the bone diameter that occurred 
during the research project (Figure 133, Tables A-34 and B-132).  There was a trend for 
day to affect the bone diameter at site 2 (P=.06), but there were no significant affects due 
to treatment or to any day*treatment interaction.  There was an increase in the lateral to 
medial bone diameter that was not significant from day 0 to day 64 or from day 64 to day 
128, but was significant from day 0 to day 128 (P=.02).  Neither of the two treatment 
groups had significant changes in the lateral to medial bone diameter at site 2 from day 0 
to day 64 or from day 64 to day 128, but there was a trend for the increase in the bone 
diameter from day 0 to day 128 to be significant in both the Con group (P=.100) and the 
eST group (P=.09).  The two treatment groups did not differ from each other statistically. 
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Figure 133. Change in lateral to medial bone diameter in mm, at site 2, vs day of study.
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Site 3 
There were no significant effects caused by day, treatment, or a day*treatment 
interaction that affected the lateral to medial bone diameter at site 3 (Figure 134, Tables 
A-33 and B-133).  There was no significant change in the bone diameter either overall in 
the entire number of horses or in the Con group of horses during the trial.  The eST 
group of horses also had no significant change in bone diameter at site 3 from day 0 to 
day 64 or from day 64 to day 128, however there was a trend for the bone diameter on 
day 128 to be greater than on day 0 (P=.08).  The non-significantly greater bone diameter 
on day 0 in the Con group as compared to the eST group continued through day 128. 
Data from the lateral to medial bone diameter at site 3 were normalized by subtracting 
day 0 values, and the normalized data were analyzed statistically to evaluate changes in 
bone diameter that may have occurred during this experiment (Figure 135, Tables A-34 
and B-134).  The bone diameter at site 3 was not significantly affected by treatment, day, 
or day*treatment interaction.  There were no significant changes in the bone diameter 
over the course of the project.  The two treatment groups did not differ from each other 
on any of the sampled days. 
  
140 
Figure 134. Lateral to medial bone diameter in mm, at site 3, vs day of study.
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Figure 135. Change in lateral to medial bone diameter in mm, at site 3, vs day of study.
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Site 4 
The lateral to medial bone diameter at site 4 was not significantly affected by 
treatment, day, or any day*treatment interaction (Figure 136, Tables A-33 and B-135).  
There was an increase in the bone diameter at this site that had a trend to be significant 
from day 0 to day 128 (P=.07), but was not significant from day 0 to day 64 or from day 
64 to day 128.  The Con group did not have a statistical change in bone diameter.  The 
eST group did not have a statistical change in bone diameter from day 0 to day 64, but an 
increase in the bone diameter after day 64 resulted in a trend for day 128 values to be 
greater than day 64 values (P=.08), and a significant difference between day 0 and day 
128 (P=.02).  The Con group had a larger bone diameter than the eST group for the 
duration of the trial, but this difference was not significant. 
 
 
Figure 136. Lateral to medial bone diameter in mm, at site 4, vs day of study.
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Data from the lateral to medial bone diameter at site 4 were normalized to day 0 
values and statistics were re-run to better evaluate any changes in the width of the bone 
at site 4 over the duration of this project (Figure 137, Tables A-34 and B-136).  The bone 
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diameter at this site was not significantly affected by day, treatment, or by any 
day*treatment interaction.  The width of the bone did not change significantly from day 0 
to day 64 or from day 64 to day 128, but the bone width did change enough for there to 
be a trend for day 128 values to be greater than day 0 values (P=.07).  The Con group did 
not have a significant change in lateral to medial bone diameter at site 4 during this trial.  
The eST group had a non-significant decrease in bone diameter from day 0 to day 64 and 
a significant gain in the bone diameter from day 64 to day 128 (P=.02).  In the eST 
group, day 128 had a trend to bone diameter that was greater than day 0 (P=.08).  The 
two treatment groups did not differ from each other statistically. 
 
 
Figure 137. Change in lateral to medial bone diameter in mm, at site 4, vs day of study.
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Bone Index Value of Micrometer Readings 
 
The bone index value (Figure 138, Tables A-35 and B-137) was calculated at site 3 
using the method of Larkin and Davies (1996).  The bone index was evaluated at site 3 
because this was the area Larkin and Davies (1996) evaluated and found to be an 
indicator of probablility of future shin soreness in racehorses.  This author did not find 
  
143 
any published reports of bone index values at other sites, nor any correlation of the bone 
index values at other sites to probability of injury or shin soreness, and therefore did not 
calculate bone index values at the other sites (site 1, site 2, or site 4) for this project.   
There was not a difference in the index value at site 3 from day 0 to day 64.  On day 
128 the index value was significantly greater than on day 0 (P<.0001) or on day 128 
(P<.0001).  The two treatment groups did not differ from each other in the calculated 
index value on day 0 or on day 64.  By day 128 the two groups differed from each other 
non-significantly (P=.101) with the eST group having a larger index value than the Con 
group. 
 
 
Figure 138. Computed bone index value of micrometer readings at site 3, vs day of study.
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The data were normalized to day 0 and statistics were re-run on the normalized data 
(Figure 139, Tables A-36 and B-138).  There were no significant differences between 
day 0 and day 64, but there was an increase by day 128 that was significantly greater than 
day 0 or day 64 (both P<.0001).  The two treatment groups did not differ from each other 
in the calculated normalized index value on day 0 or day 64.  On day 128, the eST group 
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had a significantly greater increase in the index of bone value than did the Con group 
(P=.007). 
 
 
Figure 139. Normalized computed bone index value of micrometer readings at site 3, vs day of 
study.
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DISCUSSION 
 
During the course of this experiment there were no observed adverse reactions to the 
daily injections of eST.  This is similar to what has been noted in other studies.  Porcine 
growth hormone caused serious injection site reactions in horses, bovine growth 
hormone caused a mild adverse reaction in one of three horses to which it was 
administered, while no adverse reactions were seen with deep intermuscular injection of 
equine growth hormone to horses in a study conducted by De Kock et al. (2001).  
Bresegen, the manufacturer of the recombinant equine growth hormone used in this trial, 
does recommend deep intermuscular administration of their product to equines (as 
compared to subcutaneous injection of growth hormone, a frequent administration route 
of growth hormone to humans) as swelling and pain have been reported with 
subcutaneous injection of growth hormone in the horse.  No significant increases in heart 
rate (and therefore no indication of significant pain) were associated with the actual 
injection of eST in six horses given up to five times the recommended dose of 
recombinant growth hormone in an experiment in Australia (Dart et al. 1998). 
Site 4 micrometer readings were hard to obtain.  At this location the trabecular bone 
merges with the cortical bone without a distinct margin between the two types of bone.  
Through repeated measurements it was possible to obtain two readings from site 4 that 
were within the exceptable margin of error for every radiograph.  However, it is the 
opinion of this investigator that the site 4 measurements had a low repeateability and a 
much greater margin of error than did the other three sites that were evaluated in this 
trial.  Additionally, the pattern of change over time at site 4 did not always correspond 
with patterns of change over time seen at site 1, site 2, and site 3.  The thinner cortical 
bone and much more prevelant trabecular bone seen at site 4 that were present on day 0 
and continued through the entire 128 day study, as well as the different patterns of 
change over time are likely the result of different stresses influencing the modeling of 
bone in this location as compared to the more mid-diaphasis locations of site 1, site 2, 
and site 3.   
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The two treatment groups differed in average body weight on day 0.  Efforts were 
made to pair the animals based on sex and age, then one animal from each pair was 
randomly assigned to each treatment group.  By random chance, more of the lighter 
weight animals ended up in one treatment group.  The difference in body weight between 
the two treatment groups on day 0 was unfortunate, especially as bone development is 
greatly influenced by body weight.  Normalizing the data to day 0 values helped to 
negate the diffences that existed between the two treatment groups at the start of the trial.  
However, it may be possible that some of the differences in bone growth seen between 
the treatment groups may be the result, at least in part, of the difference in bone 
development between the two groups at the start of the trial.  Ideally the animal pairs 
would have been matched by body weight along with age and sex, but this would have 
required a larger group of animals.  Since the horses used in this trial were loaned to us 
from various owners across the United States it was not possible to eliminate all the 
differences between the animal pairs. 
Stress is based on amount of force applied and the rate with which it is applied.  The 
force applied would have been greater in the heavier horses (the Con group) than in the 
lighter weight horses (the eST group) because of the difference in body weight.  
Therefore, the stress of the exercise regime was greater in the Con group at the start of 
the trial.  The eST group of horses gained a significantly greater amount of weight during 
the trial than did the Con group (Sutfin, 2000), so as the trial progressed the stress of the 
exercise regime no longered differed between the two groups.   
Strain is the amount of deformation caused by the stress applied to the bone.  The 
strain would vary with the diameter and the density of the bone.  Since strain gauges 
were not used in this experiment, it can not be determined if the two groups experienced 
the same amount of strain. 
Somatotropin treatment did affect bone growth in a positive manner.  The horses that 
were in the eST treatment group had a greater increase in bone mineral density as 
measured by total RBAE than did the horses in the Con group.  By day 128 the two 
treatment groups differed in the change that occurred over the course of the experiment 
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in total RBAE at site 1, site 2, and site 3, with a greater gain in total RBAE in the eST 
group than in the Con group of horses.   
Bone that has a greater mineral density can withstand greater compression (Loveridge, 
1999).  Increase in mineral density increases the strength of bone by affecting material 
properties of the bone.  When the bone becomes highly mineralized (mineral content 
greater than 60% of ash weight), however, it is easier for microfractures to propagate 
through the bone (Loveridge, 1999).  The bones of the horses in this study were not 
examined in vitro, so the % mineral content is not known.  There were not any in vivo 
indications of microfractures, as the horses did not display signs of shin soreness or other 
lamenesses except for the afore noted stone bruising of the feet exhibited by two horses, 
and the pre-existing bone cyst exhibited by one horse (all three of which were removed 
from the study).  Thus, the increase in total bone mineral density of the eST horses in 
this study appears to correspond with a positive increase in bone strength.   
In the medial cortex and the dorsal cortex, at all four sites, the gain in RBAE over the 
128 days was greater in the eST group than the Con group, though none of the overall 
treatment differences were significant.  In the palmar cortex, the opposite occurred, 
where the gain in RBAE over the 128 days was non-significantly greater in the Con 
group than in the eST group.  In the lateral cortex, the RBAE change was no different 
between the two treatment groups by day 128.   
The dorsomedial part of the third metacarpus of the horse undergoes the greatest 
stress during exercise (Ordige, 1985).  This is the area where the greatest increase in 
bone mineral density occurred in the eST group of horses, presumably because the eST 
treated horses were selectively depositing bone mineral in the area of greatest strain to 
decrease the exercise-induced deformation of the bone in that area.  The increase in 
RBAE in the dorsal cortex and the medial cortex could be because of somatotrophin 
repartioning nutrients to increased bone growth throughout the animal.  But, if that were 
the case, the eST group should have also exhibited greater bone mineral deposition in the 
lateral and palmar aspects of the third metacarpus than what was seen in the Con group.  
That was not the case.  Instead, it appears that the eST group of horses selectively 
increased the bone mineral density of the third metacarpal in the areas that undergo the 
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greatest strain.  This may be due to somatostatin treatment causing repartioning of the 
dietary nutrients to preferentially increase the amount of bone mineral that is deposited at 
the sites of greatest strain.  Alternatively, this may be due to somatostatin treatment 
causing a reset of the “mechanostat” Frost has proposed (1987), causing the eST treated 
horses to remodel bone at a lower strain magnitude than the Con horses.  If this is the 
case, the eST treated group of horses would have bone that was better able to withstand 
the rigors of training at any given stress level than non-treated horses. 
The ratio of dorsal to palmar cortices was more dramatically increased in the eST 
treated horses than in the Con horses.  No difference occurred between the two treatment 
groups in the amount of increase in the ratio of lateral to palmar cortices.  The eST group 
had a non-significantly greater increase in the medial to lateral cortices and in the ratio of 
the medial to palmar cortices than did the Con group.   
Treatment with somatotropin did positively influence the eST group to preferentially 
increase the bone mineral density of the cortices that undergo the greatest strain. 
Bone strength is influenced not only by the material makeup of the bone, but also by 
the geometric structure of the bone.  Bone that has a larger diameter has a greater 
moment of inertia, decreasing the strain the bone experiences at any given level of stress.   
The eST treated horses had a greater increase in cross-sectional geometry of the bone 
as measured by micrometer readings of radiographs than did the Con horses.  The 
increase in the width of the dorsal cortex was significantly greater in the eST group than 
in the Con group at all four of the measured sites by day 128.  There was also a greater 
increase in the width of the medial cortex of the eST group than the Con group at all four 
sites by day 128, though this difference did not reach significance at two of the four sites.  
The eST group had a non-significantly greater increase in the width of the palmar cortex 
than did the Con group at all four of the measured sites.  The two treatment groups did 
not differ in the amount of increase seen in the width of the lateral cortex.   
The eST group actually had a decrease in the dorsal to palmar medulary cavity width 
at all four sites, while the Con group showed little change in the medulary cavity width.  
For there to be a decrease in medulary cavity width, the eST group of horses had to 
undergo deposition of new bone on the endosteal surface.   
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The two groups did not have a consitent pattern of change in the lateral to medial 
medulary cavity width. 
The eST group had a significantly greater increase in the dorsal to palmar bone 
diameter at site 1, site 2, and site 3, and a non-significantly greater increase in dorsal to 
palmar bone diameter at site 4 than did the Con group.  The eST group had a non-
significantly greater increase in lateral to medial bone diameter than did the Con group at 
site 1, site 3, and site 4, with no difference between the two treatment groups in the gain 
in lateral to medial bone diameter at site 2. 
In the cortices experiencing the greatest strain, the eST group selectively deposited 
more bone on the periosteal surface and/or endosteal surfaces and/or decreased the 
resorption of bone from the endosteal surface to result in a greater width of the cortical 
bone.  These changes would positively influence the moment of inertia, thus decreasing 
the strain the eST horses experienced at a given level of stress.  The Con group of horses 
experienced the same type of changes, with a potential increased moment of intertia 
resulting from positive changes in the bone geometry, but the changes were less 
pronounced in the Con group than in the eST group. 
The micrometer readings from site 3 were used to calculate a bone index using the 
method reported by Larkin and Davies (1996).  The bone index compares the width of 
cortical bone in relationship to the width of the medullary cavity, and compares the width 
of the dorsal cortical bone in relationship to the width of the palmar cortical bone.  
Horses that are depositing more bone in the dorsal cortex, which is the cortex that 
experiences the greatest amount of strain in young racehorses, would have a greater 
increase in the bone index than would horses that were not as selective in modeling their 
bones to best withstand the stress of race training.  The significantly greater increase in 
the index in the eST treated horses than in the Con horses is yet another indication of the 
positive effects that eST treatment had on bone modeling in the treated horses. 
Overall, the greater positive changes in bone density and bone geometry in the eST 
treatment group show that somatotropin treatment can positively influence bone 
modeling and/or remodeling in juvenile horses in race training.  The greater question, in 
this investigator’s opinion, is if these positive changes in bone modeling/remodeling 
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warrant consideration of somatotropin treatment of juvenile racehorses as a routine 
practice in the racehorse industry.   
McKeever et al. (1998) looked at chronic administration of eST and its potential 
benefits to exercise performance.  The aged mares in McKeever’s study did not have a 
positive effect on aerobic capacity or on exercise performance.  Rose (1998) states that 
“if there were a physiological mechanism for eST improving aerobic capacity and 
exercise tolerance, a positive effect should have been evident in older untrained mares 
just as much as in younger trained racehorses”.  It does not appear that eST has a direct 
affects on a horse’s exercise tolerance, but potential benefits to the juvenile racehorse 
include increased growth, increased bone mineral density, earlier maturity, and 
preferential partitioning of nutrients to muscle and lean body mass. 
The racehorse industry has looked for a way to test for the abuse of exogenous 
somatotropin administration in racehorses.  Because of its normal pusitile secretion and 
its short half-life, somatotropin levels in an animal can not be determined based on a 
single blood sample.  The exogenous somatotropin used in this study varies only slightly 
(one amino acid) from naturally occurring somatotropin.  De Kock et al. (2001) 
investigated the possibility of using IGF-1 as a marker of eST administration and found 
the results promising.  Noble et al. (2000) documented that IGF-1 levels rise significantly 
above naturally occurring IGF-1 levels in somatotropin treated racehorses, and that the 
increased IGF-1 levels can be detected based on a single blood sample.  In that study the 
increased level of IGF-1 could be detected after the horses had been on exogenous 
somatotropin treatment for 15 days, and continued to remain significantly eleveated 
throughout somatotropin treatment.  The levels of IGF-1 returned to normal 10 days after 
somatotropin treatment was discontinued.  Price et al. (2000) have noted that pro-
collegen peptide of type I collagen (PICP) a marker of bone formation, and cross-linked 
telopeptide of type I collagen (ICTP) a marker of bone resorption, were both significantly 
elevated in somatotropin treated horses, offering another means of detecting exogenous 
somaotropin administration via a blood test. 
In this researcher’s opinion, it is unlikely that racehorses will be allowed to compete 
while undergoing detectable levels of exogenous somatotropin treatment.  Treatment of 
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juvenile racehorses in training, before they are raced competively and subjected to blood 
testing requirements, may become a standard use of somatotropin in the racehorse, as 
trainers are attempting to reduce the amount of bone injuries in racehorses.  However, 
the question of the advisability of using eST on a routine basis can not be answered until 
research has been conducted to determine what effects discontinuing somatotropin 
treatment may have on bone mineral density and bone growth in the horse.   
Future research needs to investigate any changes in bone mineral density and bone 
geometry that may occur in horses after chronic eST administration has been 
discontinued.   
It may be that the positive changes in bone density and bone geometry that occurs in 
eST treated horses compared to control horses will continue to be apparent even after 
eST treatment has been discontinued.  If the treated horses continue to show advantages 
in bone remodeling and modeling or at least do not lose the advantage that was gained 
during eST treatment, the long term benefits of eST treatment will be well worth the 
administration of the hormone. 
Alternatively, and more likely in this researcher’s opinion, with the cessation of eST 
treatement the advantage in bone growth seen with eST treatment may disappear in a 
short amount of time.  This could occur due to the “mechanostat” being re-set to the pre-
treatment level.  In this senereo, the previously somatotropin treated horses would no 
longer remodel their bones until the strain levels of these bones reached the new set 
point.  This would result in these horses soon adjusting to the bone mineral density and 
bone geometry that they would have had if they had not undergone somatotropin 
treatment.  In this senereo, the eST treatment would not have long-term benefits, but 
short-term benefits may include these horses being able to adjust to the rigors of race 
horse training with fewer bone injuries than untreated horses. 
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CONCLUSIONS 
 
No adverse side effects due to somatotropin treatment were observed during this 
study.   
The somatotropin treated horses in this research project had a greater increase in the 
total bone mineral density of the third metacarpal at the four sites measured than did the 
control horses.  The eST treated horses had a greater increase in the dorsal to palmar 
bone diameter than the control horses.  The eST horses had a decrease in the dorsal to 
palmar medullary cavity width, which was not seen in the control horses.  All of these 
changes show that eST treatment does cause changes in bone remodeling and modeling 
that are associated with increased bone strength.  The positive changes in bone geometry 
are reflected in the significantly greater positive changes in the bone index in the eST 
treated horses than in the Con horses.  The increase in bone strength decreases the 
expected incidence of bone injury in these horses. 
This study did not continue to follow the long term changes in bone density and 
geometry in these horses after the eST treatment was discontinued.  It is not known if 
these positive changes in bone strength were negated after the eST treatment was 
discontinued or if the gain in bone strength had a long term positive effect on the 
somatotropin treated group of horses. 
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Table A-1.  Total RBAE in mm2 Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 606.30  ±  31.02 xy 610.46  ±  31.46 xy 597.73  ±  31.47 x 615.81  ±  31.02 xy 655.18  ±  31.47 yz 644.51  ±  31.02 xyz 670.84  ±  31.02 z 
eST 535.18  ±  29.97 w 599.83  ±  29.97 x 538.11  ±  30.84 wy 583.17  ±  29.97 yx 628.40  ±  30.84 xz 629.49  ±  29.97 x 676.91  ±  29.97 z 
        
Site 2       
Con 568.55  ±  29.24 wx 573.49  ±  29.64 wxy 559.03  ±  29.65 w 575.83  ±  29.24 wxy 615.83  ±  29.65 yz 606.57  ±  29.24 xyz 640.74  ±  29.24 z 
eST 505.31  ±  28.25 w 567.99  ±  28.25 xy 505.99  ±  29.04 w 546.33  ±  28.25 wx 595.45  ±  29.04 y 591.77  ±  28.25 y 642.76  ±  28.25 z 
        
Site 3       
Con 545.45  ±  28.24 wx 555.24  ±  28.65 wxy 536.15  ±  28.66 w 554.99  ±  28.24 wxy 594.74  ±  28.66 yz 587.76  ±  28.24 xyz 626.09  ±  28.24 z 
eST 483.84  ±  27.28 v 552.38  ±  27.28 wx 485.18  ±  28.08 vy 527.98  ±  27.28 wy 579.22  ±  28.08 x 569.52  ±  27.28 wx 625.93  ±  27.28 z 
        
Site 4       
Con 526.24  ±  34.62 x 543.09  ±  35.16 xy 524.48  ±  35.18 x 537.62  ±  34.62 xy 592.68  ±  35.18 yz 582.21  ±  34.62 xyz 639.40  ±  34.62 z 
eST 456.95  ±  33.44 v 557.60  ±  33.44 wx 477.65  ±  34.52 vy 527.05  ±  33.44 wy 585.63  ±  34.52 xz 564.74  ±  33.44 wx 643.21  ±  33.44 z 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-2.  Normalized total RBAE in mm2 Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 0  ±  26.39 xy 3.21  ±  26.90 xy -8.49  ±  26.91 x 9.52  ±  26.39 xy 48.96  ±  26.91yz 38.21  ±  26.39 xyz 64.55  ±  26.39 a,z 
eST 0  ±  25.49 w 64.65  ±  25.49 x 4.65  ±  26.49 wy 47.99  ±  25.49 xy 94.95  ±  26.49 xz 94.31  ±  25.49 x 141.73  ±  25.49 z 
        
Site 2        
Con 0  ±  25.15 wx 4.47  ±  25.63 wxy -9.63  ±  25.64 w 12.88  ±  25.15 wxy 47.17  ±  25.64 yz 38.02  ±  25.15 xyz 72.18  ±  25.15 b,z 
eST 0  ±  24.30 w 62.38  ±  24.30 x 2.04  ±  25.23 wy 46.98  ±  24.30 xy 91.50  ±  25.23 x 86.46  ±  24.30 x 137.46  ±  24.30 z 
        
Site 3        
Con 0  ±  24.56 wx 9.04  ±  25.02 b,wxy -9.36  ±  25.04 w 9.54  ±  24.56 wxy 49.23  ±  25.04 yz 42.32  ±  24.56 xyz 80.65  ±  24.56 b,z 
eST 0  ±  23.73 v 68.54  ±  23.73 wx 2.82  ±  24.64 vy 44.13  ±  23.73 wy 96.85  ±  24.64 x 85.67  ±  23.73 wx 142.08  ±  23.73 z 
        
Site 4        
Con 0  ±  32.90 x 15.93  ±  33.48 b,xy -1.99  ±  33.49 x 11.37  ±  32.90 xy 66.21  ±  33.49 yz 55.96  ±  32.90 xyz 113.16  ±  32.90 z 
eST 0  ±  31.79 v 100.65  ±  31.79 wx 22.70  ±  32.91 vy 70.10  ±  31.79 wy 130.68  ±  32.91 xz 107.79  ±  31.79 wx 186.44  ±  31.79 z 
a Treatments differ (p.05). 
b Trend for treatments to differ (p.10). 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
 
  
170
 
Table A-3.  Dorsal RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 18.15  ±  0.25 wxy 17.84  ±  0.25 w 18.04  ±  0.25 a,wx 18.02  ±  0.25 wx 18.37  ±  0.25 xyz 18.47  ±  0.25 yz 18.69  ±  0.25 z 
eST 17.47  ±  0.24 wx 17.28  ±  0.24 w 17.27  ±  0.25 w 17.67  ±  0.24 xy 18.04  ±  0.25 z 17.90  ±  0.24 yz 18.22  ±  0.24 z 
        
Site 2        
Con 17.53  ±  0.24 vwx 17.09  ±  0.24 y 17.31  ±  0.24 vwy 17.24  ±  0.24 wy 17.67  ±  0.24 vxz 17.71  ±  0.24 xz 16.90  ±  0.24 z 
eST 16.90  ±  0.23 x 16.68  ±  0.23 x 16.64  ±  0.23 x 16.95  ±  0.23 xy 17.32  ±  0.23 z 17.24  ±  0.23 yz 17.41  ±  0.23 z 
        
Site 3        
Con 17.19  ±  0.24 wx 16.76  ±  0.24 y 16.94  ±  0.24 wy 16.95  ±  0.24 wy 17.34  ±  0.24 xz 17.31  ±  0.24 wxz 17.56  ±  0.24 z 
eST 16.53  ±  0.23 wx 16.28  ±  0.23 w 16.38  ±  0.24 w 16.59  ±  0.23 wxy 16.92  ±  0.24 yz 16.83  ±  0.23 xyz 17.09  ±  0.23 z 
        
Site 4        
Con 15.96  ±  0.26 wxy 15.39  ±  0.27 z 15.55  ±  0.26 wz 15.73  ±  0.26 wxz 15.92  ±  0.26 wxy 16.05  ±  0.26 xy 16.33  ±  0.26 y 
eST 15.46  ±  0.25 xy 15.28  ±  0.25 x 15.47  ±  0.26 xy 15.52  ±  0.25 xy 15.91  ±  0.26 yz 15.80  ±  0.25 yz 16.15  ±  0.25 z 
a Treatments differ (p.05). 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-4.  Normalized dorsal RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 196 128 
Site 1        
Con 0  ±  0.19 wxy -0.31  ±  0.20 w -0.11  ±  0.19 wx -0.13  ±  0.19 wx 0.22  ±  0.19 xyz 0.32  ±  0.19 yz 0.55  ±  0.19 z 
eST 0  ±  0.18 wx -0.11  ±  0.18 w -0.19  ±  0.19 w 0.20  ±  0.18 xy 0.58  ±  0.19 z 0.44  ±  0.18 yz 0.75  ±  0.18 z 
        
Site 2        
Con 0  ±  0.18 vwx -0.45  ±  0.19 y -0.22  ±  0.18 vwy -0.29  ±  0.18 vy 0.14  ±  0.18 wxz 0.18  ±  0.18 xz 0.35  ±  0.18 z 
eST 0  ±  0.17 x -0.22  ±  0.17 x -0.25  ±  0.18 x 0.06  ±  0.17 xy 0.43  ±  0.18 z 0.34  ±  0.17 yz 0.51  ±  0.17 z 
        
Site 3        
Con 0  ±  0.19 wx -0.43  ±  0.19 y -0.25  ±  0.19 wy -0.25  ±  0.19 wy 0.15  ±  0.19 xz 0.01  ±  0.19 wxz 0.36  ±  0.19 z 
eST 0  ±  0.18 wx -0.25  ±  0.18 w -0.14  ±  0.19 w 0.06  ±  0.18 wxy 0.40  ±  0.19 yz 0.30  ±  0.18 xyz 0.56  ±  0.18 z 
        
Site 4        
Con 0  ±  0.22 wxy -0.57  ±  0.23 z -0.41  ±  0.22 wz -0.23  ±  0.22 xyz -0.04  ±  0.22 wxy 0.10  ±  0.22 xy 0.37  ±  0.22 y 
eST 0  ±  0.21 wx -0.18  ±  0.21 w 0.02  ±  0.22 wxy 0.06  ±  0.21 wxy 0.46  ±  0.22 yz 0.34  ±  0.21 xyz 0.68  ±  0.21 z 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-5.  Lateral RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 19.17  ±  0.44 y 19.74  ±  0.45 y 19.14  ±  0.45 y 19.53  ±  0.44 y 19.65  ±  0.45 y 19.78  ±  0.44 y 20.83  ±  0.44 z 
eST 18.09  ±  0.42 x 18.98  ±  0.42 xy 18.81  ±  0.44 x 19.07  ±  0.42 xy 19.36  ±  0.44 xy 19.66  ±  0.42 yz 20.38  ±  0.42 z 
        
Site 2        
Con 19.14  ±  0.47 wx 19.73  ±  0.48 wxy 18.84  ±  0.48 w 19.58  ±  0.47 wx 19.68  ±  0.48 wx 19.83  ±  0.47 xy 21.07  ±  0.47 z 
eST 18.65  ±  0.46 x 19.10  ±  0.46 xy 18.73  ±  0.47 x 19.04  ±  0.46 xy 19.44  ±  0.47 xy 19.68  ±  0.46 y 20.59  ±  0.46 z 
        
Site 3        
Con 18.87  ±  0.49 xy 19.49  ±  0.50 x 18.48  ±  0.50 y 19.23  ±  0.49 xy 19.25  ±  0.50 xy 19.54  ±  0.49 x 20.97  ±  0.49 z 
eST 18.38  ±  0.47 x 18.83  ±  0.47 xy 18.35  ±  0.49 x 18.57  ±  0.47 xy 19.29  ±  0.49 xy 19.41  ±  0.47 y 20.45  ±  0.47 z 
        
Site 4        
Con 16.89  ±  0.44 x 17.54  ±  0.45 xyz 17.00  ±  0.45 xy 17.29  ±  0.44 xy 17.20  ±  0.45 xy 17.76  ±  0.44 yz 19.37  ±  0.44 z 
eST 16.34  ±  0.43 w 16.96  ±  0.43 wxy 16.71  ±  0.44 wx 17.04  ±  0.43 wxy 17.33  ±  0.44 xy 17.63  ±  0.43 y 18.67  ±  0.43 z 
wxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-6.  Normalized lateral RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 0  ±  0.36 y 0.55  ±  0.37 y -0.04  ±  0.37 y 0.36  ±  0.36 y 0.47  ±  0.37 y 0.61  ±  0.36 y 1.66  ±  0.36 z 
eST 0  ±  0.35 x 0.17  ±  0.35 xy -0.01  ±  0.37 x 0.27  ±  0.35 xy 0.54  ±  0.37 xy 0.86  ±  0.35 yz 1.57  ±  0.35 z 
        
Site 2        
Con 0  ±  0.41 xy 0.57  ±  0.42 xy -0.32  ±  0.42 y 0.44  ±  0.41 xy 0.51  ±  0.42 xy 0.69  ±  0.41 x 1.94  ±  0.41 z 
eST 0  ±  0.40 w 0.44  ±  0.40 wx 0.07  ±  0.42 w 0.39  ±  0.40 wx 0.78  ±  0.42 wxy 1.03  ±  0.40 y 1.94  ±  0.40 z 
        
Site 3        
Con 0  ±  0.43 xy 0.59  ±  0.44 x -0.43  ±  0.44 y 0.35  ±  0.43 xy 0.35  ±  0.44 xy 0.67  ±  0.43 x 2.10  ±  0.43 z 
eST 0  ±  0.42 x 0.45  ±  0.42 xy -0.04  ±  0.44 x 0.19  ±  0.42 xy 0.90  ±  0.44 xy 1.03  ±  0.42 y 2.07  ±  0.42 z 
        
Site 4        
Con 0  ±  0.41 x 0.63  ±  0.42 xy 0.08  ±  0.42 xy 0.40  ±  0.41 xy 0.27  ±  0.42 xy 0.87  ±  0.41 y 2.48  ±  0.41 z 
eST 0  ±  0.39 w 0.62  ±  0.39 wxy 0.38  ±  0.41 wx 0.70  ±  0.39 wxy 1.00  ±  0.41 xy 1.29  ±  0.39 y 2.53  ±  0.39 z 
wxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-7.  Medial RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 20.51  ±  0.38 v 21.07  ±  0.39 vwx 20.99  ±  0.39 vw 21.27  ±  0.38 wxy 21.91  ±  0.39 yz 21.68  ±  0.38 xy 22.43  ±  0.38 z 
eST 19.79  ±  0.37 w 20.56  ±  0.37 x 20.82  ±  0.38 x 21.16  ±  0.37 xy 21.70  ±  0.38 y 21.62  ±  0.37 y 22.39  ±  0.37 z 
        
Site 2        
Con 20.66  ±  0.38 v 21.25  ±  0.39 vwx 21.16  ±  0.39 vw 21.50  ±  0.38 wxy 22.12  ±  0.39 yz 21.90  ±  0.38 y 22.72  ±  0.38 z 
eST 19.97  ±  0.37 w 20.81  ±  0.37 x 21.06  ±  0.38 x 21.34  ±  0.37 xy 21.84  ±  0.38 y 21.84  ±  0.37 y 22.55  ±  0.37 z 
        
Site 3        
Con 20.46  ±  0.39 v 21.12  ±  0.39 vwx 21.02  ±  0.39 vw 21.25  ±  0.39 wxy 21.92  ±  0.39 yz 21.73  ±  0.39 xy 22.60  ±  0.39 z 
eST 19.90  ±  0.37 v 20.67  ±  0.37 w 20.88  ±  0.39 wx 21.25  ± 0.37 wxy 21.65  ±  0.39 y 21.53  ±  0.37 xy 22.40  ±  0.37 z 
        
Site 4        
Con 18.59  ±  0.43 x 19.27  ±  0.44 xy 19.41  ±  0.44 y 19.29  ±  0.43 y 19.67  ±  0.44 y 19.75  ±  0.43 y 20.86  ±  0.43 z 
eST 18.02  ±  0.42 w 18.87  ±  0.42 x 19.17  ±  0.43 x 19.28  ±  0.42 xy 19.99  ±  0.43 yz 19.42  ±  0.42 xy 20.48  ±  0.42 z 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-8.  Normalized medial RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 0  ±  0.37 v 0.55  ±  0.38 vwx 0.46  ±  0.38 vw 0.76  ±  0.37 wxy 1.39  ±  0.38 yz 1.17  ±  0.37 xy 1.92  ±  0.37 z 
eST 0  ±  0.36 v 0.77  ±  0.36 w 1.05  ±  0.37 wx 1.37  ±  0.36 xy 1.93  ±  0.37 yz 1.83  ±  0.36 y 2.60  ±  0.36 z 
        
Site 2        
Con 0  ±  0.38 v 0.58  ±  0.38 vwx 0.45  ±  0.38 vw 0.84  ±  0.38 wxy 1.44  ±  0.38 yz 1.24  ±  0.38 xy 2.06  ±  0.38 z 
eST 0  ±  0.36 w 0.84  ±  0.36 x 1.11  ±  0.38 x 1.37  ±  0.36 xy 1.89  ±  0.38 y 1.87  ±  0.36 y 2.58  ±  0.36 z 
        
Site 3        
Con 0  ±  0.39 v 0.65  ±  0.40 vwx 0.54  ±  0.40 vw 0.79  ±  0.39 wxy 1.44  ±  0.40 yz 1.27  ±  0.39 xy 2.14  ±  0.39 z 
eST 0  ±  0.38 v 0.77  ±  0.38 w 1.00  ±  0.39 wx 1.34  ±  0.38 wxy 1.77  ±  0.39 y 1.62  ±  0.38 xy 2.50  ±  0.38 z 
        
Site 4        
Con 0  ±  0.40 x 0.68  ±  0.41 xy 0.82  ±  0.41 y 0.71  ±  0.40 xy 1.08  ±  0.41 y 1.17  ±  0.40 y 2.28  ±  0.40 z 
eST 0  ±  0.39 w 0.84  ±  0.39 x 1.17  ±  0.40 x 1.26  ±  0.39 xy 1.99  ±  0.40 yz 1.40  ±  0.39 xy 2.69  ±  0.39 z 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-9.  Palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 15.69  ±  0.24 y 15.14  ±  0.26 z 15.40  ±  0.25 yz 15.61  ±  0.24 yz 15.66  ±  0.25 y 15.82  ±  0.24 y 15.83  ±  0.24 y 
eST 15.44  ±  0.23 xyz 15.04  ±  0.23 xy 14.99  ±  0.24 x 15.26  ±  0.23 xyz 15.48  ±  0.24 yz 15.36  ±  0.23 xyz 15.55  ±  0.23 z 
        
Site 2       
Con 14.66  ±  0.24 xy 14.21  ±  0.25 xz 14.17  ±  0.25 z 14.47  ±  0.24 xyz 14.56  ±  0.25 xyz 14.68  ±  0.24 xy 14.77  ±  0.24 y 
eST 14.50  ±  0.24 x 14.05  ±  0.24 yz 13.90  ±  0.26 y 14.23  ±  0.24 xyz 14.41  ±  0.25 xz 14.36  ±  0.24 xyz 14.35  ±  0.24 xyz 
        
Site 3       
Con 14.21  ±  0.26 xyz 13.75  ±  0.27 xy 13.73  ±  0.27 x 13.91  ±  0.27 xyz 14.06  ±  0.27 xyz 14.21  ±  0.26 yz 14.25  ±  0.26 z 
eST 14.06  ±  0.26 y 13.61  ±  0.25 z 13.49  ±  0.28 z 13.76  ±  0.26 yz 13.99  ±  0.27 yz 13.89  ±  0.25 yz 13.87  ±  0.26 yz 
        
Site 4       
Con 13.71  ±  0.29 yz 13.23  ±  0.30 y 13.43  ±  0.31 yz 13.57  ±  0.30 yz 13.58  ±  0.30 yz 13.93  ±  0.29 z 13.91  ±  0.30 z 
eST 13.44  ±  0.28 z 13.04  ±  0.28 z 13.12  ±  0.31 z 13.15  ±  0.28 z 13.44  ±  0.30 z 13.33  ±  0.28 z 13.38  ±  0.28 z 
vwxyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-10.  Normalized palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 0  ±  0.22 y -0.55  ±  0.24 z -0.30  ±  0.23 yz -0.08  ±  0.22 y -0.04  ±  0.23 y 0.13  ±  0.22 y 0.14  ±  0.22 y 
eST 0  ±  0.22 xyz -0.40  ±  0.22 xy -0.45  ±  0.23 x -0.18  ±  0.22 xyz 0.04  ±  0.23 yz -0.08  ±  0.22 xyz 0.11  ±  0.22 z 
        
Site 2        
Con 0  ±  0.21 xy -0.45  ±  0.23 xz -0.50  ±  0.22 z -0.18  ±  0.21 xyz -0.12  ±  0.22 xyz 0.03  ±  0.21 y 0.11  ±  0.21 y 
eST 0  ±  0.21 x -0.45  ±  0.21 yz -0.63  ±  0.23 y -0.27  ±  0.22 xyz -0.10  ±  0.22 xz -0.14  ±  0.21 xz -0.15  ±  0.21 xz 
        
Site 3        
Con 0  ±  0.21 x -0.46  ±  0.22 xy -0.50  ±  0.22 y -0.32  ±  0.22 xyz -0.17  ±  0.22 xyz -0.01  ±  0.21 xz 0.04  ±  0.21 z 
eST 0  ±  0.20 y -0.40  ±  0.21 yz -0.60  ±  0.24 z -0.30  ±  0.21 yz -0.11  ±  0.23 yz -0.20  ±  0.21 yz -0.19  ±  0.21 yz 
        
Site 4        
Con 0  ±  0.24 yz -0.49  ±  0.26 y -0.26  ±  0.27 yz -0.17  ±  0.25 yz -0.19  ±  0.25 yz 0.24  ±  0.25 z 0.22  ±  0.25 z 
eST 0  ±  0.23 z -0.39  ±  0.24 z -0.31  ±  0.27 z -0.29  ±  0.24 z 0.02  ±  0.26 z -0.12  ±  0.24 z -0.04  ±  0.24 z 
xyz Means in the same row not sharing the same superscript differ (p.05). 
 
 
  
178
 
Table A-11.  Dorsal by palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 1.16  ±  0.01 xy 1.18  ±  0.01 a,xz 1.17  ±  0.01 xyz 1.16  ±  0.01 y 1.18  ±  0.01 xyz 1.17  ±  0.01 xyz 1.18  ±  0.01 z 
eST 1.13  ±  0.01 y 1.15  ±  0.01 yz 1.15  ±  0.01 yz 1.16  ±  0.01 z 1.17  ±  0.01 z 1.17  ±  0.01 z 1.17  ±  0.01 z 
        
Site 2        
Con 1.20  ±  0.01 yz 1.21  ±  0.01 yz 1.22  ±  0.01 y 1.19  ±  0.01 z 1.22  ±  0.01 yz 1.21  ±  0.01 yz 1.21  ±  0.01 yz 
eST 1.17  ±  0.01 x 1.19  ±  0.01 xy 1.20  ±  0.01 yz 1.20  ±  0.01 yz 1.20  ±  0.01 yz 1.20  ±  0.01 yz 1.21  ±  0.01 z 
        
Site 3        
Con 1.21  ±  0.02 z 1.22  ±  0.02 z 1.24  ±  0.02 z 1.22  ±  0.02 z 1.24  ±  0.02 z 1.22  ±  0.02 z 1.24  ±  0.02 z 
eST 1.18  ±  0.02 x 1.20  ±  0.02 xy 1.23  ±  0.02 yz 1.21  ±  0.02 yz 1.21  ±  0.02 yz 1.21  ±  0.02 yz 1.23  ±  0.02 z 
        
Site 4        
Con 1.17  ±  0.02 z 1.17  ±  0.02 z 1.17  ±  0.02 z 1.16  ±  0.02 z 1.18  ±  0.02 z 1.15  ±  0.02 z 1.18  ±  0.02 z 
eST 1.16  ±  0.02 x 1.18  ±  0.02 xy 1.19  ±  0.02 xyz 1.19  ±  0.02 xyz 1.19  ±  0.02 xyz 1.19  ±  0.02 yz 1.21  ±  0.02 z 
a Trend for treatments to differ (p.10). 
xyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-12.  Normalized dorsal by palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con  0.000  ±  0.011 xy  0.023  ±  0.011 xz  0.015  ±  0.011 xyz -0.003  ±  0.011 a, y  0.017  ±  0.011 xyz  0.009  ±  0.011 b, xyz  0.025  ±  0.011 z 
eST  0.000  ±  0.010 y  0.019  ±  0.010 yz  0.020  ±  0.011 yz  0.026  ±  0.011 z  0.034  ±  0.011 z  0.034  ±  0.010 z  0.039  ±  0.010 z 
        
Site 2        
Con  0.000  ±  0.012 x  0.007  ±  0.013 xy  0.026  ±  0.012 y -0.006  ±  0.012 a, x  0.019  ±  0.012 xy  0.008  ±  0.012 xy  0.015  ±  0.012 b, xy 
eST  0.000  ±  0.012 x  0.022  ±  0.012 xy  0.035  ±  0.013 yz  0.029  ±  0.012 yz  0.036  ±  0.012 yz  0.034  ±  0.012 yz  0.047  ±  0.012 z 
 
       
Site 3        
Con  0.000  ±  0.013 z  0.009  ±  0.013 z  0.026  ±  0.013 z  0.010  ±  0.013 z  0.025  ±  0.013 z  0.005  ±  0.013 z  0.021  ±  0.013 z 
eST  0.000  ±  0.013 x  0.018  ±  0.013 xy  0.048  ±  0.014 z  0.030  ±  0.013 yz  0.031  ±  0.014 yz  0.032  ±  0.013 yz  0.052  ±  0.013 z 
 
       
Site 4        
Con  0.000  ±  0.015 z  0.001  ±  0.016 z -0.000  ±  0.016 z -0.005  ±  0.015 z  0.011  ±  0.015 z -0.015  ±  0.015 a, z  0.013  ±  0.015 b, z 
eST  0.000  ±  0.014 y  0.020  ±  0.014 y  0.027  ±  0.016 yz  0.026  ±  0.014 yz  0.031  ±  0.016 yz  0.028  ±  0.014 yz  0.050  ±  0.015 z 
a Treatments differ (p.05). 
b Trend for treatments to differ (p.10). 
xyz Means in the same row not sharing the same superscript differ (p.05).     
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Table A-13.  Lateral by palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 1.22  ±  0.02 x 1.31  ±  0.03 yz 1.24  ±  0.03 x 1.25  ±  0.02 x 1.26  ±  0.03 xy 1.25  ±  0.02 xy 1.32  ±  0.02 z 
eST 1.22  ±  0.02 x 1.26  ±  0.02 xyz 1.26  ±  0.02 xy 1.25  ±  0.02 xy 1.25  ±  0.02 xy 1.28  ±  0.02 yz 1.31  ±  0.02 z 
        
Site 2        
Con 1.31  ±  0.03 x 1.39  ±  0.03 yz 1.33  ±  0.03 xy 1.35  ±  0.03 xy 1.35  ±  0.03 xy 1.35  ±  0.03 xy 1.43  ±  0.03 z 
eST 1.29  ±  0.03 x 1.36  ±  0.03 y 1.36  ±  0.03 xy 1.35  ±  0.03 xy 1.35  ±  0.03 xy 1.37  ±  0.03 yz 1.44  ±  0.03 z 
        
Site 3        
Con 1.33  ±  0.03 x 1.42  ±  0.03 yz 1.34  ±  0.03 x 1.38  ±  0.03 xy 1.37  ±  0.03 xy 1.37  ±  0.03 xy 1.48  ±  0.03 z 
eST 1.31  ±  0.03 x 1.39  ±  0.03 y 1.38  ±  0.04 xy 1.36  ±  0.03 xy 1.37  ±  0.03 xy 1.40  ±  0.03 y 1.48  ±  0.03 z 
        
Site 4        
Con 1.25  ±  0.03 x 1.34  ±  0.03 yz 1.26  ±  0.04 xy 1.27  ±  0.03 xy 1.27  ±  0.03 xy 1.28  ±  0.03 xy 1.40  ±  0.03 z 
eST 1.22  ±  0.03 x 1.31  ±  0.03 y 1.28  ±  0.04 xy 1.31  ±  0.03 y 1.28  ±  0.03 xy 1.33  ±  0.03 yz 1.40  ±  0.03 z 
xyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-14.  Normalized lateral by palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 0.000  ±  0.026 x 0.082  ±  0.028 yz 0.020  ±  0.027 x 0.026  ±  0.026 y 0.036  ±  0.027 xy 0.028  ±  0.026 xy 0.097  ±  0.026 z 
eST 0.000  ±  0.025 x 0.045  ±  0.025 xyz 0.036  ±  0.027 xy 0.033  ±  0.025 xy 0.033  ±  0.027 xy 0.063  ±  0.025 yz 0.092  ±  0.025 z 
        
Site 2        
Con 0.000  ±  0.032 x 0.084  ±  0.034 yz 0.022  ±  0.033 xy 0.043  ±  0.032 xy 0.047  ±  0.033 xy 0.043  ±  0.032 xy 0.123  ±  0.032 z 
eST 0.000  ±  0.031 x 0.073  ±  0.031 y 0.066  ±  0.034 xy 0.057  ±  0.032 xy 0.062  ±  0.032 xy 0.084  ±  0.031 y 0.147  ±  0.031 z 
 
 
      
Site 3        
Con 0.000  ±  0.035 x 0.090  ±  0.037 yz 0.013  ±  0.037 xy 0.049  ±  0.036 xy 0.043  ±  0.036 xy 0.044  ±  0.035 xy 0.146  ±  0.035 z 
eST 0.000  ±  0.035 x 0.075  ±  0.035 y 0.066  ±  0.039 xy 0.052  ±  0.035 xy 0.071  ±  0.038 xy 0.083  ±  0.035 y 0.166  ±  0.036 z 
 
       
Site 4        
Con 0.000  ±  0.037 x 0.087  ±  0.040 yz 0.019  ±  0.041 xy 0.030  ±  0.038 xy 0.035  ±  0.038 xy 0.030  ±  0.037 xy 0.156  ±  0.038 z 
eST 0.000  ±  0.036 x 0.082  ±  0.036 y 0.055  ±  0.041 xy 0.083  ±  0.036 y 0.063  ±  0.039 xy 0.098  ±  0.036 yz 0.170  ±  0.037 z 
xyz Means in the same row not sharing the same superscript differ (p.05).     
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Table A-15.  Medial by lateral RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 1.07  ±  0.02 y 1.07  ±  0.02 y 1.10  ±  0.02 yz 1.10  ±  0.02 yz 1.12  ±  0.02 z 1.10  ±  0.02 yz 1.08  ±  0.02 yz 
eST 1.05  ±  0.02 y 1.09  ±  0.02 y 1.11  ±  0.02 yz 1.11  ±  0.02 yz 1.12  ±  0.02 z 1.10  ±  0.02 yz 1.10  ±  0.02 yz 
        
Site 2        
Con 1.08  ±  0.02 z 1.08  ±  0.02 z 1.13  ±  0.02 z 1.11  ±  0.02 z 1.13  ±  0.02 z 1.11  ±  0.02 z 1.08  ±  0.02 z 
eST 1.07  ±  0.02 y 1.09  ±  0.02 yz 1.13  ±  0.02 z 1.12  ±  0.02 z 1.13  ±  0.02 z 1.11  ±  0.02 yz 1.10  ±  0.02 yz 
        
Site 3        
Con 1.09  ±  0.02 xy 1.09  ±  0.02 xyz 1.14  ±  0.02 z 1.11  ±  0.02 xyz 1.14  ±  0.02 xz 1.12  ±  0.02 xyz 1.08  ±  0.02 y 
eST 1.09  ±  0.02 y 1.10  ±  0.02 yz 1.15  ±  0.02 z 1.15  ±  0.02 z 1.12  ±  0.02 yz 1.11  ±  0.02 yz 1.00  ±  0.02 yz 
        
Site 4        
Con 1.10  ±  0.02 yz 1.11  ±  0.02 yz 1.15  ±  0.02 y 1.12  ±  0.02 yz 1.14  ±  0.02 y 1.12  ±  0.02 yz 1.08  ±  0.02 z 
eST 1.11  ±  0.02 z 1.12  ±  0.02 z 1.15  ±  0.02 z 1.13  ±  0.02 z 1.15  ±  0.02 z 1.11  ±  0.02 z 1.10  ±  0.02 z 
xyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-16.  Normalized medial by lateral RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con  0.000  ±  0.017 y -0.001  ±  0.017 y  0.026  ±  0.017 yz  0.023  ±  0.017 yz  0.044  ±  0.017 z  0.028  ±  0.017 yz  0.008  ±  0.017 a, yz 
eST  0.000  ±  0.016 x  0.032  ±  0.016 xy  0.059  ±  0.017 yz  0.057  ±  0.016 yz  0.072  ±  0.017 z  0.050  ±  0.016 yz  0.049  ±  0.016 yz 
        
Site 2        
Con  0.000  ±  0.023 z  0.001  ±  0.024 z  0.046  ±  0.024 z  0.024  ±  0.023 z  0.045  ±  0.024 z  0.0298  ±  0.023 z  0.001  ±  0.023 z 
eST  0.000  ±  0.022 y  0.018  ±  0.022 yz  0.057  ±  0.023 z  0.048  ±  0.022 z  0.053  ±  0.023 z  0.039  ±  0.022 yz  0.024  ±  0.022 yz 
 
       
Site 3        
Con  0.000  ±  0.026 y  0.005  ±  0.027 yz  0.059  ±  0.027 z  0.027  ±  0.026 yz  0.056  ±  0.027 z  0.033  ±  0.026 yz -0.004  ±  0.026 y 
eST  0.000  ±  0.025 y  0.013  ±  0.025 yz  0.058  ±  0.026 z  0.058  ±  0.025 z  0.037  ±  0.026 yz  0.026  ±  0.025 yz  0.011  ±  0.025 yz 
 
       
Site 4        
Con  0.000  ±  0.031 yz  0.003  ±  0.031 yz  0.047  ±  0.031 y  0.021  ±  0.031 yz  0.044  ±  0.031 y  0.016  ±  0.031 yz -0.021  ±  0.031 z 
eST  0.000  ±  0.030 z  0.008  ±  0.030 z  0.044  ±  0.031 z  0.025  ±  0.030 z  0.048  ±  0.031 z -0.002  ±  0.030 z -0.010  ±  0.030 z 
a Trend for treatments to differ (p.10). 
xyz Means in the same row not sharing the same superscript differ (p.05).     
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Table A-17.  Medial by palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1        
Con 1.31  ±  0.03 x 1.39  ±  0.03 yz 1.36  ±  0.03 y 1.36  ±  0.03 y 1.40  ±  0.03 yz 1.37  ±  0.03 yz 1.42  ±  0.03 z 
eST 1.28  ±  0.02 x 1.37  ±  0.02 y 1.39  ±  0.03 yz 1.39  ±  0.02 y 1.40  ±  0.03 yz 1.41  ±  0.02 yz 1.44  ±  0.02 z 
        
Site 2        
Con 1.41  ±  0.03 y 1.50  ±  0.03 z 1.49  ±  0.03 z 1.49  ±  0.03 z 1.52  ±  0.03 z 1.49  ±  0.03 z 1.54  ±  0.03 z 
eST 1.38  ±  0.03 x 1.49  ±  0.03 y 1.53  ±  0.03 yz 1.51  ±  0.03 y 1.52  ±  0.03 yz 1.52  ±  0.03 yz 1.57  ±  0.03 z 
        
Site 3        
Con 1.44  ±  0.03 y 1.54  ±  0.03 z 1.54  ±  0.03 z 1.53  ±  0.03 z 1.56  ±  0.03 z 1.53  ±  0.03 z 1.59  ±  0.03 z 
eST 1.43  ±  0.03 x 1.53  ±  0.03 y 1.57  ±  0.03 yz 1.56  ±  0.03 yz 1.54  ±  0.03 y 1.55  ±  0.03 y 1.62  ±  0.03 z 
        
Site 4        
Con 1.39  ±  0.03 x 1.47  ±  0.03 yz 1.46  ±  0.03 xyz 1.42  ±  0.03 xy 1.45  ±  0.03 xyz 1.42  ±  0.03 xy 1.50  ±  0.03 z 
eST 1.36  ±  0.03 x 1.45  ±  0.03 y 1.47  ±  0.04 yz 1.48  ±  0.03 yz 1.48  ±  0.03 yz 1.46  ±  0.03 y 1.53  ±  0.03 z 
xyz Means in the same row not sharing the same superscript differ (p.05). 
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Table A-18.  Normalized medial by palmar RBAE in mm Al equivalence (mean ± SE). 
day 0 32 50 64 82 96 128 
Site 1 
 
      
Con 0.000  ±  0.028 x 0.086  ±  0.029 yz 0.057  ±  0.028 y 0.056  ±  0.028 y 0.096  ±  0.028 yz 0.065  ±  0.028 yz 0.115  ±  0.028 z 
eST 0.000  ±  0.027 x 0.089  ±  0.027 y 0.108  ±  0.028 yz 0.105  ±  0.027 y 0.122  ±  0.028 yz 0.126  ±  0.027 yz 0.157  ±  0.027 z 
        
Site 2 
 
      
Con 0.000  ±  0.031 y 0.088  ±  0.032 z 0.084  ±  0.031 z 0.075  ±  0.030 z 0.112  ±  0.031 z 0.082  ±  0.030 z 0.132  ±  0.030 z 
eST 0.000  ±  0.029 x 0.107  ±  0.029 y 0.150  ±  0.032 yz 0.130  ±  0.030 y 0.139  ±  0.030 yz 0.143  ±  0.029 yz 0.192  ±  0.029 z 
 
 
      
Site 3 
 
      
Con 0.000  ±  0.030 y 0.098  ±  0.032 z 0.096  ±  0.032 z 0.088  ±  0.031 z 0.122  ±  0.031 z 0.089  ±  0.030 z 0.149  ±  0.030 z 
eST 0.000  ±  0.030 x 0.096  ±  0.030 y 0.134  ±  0.034 yz 0.127  ±  0.030 yz 0.113  ±  0.033 yz 0.116  ±  0.030 yz 0.176  ±  0.031 z 
 
       
Site 4 
 
      
Con 0.000  ±  0.032 x 0.073  ±  0.034 yz 0.066  ±  0.035 xyz 0.038  ±  0.033 a, xy 0.088  ±  0.033 yz 0.033  ±  0.032 a, xy 0.114  ±  0.033 z 
eST 0.000  ±  0.031 y 0.101  ±  0.031 z 0.112  ±  0.035 z 0.118  ±  0.031 z 0.122  ±  0.034 z 0.107  ±  0.031 z 0.166  ±  0.032 z 
a Trend for treatments to differ (p.10).      
xyz Means in the same row not sharing the same superscript differ (p.05).     
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Table A-19.  Dorsal cortical bone width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 11.9243 ± 0.5031 z 12.3161 ± 0.5031 yz 13.0104 ± 0.5031 y 
eST 11.4877 ± 0.4860 y 11.9970 ± 0.4860 y 13.9570 ± 0.4860 z 
          
Site 2          
Con 11.6093 ± 0.4767 y 11.9771 ± 0.4767 yz 12.7446 ± 0.4767 z 
eST 11.1283 ± 0.4605 y 11.6677 ± 0.4605 y 13.7017 ± 0.4605 z 
          
Site 3          
Con 10.9300 ± 0.4314 y 11.3075 ± 0.4314 y 12.1154 ± 0.4314 z 
eST 10.4557 ± 0.4168 y 10.7980 ± 0.4168 y 12.8560 ± 0.4168 z 
          
Site 4          
Con 7.2889 ± 0.3218 y 7.5689 ± 0.3218 y 8.6918 ± 0.3218 z 
eST 7.1160 ± 0.3109 y 7.4473 ± 0.3109 y 9.0100 ± 0.3109 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
Table A-20.  Normalized dorsal cortical bone width micrometer readings in mm (mean ± 
SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.3188 y 0.3918 ± 0.3188 yz 1.0861 ± 0.3188 a,z 
eST 0.0000 ± 0.3080 y 0.5093 ± 0.3080 y 2.4693 ± 0.3080 z 
 
 
 
  
 
  
 
 
Site 2 
 
 
  
 
  
 
 
Con 0.0000 ± 0.3167 y 0.3679 ± 0.3167 yz 1.1354 ± 0.3167 a,z 
eST 0.0000 ± 0.3060 y 0.5393 ± 0.3060 y 2.5733 ± 0.3060 z 
 
 
 
  
 
  
 
 
Site 3 
 
 
  
 
  
 
 
Con 0.0000 ± 0.2930 y 0.3775 ± 0.2930 y 1.1854 ± 0.2930 a,z 
eST 0.0000 ± 0.2831 y 0.3423 ± 0.2831 y 2.4003 ± 0.2831 z 
 
 
 
  
 
  
 
 
Site 4 
 
 
  
 
  
 
 
Con 0.0000 ± 0.1987 y 0.2800 ± 0.1987 y 1.4029 ± 0.1987 b,z 
eST 0.0000 ± 0.1920 y 0.3313 ± 0.1920 y 1.8940 ± 0.1920 z 
a
 Treatments differ (p.01). 
b
 Trend for treatments to differ (p.10). 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-21.  Lateral cortical bone width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 10.5232 ± 0.3417 z 10.7296 ± 0.3417 z 10.5950 ± 0.3417 z 
eST 10.4437 ± 0.3302 z 10.5367 ± 0.3302 z 10.5313 ± 0.3302 z 
          
Site 2          
Con 10.7064 ± 0.3696 z 10.8854 ± 0.3696 z 10.7796 ± 0.3696 z 
eST 10.5857 ± 0.3571 z 10.7647 ± 0.3571 z 10.5767 ± 0.3571 z 
          
Site 3          
Con 10.3839 ± 0.3677 yz 10.6179 ± 0.3677 y 10.3232 ± 0.3677 z 
eST 10.2167 ± 0.3552 z 10.4243 ± 0.3552 z 10.3557 ± 0.3552 z 
          
Site 4          
Con 8.4393 ± 0.3172 z 8.5750 ± 0.3172 z 8.7346 ± 0.3172 z 
eST 7.9810 ± 0.3065 z 8.1173 ± 0.3065 z 8.0460 ± 0.3065 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
 
Table A-22.  Normalized lateral cortical bone width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.08141 z 0.2064 ± 0.08141 z 0.0718 ± 0.08141 z 
eST 0.0000 ± 0.07865 z 0.0930 ± 0.07865 z 0.0877 ± 0.07865 z 
          
Site 2          
Con 0.0000 ± 0.08811 z 0.1789 ± 0.08811 z 0.0732 ± 0.08811 z 
eST 0.0000 ± 0.08512 z 0.1790 ± 0.08512 z -0.0090 ± 0.08512 z 
          
Site 3          
Con 0.0000 ± 0.1138 yz 0.2339 ± 0.1138 y -0.0607 ± 0.1138 z 
eST 0.0000 ± 0.1099 z 0.2077 ± 0.1099 z 0.1390 ± 0.1099 z 
          
Site 4          
Con 0.0000 ± 0.1731 z 0.1357 ± 0.1731 z 0.2954 ± 0.1731 z 
eST 0.0000 ± 0.1673 z 0.1363 ± 0.1673 z 0.0650 ± 0.1673 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-23.  Medial cortical bone width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 13.0911 ± 0.4780 z 13.2061 ± 0.4780 z 13.3004 ± 0.4780 z 
eST 12.4007 ± 0.4618 y 12.3930 ± 0.4618 y 13.1040 ± 0.4618 z 
          
Site 2          
Con 12.8529 ± 0.5165 y 13.0118 ± 0.5165 yz 13.2993 ± 0.5165 z 
eST 12.1653 ± 0.4990 y 12.2473 ± 0.4990 y 12.7957 ± 0.4990 z 
          
Site 3          
Con 12.8289 ± 0.5133 z 13.0661 ± 0.5133 z 13.1404 ± 0.5133 z 
eST 12.1660 ± 0.4959 y 12.1557 ± 0.4959 y 12.7267 ± 0.4959 z 
          
Site 4          
Con 11.2800 ± 0.4904 z 11.4693 ± 0.4904 z 11.2279 ± 0.4904 z 
eST 10.3957 ± 0.4737 y 10.7853 ± 0.4737 yz 11.2057 ± 0.4737 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
 
Table A-24.  Normalized medial cortical bone width micrometer readings in mm (mean ± 
SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.2103 z 0.1150 ± 0.2103 z 0.2093 ± 0.2103 a,z 
eST 0.0000 ± 0.2032 y -0.0013 ± 0.2032 y 0.7033 ± 0.2032 z 
          
Site 2          
Con 0.0000 ± 0.1785 y 0.1589 ± 0.1785 yz 0.4464 ± 0.1785 z 
eST 0.0000 ± 0.1724 y 0.0820 ± 0.1724 y 0.6303 ± 0.1724 z 
          
Site 3          
Con 0.0000 ± 0.1822 z 0.2371 ± 0.1822 z 0.3114 ± 0.1822 z 
eST 0.0000 ± 0.1760 y -0.0103 ± 0.1760 y 0.5607 ± 0.1760 z 
          
Site 4          
Con 0.0000 ± 0.2678 z 0.1893 ± 0.2678 z -0.0521 ± 0.2678 b,z 
eST 0.0000 ± 0.2587 y 0.3897 ± 0.2587 yz 0.8100 ± 0.2587 z 
a
 Trend for treatments to differ (p.10). 
b
 Treatments differ (p.05). 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-25.  Palmar cortical bone width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 6.7646 ± 0.3475 z 6.6279 ± 0.3475 z 6.5589 ± 0.3475 z 
eST 6.6000 ± 0.3357 z 6.8100 ± 0.3357 z 6.8260 ± 0.3357 z 
          
Site 2          
Con 6.8139 ± 0.2547 z 6.7189 ± 0.2547 z 6.7800 ± 0.2547 z 
eST 6.8713 ± 0.2461 z 7.0480 ± 0.2461 z 6.9557 ± 0.2461 z 
          
Site 3          
Con 6.7993 ± 0.2582 z 6.6464 ± 0.2582 z 6.7875 ± 0.2582 z 
eST 6.6790 ± 0.2495 z 6.9177 ± 0.2495 z 6.9900 ± 0.2495 z 
          
Site 4          
Con 4.9689 ± 0.2370 y 5.0461 ± 0.2370 yz 5.4661 ± 0.2370 z 
eST 4.9350 ± 0.2289 y 5.3300 ± 0.2289 y 5.8183 ± 0.2289 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
 
Table A-26.  Normalized palmar cortical bone width micrometer readings in mm (mean ± 
SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.2737 z -0.1368 ± 0.2737 z -0.2057 ± 0.2737 z 
eST 0.0000 ± 0.2644 z 0.2100 ± 0.2644 z 0.2260 ± 0.2644 z 
          
Site 2          
Con 0.0000 ± 0.1660 z -0.0950 ± 0.1660 z -0.0339 ± 0.1660 z 
eST 0.0000 ± 0.1604 z 0.1767 ± 0.1604 z 0.0843 ± 0.1604 z 
          
Site 3          
Con 0.0000 ± 0.1962 z -0.1529 ± 0.1962 z -0.0118 ± 0.1962 z 
eST 0.0000 ± 0.1895 z 0.2387 ± 0.1895 z 0.3110 ± 0.1895 z 
          
Site 4          
Con 0.0000 ± 0.1903 y 0.0771 ± 0.1903 yz 0.4971 ± 0.1903 z 
eST 0.0000 ± 0.1838 y 0.3950 ± 0.1838 y 0.8833 ± 0.1838 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-27.  Dorsal to palmar medullary cavity width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 12.3736 ± 0.4408 z 12.2661 ± 0.4408 z 12.2036 ± 0.4408 z 
eST 12.2757 ± 0.4258 y 11.9853 ± 0.4258 y 11.6130 ± 0.4258 z 
          
Site 2          
Con 13.1675 ± 0.4298 z 13.1564 ± 0.4298 z 12.9518 ± 0.4298 z 
eST 13.0883 ± 0.4152 y 12.6663 ± 0.4152 z 12.4273 ± 0.4152 z 
          
Site 3          
Con 13.7611 ± 0.4265 z 13.7586 ± 0.4265 z 13.7854 ± 0.4265 z 
eST 13.5443 ± 0.4121 y 13.3757 ± 0.4121 yz 13.1643 ± 0.4121 z 
          
Site 4          
Con 19.2679 ± 0.5088 z 19.2793 ± 0.5088 z 19.1836 ± 0.5088 z 
eST 18.9760 ± 0.4915 z 18.8953 ± 0.4915 z 18.5660 ± 0.4915 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
Table A-28.  Normalized dorsal to palmar medullary cavity width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.1519 z -0.1075 ± 0.1519 z -0.1700 ± 0.1519 a,z 
eST 0.0000 ± 0.1468 y -0.2903 ± 0.1468 y -0.6627 ± 0.1468 z 
          
Site 2          
Con 0.0000 ± 0.1233 z -0.0111 ± 0.1233 a,z -0.2157 ± 0.1233 a,z 
eST 0.0000 ± 0.1192 y -0.4220 ± 0.1192 z -0.6610 ± 0.1192 z 
          
Site 3          
Con 0.0000 ± 0.1261 z -0.0025 ± 0.1261 z 0.0243 ± 0.1261 a,z 
eST 0.0000 ± 0.1219 y -0.1687 ± 0.1219 yz -0.3800 ± 0.1219 z 
          
Site 4          
Con 0.0000 ± 0.1725 z 0.0114 ± 0.1725 z -0.0843 ± 0.1725 z 
eST 0.0000 ± 0.1667 z -0.0807 ± 0.1667 z -0.4100 ± 0.1667 z 
a
 Treatments differ (p.05). 
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Table A-29.  Dorsal to palmar bone diameter micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 31.0625 ± 0.6095 z 31.2100 ± 0.6095 z 31.7729 ± 0.6095 z 
eST 30.3633 ± 0.5888 y 30.7923 ± 0.5888 y 32.3960 ± 0.5888 z 
          
Site 2          
Con 31.5907 ± 0.5450 z 31.8525 ± 0.5450 z 32.4764 ± 0.5450 z 
eST 31.0880 ± 0.5265 y 31.3820 ± 0.5265 y 33.0847 ± 0.5265 z 
          
Site 3          
Con 31.4904 ± 0.5379 y 31.7125 ± 0.5379 y 32.6882 ± 0.5379 z 
eST 30.6790 ± 0.5197 y 31.0913 ± 0.5197 y 33.0103 ± 0.5197 z 
          
Site 4          
Con 31.5257 ± 0.5447 y 31.8943 ± 0.5447 y 33.3414 ± 0.5447 z 
eST 31.0270 ± 0.5262 y 31.6727 ± 0.5262 y 33.3943 ± 0.5262 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
Table A-30.  Normalized dorsal to palmar bone diameter micrometer readings in mm (mean 
± SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.4835 z 0.1475 ± 0.4835 z 0.7104 ± 0.4835 a,z 
eST 0.0000 ± 0.4671 y 0.4290 ± 0.4671 y 2.0327 ± 0.4671 z 
          
Site 2          
Con 0.0000 ± 0.3845 z 0.2618 ± 0.3845 z 0.8857 ± 0.3845 b,z 
eST 0.0000 ± 0.3714 y 0.2940 ± 0.3714 y 1.9967 ± 0.3714 z 
          
Site 3          
Con 0.0000 ± 0.3729 y 0.2221 ± 0.3729 y 1.1979 ± 0.3729 a,z 
eST 0.0000 ± 0.3602 y 0.4123 ± 0.3602 y 2.3313 ± 0.3602 z 
          
Site 4          
Con 0.0000 ± 0.3144 y 0.3686 ± 0.3144 y 1.8157 ± 0.3144 z 
eST 0.0000 ± 0.3038 y 0.6457 ± 0.3038 y 2.3673 ± 0.3038 z 
a
 Treatments differ (p.05).        
b
 Treatments differ (p.05).        
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-31.  Lateral to medial medullary cavity width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 17.5514 ± 0.7477 z 17.6093 ± 0.7477 z 17.3850 ± 0.7477 z 
eST 17.1853 ± 0.7223 z 16.9907 ± 0.7223 z 17.1130 ± 0.7223 z 
          
Site 2          
Con 16.9950 ± 0.7181 z 17.0496 ± 0.7181 z 16.9889 ± 0.7181 z 
eST 16.9397 ± 0.6937 z 16.7453 ± 0.6937 z 16.8397 ± 0.6937 z 
          
Site 3          
Con 17.4179 ± 0.6850 z 17.3346 ± 0.6850 z 17.3989 ± 0.6850 z 
eST 17.3380 ± 0.6618 z 17.2943 ± 0.6618 z 17.0303 ± 0.6618 z 
          
Site 4          
Con 23.9496 ± 0.7655 z 23.9979 ± 0.7655 z 23.9886 ± 0.7655 z 
eST 24.5763 ± 0.7395 y 23.8210 ± 0.7395 z 24.3103 ± 0.7395 yz 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
 
Table A-32.  Normalized lateral to medial medullary cavity width micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.1285 z 0.0579 ± 0.1285 z -0.1664 ± 0.1285 z 
eST 0.0000 ± 0.1241 z -0.1947 ± 0.1241 z -0.0723 ± 0.1241 z 
          
Site 2          
Con 0.0000 ± 0.1189 z 0.0546 ± 0.1189 z -0.0061 ± 0.1189 z 
eST 0.0000 ± 0.1149 z -0.1943 ± 0.1149 z -0.1000 ± 0.1149 z 
          
Site 3          
Con 0.0000 ± 0.1488 z -0.0832 ± 0.1488 z -0.0189 ± 0.1488 z 
eST 0.0000 ± 0.1438 z -0.0437 ± 0.1438 z -0.3077 ± 0.1438 z 
          
Site 4          
Con 0.0000 ± 0.2728 z 0.0482 ± 0.2728 a,z 0.0389 ± 0.2728 z 
eST 0.0000 ± 0.2635 y -0.7553 ± 0.2635 z -0.2660 ± 
0.2635 
yz
 
a
 Treatments differ (p.05). 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-33.  Lateral to medial bone diameter micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 41.1657 ± 0.6575 z 41.5450 ± 0.6575 a, z 41.2804 ± 0.6575 z 
eST 40.0297 ± 0.6352 y 39.9267 ± 0.6352 y 40.7483 ± 0.6352 z 
          
Site 2          
Con 40.5543 ± 0.6327 z 40.9468 ± 0.6327 z 41.0679 ± 0.6327 z 
eST 39.6907 ± 0.6112 z 39.7573 ± 0.6112 z 40.2120 ± 0.6112 z 
          
Site 3          
Con 40.6307 ± 0.6662 z 41.0186 ± 0.6662 z 40.8625 ± 0.6662 z 
eST 39.7207 ± 0.6436 z 39.8743 ± 0.6436 z 40.1127 ± 0.6436 z 
          
Site 4          
Con 43.6689 ± 0.7174 z 44.0421 ± 0.7174 z 43.9511 ± 0.7174 z 
eST 42.9530 ± 0.6931 yz 42.7237 ± 0.6931 y 43.5620 ± 0.6931 z 
a
 Trend for treatments to differ (p.10). 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
 
 
 
 
Table A-34.  Normalized lateral to medial bone diameter micrometer readings in mm (mean ± SE). 
day 0 64 128 
Site 1          
Con 0.0000 ± 0.2857 z 0.3793 ± 0.2857 z 0.1146 ± 0.2857 z 
eST 0.0000 ± 0.2760 y -0.1030 ± 0.2760 y 0.7187 ± 0.2760 z 
          
Site 2          
Con 0.0000 ± 0.2367 z 0.3925 ± 0.2367 z 0.5136 ± 0.2367 z 
eST 0.0000 ± 0.2287 z 0.0667 ± 0.2287 z 0.5213 ± 0.2287 z 
          
Site 3          
Con 0.0000 ± 0.2432 z 0.3879 ± 0.2432 z 0.2318 ± 0.2432 z 
eST 0.0000 ± 0.2349 z 0.1537 ± 0.2349 z 0.3920 ± 0.2349 z 
          
Site 4          
Con 0.0000 ± 0.3127 z 0.3732 ± 0.3127 z 0.2821 ± 0.3127 z 
eST 0.0000 ± 0.3021 yz -0.2293 ± 0.3021 y 0.6090 ± 0.3021 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table A-35.  Computed bone index value of micrometer readings at site 3, (mean ± SE). 
day 0 64 128 
Site 3          
Con 2.2946 ± 0.1996 y 2.3806 ± 0.1996 yz 2.6156 ± 0.19967 z 
eST 2.2966 ± 0.2760 y 2.4006 ± 0.2760 y 3.0676 ± 0.2760 z 
yz
 Means in the same row not sharing the same superscript differ (p.05). 
   
 
 
 
Table A-36.  Normalized computed bone index value of micrometer readings at site 3, (mean ± SE). 
day 0 64 128 
Site 3          
Con 0.0000 ± 0.1175 y 0.0860 ± 0.1175 yz 0.3210 ± 0.1175 a,z 
eST 0.0000 ± 0.1135 y 0.1039 ± 0.1135 y 0.7710 ± 0.1135 z 
a
 Treatments differ (p.01).  
      
yz
 Means in the same row not sharing the same superscript differ (p.05). 
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Table B-1. ANOVA table for total radiographic bone aluminum equivalency 
(mm2Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 9.88 <.0001 
Treatment 1   27.1 0.66 0.4223 
Treatment*Day 6 155 1.22 0.3007 
 
 
 
 
Table B-2. ANOVA table for normalized total radiographic bone aluminum 
equivalency (mm2Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 9.86 <.0001 
Treatment 1   27.1 2.08 0.1606 
Treatment*Day 6 155 1.21 0.3064 
 
 
 
 
 
 
Table B-3. ANOVA table for total radiographic bone aluminum equivalency 
(mm2Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 11.66 <.0001 
Treatment 1 27.1  0.57 0.4550 
Treatment*Day 6 155  1.09 0.3736 
 
 
Table B-4. ANOVA table for normalized total radiographic bone aluminum 
equivalency (mm2Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 11.13 <.0001 
Treatment 1   27.1  1.18 0.1892 
Treatment*Day 6 155  1.05 0.3972 
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Table B-5. ANOVA table for total radiographic bone aluminum equivalency 
(mm2Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 13.18 <.0001 
Treatment 1   27.1  0.57 0.4567 
Treatment*Day 6 155  1.04 0.3998 
 
 
 
Table B-6. ANOVA table for normalized total radiographic bone aluminum 
equivalency (mm2Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 13.15 <.0001 
Treatment 1   27.1  1.85 0.1848 
Treatment*Day 6 155  1.04 0.4015 
 
 
 
Table B-7. ANOVA table for total radiographic bone aluminum equivalency 
(mm2Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 12.82 <.0001 
Treatment 1   27.1  0.22 0.6399 
Treatment*Day 6 155  1.00 0.4244 
 
 
 
Table B-8. ANOVA table for normalized total radiographic bone aluminum 
equivalency (mm2Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 12.81 <.0001 
Treatment 1   27.1  1.88 0.1811 
Treatment*Day 6 155  1.01 0.4231 
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Table B-9. ANOVA table for dorsal radiographic bone aluminum equivalency 
(mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 154 12.09 <.0001 
Treatment 1   27.1  3.14 0.0877 
Treatment*Day 6 154  0.75 0.6119 
 
 
 
Table B-10. ANOVA table for normalized dorsal radiographic bone aluminum 
equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 12.12 <.0001 
Treatment 1   27.3  0.56 0.4606 
Treatment*Day 6 155  0.75 0.6135 
 
 
 
Table B-11. ANOVA table for dorsal radiographic bone aluminum equivalency 
(mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 154 10.52 <.0001 
Treatment 1   27.1  2.72 0.1103 
Treatment*Day 6 154  0.62 0.7143 
 
 
Table B-12. ANOVA table for normalized dorsal radiographic bone aluminum 
equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 10.53 <.0001 
Treatment 1   27.1  0.75 0.3932 
Treatment*Day 6 155  0.62 0.7173 
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Table B-13. ANOVA table for dorsal radiographic bone aluminum equivalency 
(mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 154  9.41 <.0001 
Treatment 1   27.1 2.93 0.0983 
Treatment*Day 6 154 0.30 0.9371 
 
 
 
Table B-14. ANOVA table for normalized dorsal radiographic bone aluminum 
equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  9.11 <.0001 
Treatment 1   27.1 0.95 0.3393 
Treatment*Day 6 155 0.35 0.9072 
 
 
 
Table B-15. ANOVA table for dorsal radiographic bone aluminum equivalency 
(mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 153  7.11 <.0001 
Treatment 1   27.1 0.43 0.5166 
Treatment*Day 6 153 0.48 0.8250 
 
 
 
Table B-16. ANOVA table for normalized dorsal radiographic bone aluminum 
equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  7.12 <.0001 
Treatment 1   27.1 1.89 0.1804 
Treatment*Day 6 155 0.51 0.8000 
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Table B-17. ANOVA table for lateral radiographic bone aluminum equivalency 
(mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  8.22 <.0001 
Treatment 1   27 0.64 0.4316 
Treatment*Day 6 155 0.25 0.9595 
 
 
 
Table B-18. ANOVA table for normalized lateral radiographic bone aluminum 
equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  8.28 <.0001 
Treatment 1   27.2 0.01 0.9315 
Treatment*Day 6 156 0.23 0.9648 
 
 
 
Table B-19. ANOVA table for lateral radiographic bone aluminum equivalency 
(mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  9.08 <.0001 
Treatment 1   27 0.53 0.4714 
Treatment*Day 6 155 0.21 0.9747 
 
 
Table B-20. ANOVA table for normalized lateral radiographic bone aluminum 
equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  9.17 <.0001 
Treatment 1   27.2 0.09 0.7720 
Treatment*Day 6 156 0.20 0.9750 
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Table B-21. ANOVA table for lateral radiographic bone aluminum equivalency 
(mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  9.71 <.0001 
Treatment 1   27 0.51 0.4820 
Treatment*Day 6 155 0.33 0.9193 
 
 
 
Table B-22. ANOVA table for normalized lateral radiographic bone aluminum 
equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  9.80 <.0001 
Treatment 1   27.2 0.12 0.7316 
Treatment*Day 6 156 0.34 0.9125 
 
 
 
Table B-23. ANOVA table for lateral radiographic bone aluminum equivalency 
(mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 13.36 <.0001 
Treatment 1   27.1  0.52 0.4790 
Treatment*Day 6 155  0.44 0.8527 
 
 
Table B-24. ANOVA table for normalized lateral radiographic bone aluminum 
equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156 14.14 <.0001 
Treatment 1   27.3  0.40 0.5319 
Treatment*Day 6 156  0.35 0.9107 
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Table B-25. ANOVA table for medial radiographic bone aluminum equivalency 
(mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 19.50 <.0001 
Treatment 1   27.1  0.36 0.5549 
Treatment*Day 6 155  0.58 0.7441 
 
 
 
Table B-26. ANOVA table for normalized medial radiographic bone aluminum 
equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 19.53 <.0001 
Treatment 1   27.2  1.33 0.2587 
Treatment*Day 6 155  0.59 0.7354 
 
 
 
Table B-27. ANOVA table for medial radiographic bone aluminum equivalency 
(mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 20.03 <.0001 
Treatment 1   27.1  0.40 0.5306 
Treatment*Day 6 155  0.43 0.8568 
 
 
Table B-28. ANOVA table for normalized medial radiographic bone aluminum 
equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 20.10 <.0001 
Treatment 1   27.1   1.07 0.3109 
Treatment*Day 6 155   0.46 0.8338 
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Table B-29. ANOVA table for medial radiographic bone aluminum equivalency 
(mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 18.69 <.0001 
Treatment 1   27.1  0.35 0.5570 
Treatment*Day 6 155  0.29 0.9391 
 
 
 
Table B-30. ANOVA table for normalized medial radiographic bone aluminum 
equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156 18.71 <.0001 
Treatment 1   27.1  0.50 0.4871 
Treatment*Day 6 156  0.30 0.9348 
 
 
 
Table B-31. ANOVA table for medial radiographic bone aluminum equivalency 
(mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 16.82 <.0001 
Treatment 1   27.1  0.21 0.6488 
Treatment*Day 6 155  0.64 0.6955 
 
 
Table B-32. ANOVA table for normalized medial radiographic bone aluminum 
equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155 17.13 <.0001 
Treatment 1   27.1  0.72 0.4027 
Treatment*Day 6 155  0.61 0.7207 
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Table B-33. ANOVA table for palmar radiographic bone aluminum equivalency 
(mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 154  3.64 0.0021 
Treatment 1   27 1.19 0.2856 
Treatment*Day 6 154 0.30 0.9353 
 
 
 
Table B-34. ANOVA table for normalized palmar radiographic bone aluminum 
equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  3.68 0.0019 
Treatment 1   27.3 0.02 0.8756 
Treatment*Day 6 156 0.31 0.9329 
 
 
 
Table B-35. ANOVA table for palmar radiographic bone aluminum equivalency 
(mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 151  3.33 0.0042 
Treatment 1   27.1 0.83 0.3689 
Treatment*Day 6 151 0.19 0.9804 
 
 
Table B-36. ANOVA table for normalized palmar radiographic bone aluminum 
equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 152  3.52 0.0027 
Treatment 1   27.3 0.17 0.6798 
Treatment*Day 6 152 0.20 0.9763 
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Table B-37. ANOVA table for palmar radiographic bone aluminum equivalency 
(mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 146  2.84 <.0121 
Treatment 1   27 0.47 0.4975 
Treatment*Day 6 146 0.22 0.9701 
 
 
 
Table B-38. ANOVA table for normalized palmar radiographic bone aluminum 
equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 144  2.75 0.0145 
Treatment 1   27.8 0.06 0.8009 
Treatment*Day 6 144 0.25 0.9594 
 
 
 
Table B-39. ANOVA table for palmar radiographic bone aluminum equivalency 
(mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 143  2.02 0.0664 
Treatment 1   27 1.16 0.2918 
Treatment*Day 6 143 0.42 0.8621 
 
 
Table B-40. ANOVA table for normalized palmar radiographic bone aluminum 
equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 138  1.86 0.0913 
Treatment 1   27.9 0.08 0.7728 
Treatment*Day 6 138 0.49 0.8118 
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Table B-41. ANOVA table for ratio of dorsal to palmar radiographic bone 
aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 154  2.99 0.0086 
Treatment 1   26.9 0.93 0.3445 
Treatment*Day 6 154 1.11 0.3615 
 
 
 
Table B-42. ANOVA table for normalized ratio of dorsal to palmar radiographic 
bone aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  3.04 0.0077 
Treatment 1   27.1 1.52 0.2278 
Treatment*Day 6 155 1.11 0.3619 
 
 
 
Table B-43. ANOVA table for ratio of dorsal to palmar radiographic bone 
aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 151  3.08 0.0071 
Treatment 1   27.2 0.51 0.4811 
Treatment*Day 6 151 1.02 0.4145 
 
 
Table B-44. ANOVA table for normalized ratio of dorsal to palmar radiographic 
bone aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 151  3.27 0.0047 
Treatment 1   26.5 2.48 0.1273 
Treatment*Day 6 151 1.01 0.4206 
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Table B-45. ANOVA table for ratio of dorsal to palmar radiographic bone 
aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 145  3.04 0.0036 
Treatment 1   27 0.47 0.4997 
Treatment*Day 6 145 0.68 0.6658 
 
 
 
Table B-46. ANOVA table for normalized ratio of dorsal to palmar radiographic 
bone aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 142  3.47 0.0032 
Treatment 1   25.8 1.55 0.2245 
Treatment*Day 6 142 0.66 0.6800 
 
 
 
Table B-47. ANOVA table for ratio of dorsal to palmar radiographic bone 
aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 142  1.97 0.0735 
Treatment 1   27.1 0.40 0.5316 
Treatment*Day 6 142 1.06 0.3870 
 
 
Table B-48. ANOVA table for normalized ratio of dorsal to palmar radiographic 
bone aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 135  1.76 0.1119 
Treatment 1   25 2.50 0.1263 
Treatment*Day 6 135 0.87 0.5181 
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Table B-49. ANOVA table for ratio of lateral to palmar radiographic bone 
aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  4.71 0.0002 
Treatment 1   27.3 0.01 0.9190 
Treatment*Day 6 155 0.63 0.7078 
 
 
 
Table B-50. ANOVA table for normalized ratio of lateral to palmar radiographic 
bone aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  4.69 0.0002 
Treatment 1   27.1 0.01 0.9427 
Treatment*Day 6 155 0.60 0.7262 
 
 
 
Table B-51. ANOVA table for ratio of lateral to palmar radiographic bone 
aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 152  6.04 <.0001 
Treatment 1   27.5 0.00 0.9770 
Treatment*Day 6 152 0.36 0.9054 
 
 
Table B-52. ANOVA table for normalized ratio of lateral to palmar radiographic 
bone aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 152  6.02 <.0001 
Treatment 1   27.2 0.31 0.5818 
Treatment*Day 6 152 0.34 0.9174 
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Table B-53. ANOVA table for ratio of lateral to palmar radiographic bone 
aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 146  6.78 <.0001 
Treatment 1   27.2 0.00 0.9971 
Treatment*Day 6 146 0.44 0.8529 
 
 
 
Table B-54. ANOVA table for normalized ratio of lateral to palmar radiographic 
bone aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 143  6.35 <.0001 
Treatment 1   25.8 0.26 0.6150 
Treatment*Day 6 143 0.35 0.9063 
 
 
 
Table B-55. ANOVA table for ratio of lateral to palmar radiographic bone 
aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 144  6.76 <.0001 
Treatment 1   27.2 0.40 0.7688 
Treatment*Day 6 144 1.06 0.7490 
 
Table B-56. ANOVA table for normalized ratio of lateral to palmar radiographic 
bone aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 135  6.08 <.0001 
Treatment 1   25.2 0.56 0.4597 
Treatment*Day 6 135 0.45 0.8469 
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Table B-57. ANOVA table for ratio of medial to lateral radiographic bone 
aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  3.95 0.0011 
Treatment 1   27.1 0.18 0.6731 
Treatment*Day 6 156 0.52 0.7915 
 
 
 
Table B-58. ANOVA table for normalized ratio of medial to lateral radiographic 
bone aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  4.06 0.0008 
Treatment 1   26.6 2.81 0.1055 
Treatment*Day 6 155 0.53 0.7878 
 
 
 
Table B-59. ANOVA table for ratio of medial to lateral radiographic bone 
aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  2.53 0.0232 
Treatment 1   27.2 0.11 0.7427 
Treatment*Day 6 156 0.13 0.9916 
 
 
Table B-60. ANOVA table for normalized ratio of medial to lateral radiographic 
bone aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  2.67 0.0170 
Treatment 1   27 0.34 0.5655 
Treatment*Day 6 155 0.13 0.9923 
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Table B-61. ANOVA table for ratio of medial to lateral radiographic bone 
aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  2.60 0.0198 
Treatment 1   27.2 0.13 0.7182 
Treatment*Day 6 156 0.32 0.9233 
 
 
 
Table B-62. ANOVA table for normalized ratio of medial to lateral radiographic 
bone aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  2.72 0.0152 
Treatment 1   27.1 0.02 0.8769 
Treatment*Day 6 155 0.33 0.9208 
 
 
 
Table B-63. ANOVA table for ratio of medial to lateral radiographic bone 
aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 156  2.12 0.0543 
Treatment 1   27.2 0.21 0.7278 
Treatment*Day 6 156 0.10 0.9962 
 
 
Table B-64. ANOVA table for normalized ratio of medial to lateral radiographic 
bone aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  2.27 0.0393 
Treatment 1   27.2 0.00 0.9872 
Treatment*Day 6 155 0.10 0.9961 
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Table B-65. ANOVA table for ratio of medial to palmar radiographic bone 
aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 155  9.80 <.0001 
Treatment 1   27.2 0.10 0.7526 
Treatment*Day 6 155 0.81 0.5674 
 
 
 
Table B-66. ANOVA table for normalized ratio of medial to palmar radiographic 
bone aluminum equivalency (mm Al) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 6 154  9.83 <.0001 
Treatment 1   27.2 1.27 0.2700 
Treatment*Day 6 154 0.80 0.5721 
 
 
 
Table B-67. ANOVA table for ratio of medial to palmar radiographic bone 
aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 152 11.59 <.0001 
Treatment 1   27.5  0.12 0.7270 
Treatment*Day 6 152  0.74 0.6192 
 
 
Table B-68. ANOVA table for normalized ratio of medial to palmar radiographic 
bone aluminum equivalency (mm Al) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 6 151 11.66 <.0001 
Treatment 1   26.9  1.60 0.2162 
Treatment*Day 6 151  0.73 0.6273 
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Table B-69. ANOVA table for ratio of medial to palmar radiographic bone 
aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 146  9.89 <.0001 
Treatment 1   27.3 0.07 0.7979 
Treatment*Day 6 146 0.47 0.8308 
 
 
 
Table B-70. ANOVA table for normalized ratio of medial to palmar radiographic 
bone aluminum equivalency (mm Al) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 6 143  9.56 <.0001 
Treatment 1   26.1 0.30 0.5885 
Treatment*Day 6 143 0.37 0.8945 
 
 
 
Table B-71. ANOVA table for ratio of medial to palmar radiographic bone 
aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 143  6.16 <.0001 
Treatment 1   27.1 0.22 0.6456 
Treatment*Day 6 143 0.75 0.6133 
 
 
Table B-72. ANOVA table for normalized ratio of medial to palmar radiographic 
bone aluminum equivalency (mm Al) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 6 135  6.07 <.0001 
Treatment 1   25.4 1.93 0.1769 
Treatment*Day 6 135 0.64 0.6958 
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Table B-73. ANOVA table for dorsal cortical bone width micrometer readings 
(in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 21.97 <.0001 
Treatment 1 27  0.01 0.9191 
Treatment*Day 2 54  3.78 0.0290 
 
 
 
Table B-74. ANOVA table for normalized dorsal cortical bone width micrometer 
readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 21.97 <.0001 
Treatment 1 27  2.70 0.1122 
Treatment*Day 2 54  3.78 0.0290 
 
 
 
Table B-75. ANOVA table for dorsal cortical bone width micrometer readings 
(in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 24.13 <.0001 
Treatment 1 27  0.01 0.9244 
Treatment*Day 2 54  3.98 0.0244 
 
 
Table B-76. ANOVA table for normalized dorsal cortical bone width micrometer 
readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 24.13 <.0001 
Treatment 1 27  3.18 0.0860 
Treatment*Day 2 54  3.98 0.0244 
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Table B-77. ANOVA table for dorsal cortical bone width micrometer readings 
(in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 25.90 <.0001 
Treatment 1 27  0.02 0.8766 
Treatment*Day 2 54  3.65 0.0327 
 
 
 
Table B-78. ANOVA table for normalized dorsal cortical bone width micrometer 
readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 25.90 <.0001 
Treatment 1 27  2.11 0.1580 
Treatment*Day 2 54  3.65 0.0327 
 
 
 
Table B-79. ANOVA table for dorsal cortical bone width micrometer readings 
(in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 44.29 <.0001 
Treatment 1 27  0.00 0.9841 
Treatment*Day 2 54  1.05 0.3571 
 
 
Table B-80. ANOVA table for normalized dorsal cortical bone width micrometer 
readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 44.29 <.0001 
Treatment 1 27  1.09 0.3061 
Treatment*Day 2 54  1.05 0.3571 
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Table B-81. ANOVA table for lateral cortical bone width micrometer readings 
(in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.86 0.1654 
Treatment 1 27 0.06 0.8120 
Treatment*Day 2 54 0.41 0.6642 
 
 
 
Table B-82. ANOVA table for normalized lateral cortical bone width micrometer 
readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.86 0.1654 
Treatment 1 27 0.22 0.6416 
Treatment*Day 2 54 0.41 0.6642 
 
 
 
Table B-83. ANOVA table for lateral cortical bone width micrometer readings 
(in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  3.30 0.0443 
Treatment 1 27 0.09 0.7722 
Treatment*Day 2 54 0.20 0.8157 
 
 
Table B-84. ANOVA table for normalized lateral cortical bone width micrometer 
readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  3.30 0.0443 
Treatment 1 27 0.10 0.7568 
Treatment*Day 2 54 0.20 0.8157 
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Table B-85. ANOVA table for lateral cortical bone width micrometer readings 
(in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  2.81 0.0690 
Treatment 1 27 0.05 0.8278 
Treatment*Day 2 54 0.77 0.4666 
 
 
 
Table B-86. ANOVA table for normalized lateral cortical bone width micrometer 
readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  2.81 0.0690 
Treatment 1 27 0.28 0.5999 
Treatment*Day 2 54 0.77 0.4666 
 
 
 
Table B-87. ANOVA table for lateral cortical bone width micrometer readings 
(in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.93 0.4009 
Treatment 1 27 1.69 0.2045 
Treatment*Day 2 54 0.47 0.6292 
 
 
Table B-88. ANOVA table for normalized lateral cortical bone width micrometer 
readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.93 0.4009 
Treatment 1 27 0.18 0.6750 
Treatment*Day 2 54 0.47 0.6292 
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Table B-89. ANOVA table for medial cortical bone width micrometer readings 
(in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  4.48 0.0159 
Treatment 1 27 0.79 0.3829 
Treatment*Day 2 54 1.90 0.1594 
 
 
 
Table B-90. ANOVA table for normalized medial cortical bone width 
micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  4.48 0.0159 
Treatment 1 27 0.33 0.5729 
Treatment*Day 2 54 1.90 0.1594 
 
 
 
Table B-91. ANOVA table for medial cortical bone width micrometer readings 
(in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  6.85 0.0022 
Treatment 1 27 0.88 0.3574 
Treatment*Day 2 54 0.39 0.6823 
 
 
Table B-92. ANOVA table for normalized medial cortical bone width 
micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  6.85 0.0022 
Treatment 1 27 0.04 0.8397 
Treatment*Day 2 54 0.39 0.6823 
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Table B-93. ANOVA table for medial cortical bone width micrometer readings 
(in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  4.26 0.0192 
Treatment 1 27 0.92 0.3462 
Treatment*Day 2 54 1.28 0.2856 
 
 
 
Table B-94. ANOVA table for normalized medial cortical bone width 
micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  4.26 0.0192 
Treatment 1 27 0.00 0.9974 
Treatment*Day 2 54 1.28 0.2856 
 
 
 
Table B-95. ANOVA table for medial cortical bone width micrometer readings 
(in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.51 0.2307 
Treatment 1 27 0.71 0.4066 
Treatment*Day 2 54 1.95 0.1515 
 
 
Table B-96. ANOVA table for normalized medial cortical bone width 
micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.51 0.2307 
Treatment 1 27 1.81 0.1894 
Treatment*Day 2 54 1.95 0.1515 
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Table B-97. ANOVA table for palmar cortical bone width micrometer readings 
(in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.02 0.9838 
Treatment 1 27 0.05 0.8224 
Treatment*Day 2 54 0.60 0.5536 
 
 
 
Table B-98. ANOVA table for normalized palmar cortical bone width 
micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.02 0.9838 
Treatment 1 27 0.78 0.3853 
Treatment*Day 2 54 0.60 0.5536 
 
 
 
Table B-99. ANOVA table for palmar cortical bone width micrometer readings 
(in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.05 0.9541 
Treatment 1 27 0.35 0.5611 
Treatment*Day 2 54 0.51 0.6008 
 
 
Table B-100. ANOVA table for normalized palmar cortical bone width 
micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.05 0.9541 
Treatment 1 27 0.58 0.4538 
Treatment*Day 2 54 0.51 0.6008 
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Table B-101. ANOVA table for palmar cortical bone width micrometer readings 
(in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.55 0.5814 
Treatment 1 27 0.14 0.7124 
Treatment*Day 2 54 1.01 0.3715 
 
 
 
Table B-102. ANOVA table for normalized palmar cortical bone width 
micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.55 0.5814 
Treatment 1 27 1.25 0.2743 
Treatment*Day 2 54 1.01 0.3715 
 
 
 
Table B-103. ANOVA table for palmar cortical bone width micrometer readings 
(in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 10.07 0.0002 
Treatment 1 27   0.53 0.4727 
Treatment*Day 2 54  0.87 0.4252 
 
 
Table B-104. ANOVA table for normalized palmar cortical bone width 
micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 10.07 0.0002 
Treatment 1 27  1.47 0.2356 
Treatment*Day 2 54  0.87 0.4252 
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Table B-105. ANOVA table for dorsal to palmar medullary cavity width 
micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  5.74 0.0055 
Treatment 1 27 0.29 0.5924 
Treatment*Day 2 54 2.05 0.1382 
 
 
 
Table B-106. ANOVA table for normalized dorsal to palmar medullary cavity 
width micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  5.74 0.0055 
Treatment 1 27 2.07 0.1617 
Treatment*Day 2 54 2.05 0.1382 
 
 
 
Table B-107. ANOVA table for dorsal to palmar medullary cavity width 
micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  8.91 0.0005 
Treatment 1 27 0.39 0.5387 
Treatment*Day 2 54 2.85 0.0667 
 
 
Table B-108. ANOVA table for normalized dorsal to palmar medullary cavity 
width micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  8.91 0.0005 
Treatment 1 27 5.42 0.0277 
Treatment*Day 2 54 2.85 0.0667 
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Table B-109. ANOVA table for dorsal to palmar medullary cavity width 
micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.42 0.2513 
Treatment 1 27 0.49 0.4893 
Treatment*Day 2 54 1.85 0.1673 
 
 
 
Table B-110. ANOVA table for normalized dorsal to palmar medullary cavity 
width micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.42 0.2513 
Treatment 1 27 2.28 0.1428 
Treatment*Day 2 54 1.85 0.1673 
 
 
 
Table B-111. ANOVA table for dorsal to palmar medullary cavity width 
micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.41 0.2534 
Treatment 1 27 0.40 0.5332 
Treatment*Day 2 54 0.55 0.5778 
 
 
Table B-112. ANOVA table for normalized dorsal to palmar medullary cavity 
width micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.41 0.2534 
Treatment 1 27 0.82 0.3729 
Treatment*Day 2 54 0.55 0.5778 
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Table B-113. ANOVA table for dorsal to palmar bone diameter micrometer 
readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  7.37 0.0015 
Treatment 1 27 0.05 0.8227 
Treatment*Day 2 54 1.71 0.1905 
 
 
 
Table B-114. ANOVA table for normalized dorsal to palmar bone diameter 
micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  7.37 0.0015 
Treatment 1 27 1.09 0.3062 
Treatment*Day 2 54 1.71 0.1905 
 
 
 
Table B-115. ANOVA table for dorsal to palmar bone diameter micrometer 
readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 10.50 0.0001 
Treatment 1 27  0.03 0.8535 
Treatment*Day 2 54  1.80 0.1758 
 
 
Table B-116. ANOVA table for normalized dorsal to palmar bone diameter 
micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 10.50 0.0001 
Treatment 1 27  1.06 0.3130 
Treatment*Day 2 54  1.80 0.1758 
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Table B-117. ANOVA table for dorsal to palmar bone diameter micrometer 
readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 17.71 <.0001 
Treatment 1 27  0.32 0.5754 
Treatment*Day 2 54  1.84 0.1681 
 
 
 
Table B-118. ANOVA table for normalized dorsal to palmar bone diameter 
micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 17.71 <.0001 
Treatment 1 27  1.44 0.2412 
Treatment*Day 2 54  1.84 0.1681 
 
 
 
Table B-119. ANOVA table for dorsal to palmar bone diameter micrometer 
readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 31.43 <.0001 
Treatment 1 27  0.10 0.7487 
Treatment*Day 2 54  0.50 0.6080 
 
 
Table B-120. ANOVA table for normalized dorsal to palmar bone diameter 
micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 31.43 <.0001 
Treatment 1 27  0.85 0.3657 
Treatment*Day 2 54  0.50 0.6080 
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Table B-121. ANOVA table for lateral to medial medullary cavity width 
micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.58 0.5626 
Treatment 1 27 0.16 0.6879 
Treatment*Day 2 54 1.30 0.2805 
 
 
 
Table B-122. ANOVA table for normalized lateral to medial medullary cavity 
width micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.58 0.5626 
Treatment 1 27 0.18 0.6744 
Treatment*Day 2 54 1.30 0.2805 
 
 
 
Table B-123. ANOVA table for lateral to medial medullary cavity width 
micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.27 0.7637 
Treatment 1 27 0.03 0.8655 
Treatment*Day 2 54 0.81 0.4520 
 
 
Table B-124. ANOVA table for normalized lateral to medial medullary cavity 
width micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.27 0.7637 
Treatment 1 27 0.92 0.3471 
Treatment*Day 2 54 0.81 0.4520 
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Table B-125. ANOVA table for lateral to medial medullary cavity width 
micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.86 0.4269 
Treatment 1 27 0.03 0.8639 
Treatment*Day 2 54 1.02 0.3658 
 
 
 
Table B-126. ANOVA table for normalized lateral to medial medullary cavity 
width micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  0.86 0.4269 
Treatment 1 27 0.31 0.5795 
Treatment*Day 2 54 1.02 0.3658 
 
 
 
Table B-127. ANOVA table for lateral to medial medullary cavity width 
micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.33 0.2718 
Treatment 1 27 0.06 0.8053 
Treatment*Day 2 54 1.69 0.1950 
 
 
Table B-128. ANOVA table for normalized lateral to medial medullary cavity 
width micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.33 0.2718 
Treatment 1 27 1.73 0.1990 
Treatment*Day 2 54 1.69 0.1950 
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Table B-129. ANOVA table for lateral to medial bone diameter micrometer 
readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.53 0.2248 
Treatment 1 27 1.58 0.2190 
Treatment*Day 2 54 2.52 0.0896 
 
 
 
Table B-130. ANOVA table for normalized lateral to medial bone diameter 
micrometer readings (in mm) at site 1. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.53 0.2248 
Treatment 1 27 0.02 0.8866 
Treatment*Day 2 54 2.52 0.0896 
 
 
 
Table B-131. ANOVA table for lateral to medial bone diameter micrometer 
readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  2.91 0.0632 
Treatment 1 27 1.32 0.2606 
Treatment*Day 2 54 0.39 0.6777 
 
 
Table B-132. ANOVA table for normalized lateral to medial bone diameter 
micrometer readings (in mm) at site 2. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  2.91 0.0632 
Treatment 1 27 0.24 0.6276 
Treatment*Day 2 54 0.39 0.6777 
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Table B-133. ANOVA table for lateral to medial bone diameter micrometer 
readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.35 0.3057 
Treatment 1 27 1.09 0.2670 
Treatment*Day 2 54 0.46 0.6315 
 
 
 
Table B-134. ANOVA table for normalized lateral to medial bone diameter 
micrometer readings (in mm) at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.35 0.2670 
Treatment 1 27 0.01 0.9190 
Treatment*Day 2 54 0.46 0.6315 
 
 
 
Table B-135. ANOVA table for lateral to medial bone diameter micrometer 
readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.93 0.1552 
Treatment 1 27 0.71 0.4061 
Treatment*Day 2 54 1.87 0.1635 
 
 
Table B-136. ANOVA table for normalized lateral to medial bone diameter 
micrometer readings (in mm) at site 4. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54  1.93 0.1552 
Treatment 1 27 0.08 0.7838 
Treatment*Day 2 54 1.87 0.1635 
 
  
230 
 
 
Table B-137. ANOVA table for bone index value of micrometer readings at site 
3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 15.46 <.0001 
Treatment 1 27  0.40 0.5321 
Treatment*Day 2 54  2.95 0.0610 
 
 
 
Table B-138. ANOVA table for normalized bone index value of micrometer 
readings at site 3. 
Source numerator df denominator df F-Value Probability > F 
Day 2 54 15.46 <.0001 
Treatment 1 27  2.03 0.1658 
Treatment*Day 2 54  2.95 0.0610 
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